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Introduction 
Eating and having a good meal is part of our everyday life and important to everybody, not least to people living with dementia. But it is still an almost totally neglected area 
of focus in relation to these diseases.
Compass Group and Alzheimer’s Disease International (ADI) have come together in 
commissioning this report to investigate how the right nutrition can help to make life 
better for people who live with dementia. This is clearly reflected in ADI’s mission and 
vision: ‘an improved quality of life for people with dementia and their carers’. Compass 
Group, as world-leading food and support services organisation, shares this vision in 
their work to support people who are affected by dementia.
This report was prepared by Professor Martin Prince, Professor Emiliano Albanese, 
Dr Maëlenn Guerchet and Dr Matthew Prina for the Global Observatory for Ageing 
and Dementia Care, King’s College London. They have reviewed a number of areas in 
existing research regarding the relevance of nutritional factors to primary and secondary 
prevention of dementia, undernutrition in dementia and interventions to improve the 
nutrition of people living with dementia.
The report shows the importance of each of these factors in the everyday nutrition 
and care of people with dementia. In addition, it identifies how we can start building 
methods and guidelines that will complement clinical treatment of the diseases. It 
highlights:
• the link between nutrition and quality of life
• the previous neglect of this important issue, as evidenced by the high prevalence of 
undernutrition and inadequate food intake among people with dementia
• the untapped potential to improve outcomes for people with dementia, given the 
evidence for effective interventions 
• the need for more research in this area.
A healthy diet and nutrition is fundamental to wellbeing at any stage of life and to 
helping to combat other life-threatening diseases. We believe it can play as important a 
role in relation to dementia. 
ADI believes that the key to winning the fight against dementia lies in a unique 
combination of global solutions and local knowledge. As such, it works globally to 
focus attention on the epidemic of dementia, while also empowering local Alzheimer 
associations to promote and offer support for people with dementia and their carers. 
Compass Group is a company that operates in more than 50,000 client locations in 
around 50 countries and serves over 4 billion meals per year. By working closely with 
our care home clients, we can improve the quality of their food and support services 
allowing them to focus on caring for their residents. People living with dementia are a 
small but growing constituency of Compass’ business.
ADI and Compass Group believe that a focus on diet, nutrition and wellbeing is a 
positive approach to supporting people with dementia and their carers in dealing with 
this terrible disease. It is not only a good collaboration but the right thing to do.
 
Marc Wortmann Mike Iddon  
Executive Director Group Healthcare Director  
Alzheimer’s Disease International Compass Group
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Key messages
1  Undernutrition is common among older people generally, particularly in low and 
middle income countries. For this age group it is, arguably, a larger public health 
problem than obesity. The consequences include increased frailty, skin fragility, 
falls, hospitalisation and mortality.
2  Undernutrition is particularly common among people with dementia in all world 
regions. It tends to be progressive, with weight loss often preceding the onset of 
dementia and then increasing in pace across the disease course.
3  Obesity in mid-life may be a risk factor for developing dementia in late-life. If so, 
this is an important modifiable risk factor, and a matter of concern given rising 
levels of obesity worldwide. However, careful examination of the existing evidence 
casts some doubt upon the validity and robustness of this finding, which requires 
more research.
4  There are many dietary factors that might plausibly increase or decrease risk for 
the onset of dementia. However, we could find no clear or consistent evidence 
to support a causal protective role for vitamins B6, B12, C or E, folate or omega-3 
PUFA (polyunsaturated fatty acids). There is quite consistent evidence from 
epidemiological cohort studies that adherence to a Mediterranean diet (with a 
high proportionate intake of cereals, fruits, fish and vegetables) may lower the 
risk of cognitive decline and dementia. However, to date, only one trial has been 
carried out, with encouraging findings.
5  The mechanisms underlying weight loss and undernutrition in dementia are 
complex, multifactorial, and only partly understood. Reduced appetite, increased 
activity, and, in the more advanced stages of the illness, the disruption of eating 
and feeding behaviours by cognitive and behavioural problems all play a part. 
For some forms of dementia, it may be that central regulation of appetite and 
metabolism is disturbed as an inherent feature of the disease.
6  A key finding in this report is that while weight loss is a common problem for 
people with dementia, undernutrition can and should be avoided. Proof of 
concept comes from a new review of the use of oral nutritional supplements, 
indicating that it is possible to stabilise or even increase the weight of people 
with dementia over relatively long periods. The nutritional benefits of education 
and training for caregivers was less apparent, although such interventions were 
popular and there are likely to be other benefits.
7  In care homes, attention to staff training and mealtime environment can lead 
to significant enhancement in calorie intake among residents. Eating is a social 
activity, and more thought should be given to how this can be optimised, 
normalised and made a core aspect of person-centred care. Sensitive and 
inclusive design of dining rooms, kitchens, furniture and tableware can all make 
important contributions. 
8  There is no current evidence that nutritional supplementation whether with 
micronutrients, ‘medical foods’ or macronutrients can modify the course of 
dementia (cognitive and functional decline). Vitamin E shows some promise, but 
at doses that may lead to harmful side effects.
9  Much more attention needs to be focused upon the problem of undernutrition 
in dementia. This has been grossly neglected in research and practice. Studies 
reviewed in this report indicate that 20-45% of those with dementia in the 
community experience clinically significant weight loss over one year, and that up 
to half of people with dementia in care homes have an inadequate food intake. 
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Recommendations
1  More research needs to be conducted into
•  The possibility that nutritional supplementation of dietary components with high 
mechanistic plausibility may be effective in reducing the incidence of dementia 
if targeted upon those with evidence of deficiency (for example vitamin B12 and 
folate).
•  The effective components of a Mediterranean diet with respect to the prevention 
of dementia and progression of Mild Cognitive Impairment, and the feasibility of 
sustained implementation of such dietary modification.
•  The possibility that some forms of micronutrient supplementation may yet be 
effective in altering the course of dementia, if targeted upon those who are 
deficient.
•  The minimum effective dose of vitamin E as a treatment for clinical progression in 
dementia, and the balance of associated risks and benefits.
•  The relative efficacy of food fortification and oral nutritional supplementation in 
maintaining weight among people with dementia at risk for undernutrition.
•  The feasibility and effectiveness of long-term fortification or oral nutritional 
supplementation strategies, including the wider health and quality of life benefits.
2  It is important that clear, consistent and independent evidence-based advice is 
provided to support decision-making on nutritional supplements by those at risk of, 
or already living with, dementia. 
3  Nutritional standards of care for people with dementia should be introduced 
throughout the health and social care sectors, and monitored for compliance.
•  All people with dementia should have their weight monitored and nutritional status 
assessed regularly. 
•  All people with dementia, and their family carers, should receive dietary advice 
from a dietician as a part of post-diagnostic care, updated, as appropriate, as 
their condition evolves, particularly with the onset of weight loss, aversive feeding 
behaviours, and need for feeding assistance.
•  Undernutrition, once established, is a serious health concern requiring medical 
attention and input from a dietician and occupational therapy as appropriate. 
Those at risk of undernutrition require a detailed assessment of diet, feeding 
behaviours and need for feeding assistance. This should inform an immediate and 
intensive nutritional intervention to restore and maintain normal nutrition. 
•  Nutritional advice and natural food fortification should be tried first, but the use of 
oral nutritional supplements should not be delayed for those with undernutrition 
and those at risk who fail to respond. 
•  All care homes and hospitals that care for people with dementia need to develop 
and implement plans to optimise and monitor their nutritional status. This should 
include staff training; attention to the nutritional content and variety of the food 
provided, and its suitability for people with different eating and feeding difficulties; 
the way in which food is prepared and delivered; and dining room design and 
mealtime environment. 
•  Staff training in care homes and hospitals should be part of a comprehensive 
programme of workforce development linking managers, nursing staff, care 
assistants and caterers all of whom need to understand the challenges involved in 
maintaining adequate nutrition for people with dementia, and the part that they have 
to play. This should address gaps in knowledge (the nutritional content of food, the 
impact of dementia on diet and nutrition) and skills (in monitoring nutritional status, 
providing feeding assistance, managing aversive feeding behaviours).
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1 Background
Dementia: numbers and burden
• The world’s population is ageing, as 
improvements in public health and health care 
contribute to people living longer and healthier 
lives. However, this has resulted in a worldwide 
increase in the number of people living with 
chronic diseases, including dementia.
• The global epidemic of dementia can no longer 
be neglected and should be considered a public 
health priority in all countries.
• Dementia is a syndrome affecting memory, 
thinking, behaviour and the ability to perform 
everyday activities, usually chronic or 
progressive by nature, which is caused by a 
variety of brain illnesses, of which Alzheimer’s 
disease, vascular dementia, dementia with Lewy 
bodies, and frontotemporal dementia are the 
most common. Dementia is not a normal part of 
ageing.
• It is estimated that 44 million people worldwide 
live with dementia in 2013, with numbers 
doubling every 20 years, to reach 135 million by 
2050. Most of this increase will occur in low and 
middle income countries (LMIC); currently 62% 
of all people with dementia live in such regions, 
this proportion rising to 66% in 2030 and 71% in 
2050. 
• It is estimated that there are 7.7 million new 
cases of dementia each year worldwide, with 
one new case every four seconds.
• Dementia and cognitive impairment are by 
far the most important contributors, among 
chronic diseases, to disability, dependence, 
and transition into residential and nursing home 
care. Behavioural and psychological symptoms 
(BPSD) typically occur later in the course of the 
disease, have an impact on the quality of life of 
the old person and increase caregiver strain. 
• The total estimated worldwide cost of dementia 
in 2010 was US$ 604 billion, equivalent to around 
1% of global gross domestic product, of which 
about 70% was incurred in western Europe and 
North America. Costs of informal care and the 
direct costs of social care contribute similar 
proportions of total costs worldwide; while the 
direct costs of medical care are much lower. 
However, in low and middle income countries 
informal care costs predominate, accounting for 
up to two-thirds of all costs.
Malnutrition, undernutrition, and 
obesity: worldwide patterns of the 
‘double burden’
• Diet and nutrition play an important role in 
maintaining health and wellbeing. Diet can be 
defined as what we habitually eat and drink 
and is best conceived as a lifestyle. Nutrition 
encompasses the processes of ingesting 
and digesting foods, and absorbing and 
metabolising their nutrients. Adequate nutrition 
is essential for healthy living.
• Malnutrition comprises both overnutrition 
(excess food/calorie intake) and undernutrition, 
which is the depletion of body energy stores 
and loss of body mass (mainly lean mass). 
Malnutrition results mainly from eating an 
inadequate diet in which either the quantity 
and/or quality of nutrients does not meet the 
needs of our body. 
• Undernutrition (insufficient calories, protein or 
other nutrients needed for tissue maintenance 
and repair) is the most common nutritional 
problem, affecting up to 10% of older people 
living at home, 30% of those living in care 
homes, and 70% of hospitalised older people. 
The prevalence of undernutrition among 
older people in LMIC is likely to be even 
higher, particularly in rural and less developed 
settings, and increases with age.
• Consequences of undernutrition include frailty, 
reduced mobility, skin fragility, an increased 
risk of falls and fractures, exacerbation of 
health conditions, and increased mortality. 
Risk factors include the older person’s social, 
economic and environmental situation; 
problems with mouth, teeth and swallowing; 
mental, neurological and other chronic physical 
diseases; and side effects of long-term 
treatment with certain drugs. 
• With progressive globalisation of western 
dietary habits and lifestyles (e.g., underactivity 
and increased consumption of saturated fat, 
animal proteins and refined carbohydrates) 
obesity is now rising dramatically in low and 
middle income countries, especially in urban 
settings. Obesity also has important adverse 
consequences for health – it is a major risk 
factor for diabetes, cardiovascular diseases 
and cancer, and is the fifth leading modifiable 
risk determinant for global deaths.
Executive summary
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2 Nutrition and dementia 
across the life course
Key life course concepts: sensitive 
periods and accumulation
• Evidence suggests that the determinants of 
dementia risk impact across the life course in 
a manner comparable to several other chronic 
diseases of late life, sometimes with relatively 
long latent periods before the onset of clinical 
dementia syndromes.
• A life course approach to late-onset dementia 
may improve our understanding of the disease, 
and provide evidence on potential additive 
effects of exposures over time (‘accumulation’), 
and on ‘sensitive periods’ of life during 
which exposure to a risk factor may be more 
detrimental for dementia risk. 
• It is therefore possible that prevention should 
begin early in life and be concerned not only 
with the onset of dementia and its progression, 
but also with trajectories of cognitive ageing 
from mid-life, when impairment likely begins.
Nutrition for optimal brain/cognitive 
development
• Micronutrients and fat stores accumulated 
during intra-uterine life are important for 
brain and nervous system maturation and 
development, which may in turn influence risk 
of cognitive impairment and dementia in older 
age. 
• Brain reserve (enhanced structural or 
functional brain capacity) may buffer the 
effects of dementia-related neuropathology 
and explain the observed variability in the 
expression and severity of the dementia 
syndrome in people with comparable levels of 
neuropathology. The extent of brain reserve is 
likely to be influenced by a variety of genetic 
and environmental factors, including early life 
nutrition.
• Low birth weight and stunting in early life, 
indicating inadequate nutrition in utero or 
early life, are independently associated with 
lower cognitive abilities in adulthood. These 
associations may then track across the life 
course; among older people studied in diverse 
geographic regions and cultures, longer 
leg length and larger skull circumference 
(indicating favourable early development), were 
associated with lower dementia prevalence. 
Role of high adiposity  
(overweight/obesity)
• While larger birth weight and high (optimal) 
body size in childhood may be associated with 
better cognition, overweight and obesity are 
generally harmful for health, and may contribute 
to the neurodegenerative and cerebrovascular 
changes underlying late-life dementia. However, 
while the relationship between obesity and 
dementia-related brain damage is biologically 
plausible, its complexity makes mechanistic 
evidence hard to reconcile. 
• Obesity might, hypothetically, impact upon 
cognitive development, cognitive ageing, and 
dementia risk – all of these pathways have been 
assessed in cohort studies reviewed in detail in 
Chapter 2.
• Any associations between early life adiposity 
(childhood overweight and obesity) and 
cognitive function or impairment in mid-
life seem to be accounted for by a strong 
confounding effect exerted by childhood 
intelligence and educational achievement. 
• Cognitive decline that leads to dementia may 
begin in mid-life. Furthermore, higher levels 
of cognitive function in mid-life have been 
suggested to potentially act as a reserve to ward 
off the consequences of accumulated brain 
damage and reduce functional impairment. 
• Studies on the relationship between adiposity 
measured in young adulthood and cognitive 
function or cognitive decline in mid-life show 
heterogeneous results but seem to indicate that 
any potential detrimental effect of adiposity 
on mid-life cognitive function may be largely 
confounded. Increasing adiposity (BMI gain) 
in younger adults is also not related to worse 
cognitive ageing before older age.
• The existence of a causal association between 
mid-life adiposity and dementia is quite widely 
accepted. A recent systematic review of 
evidence from epidemiological cohort studies 
estimated a relative risk for Alzheimer’s disease 
(AD) associated with mid-life obesity of 1.60 
(95% CI 1.34–1.92). 
• There are several plausible underlying 
mechanisms, including; insulin resistance and 
hyperinsulineamia caused by high adiposity; 
metabolic and inflammatory cytokines released 
by adipose tissue; cardiovascular risk factors 
e.g. hypertension, linked to obesity; and 
cerebrovascular disease for which obesity is a 
prominent risk factor. All of these products or 
processes have direct effects on brain regions 
linked to dementia, and may be implicated in AD 
neuropathologies. 
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• Metabolic, cognitive and behavioural changes 
associated with dementia and its long mid- to 
late-life clinical prodrome can have an impact 
on risk factor profiles, complicating elucidation 
of the direction of any causal relationships. 
• The evidence, from three systematic reviews, 
suggests that the picture is complex. Findings 
for an association with mid-life body mass 
index (BMI) vary greatly across studies, and 
pooled estimates are strongly influenced by 
the positive findings from two large studies 
that relied largely upon ascertainment of 
dementia diagnosis by health services. Bias 
may have occurred since those who are 
obese are likely to be heavier users of health 
care, and are hence more likely to have their 
dementia detected. In one of the two studies, 
no attempt was made to control for education, 
a likely confounder associated both with 
obesity and dementia risk.
• Two more recent cohort studies, not included 
in these reviews, find no independent 
association of mid-life obesity with late-life 
dementia, any observed associations being 
confounded by sociodemographic factors.
• Given these methodological limitations, overall, 
the evidence on the association between high 
adiposity in mid-life and higher dementia risk is 
weak and remains highly conflicting. 
• The association between central obesity, 
measured by waist circumference, and 
dementia risk is less studied, but much 
more consistent. This finding supports 
the hypothesis of an underlying metabolic 
mechanism, because central adiposity, 
measured by waist circumference, is a better 
indicator than global adiposity, measured by 
BMI, of obesity associated-metabolic changes 
(insulin resistance and hyperinsulinaemia). 
• Our understanding of the complex relationship 
between adiposity and dementia could 
be improved by studies that investigate 
associations with dementia-related brain 
damage. However, evidence from longitudinal, 
prospective, population-based studies on this 
topic is scanty, and no studies have explored 
the association of mid-life BMI with brain 
atrophy and vascular lesions, the structural 
changes underlying dementia.
• Further research is warranted, because 
an improved understanding of the critical 
pathways that may lead from high adiposity to 
greater dementia risk could have a significant 
impact on targeting of primary prevention 
strategies. 
• The association between adiposity and 
dementia may be explained by underlying 
genetic and environmental factors that may 
influence lifelong adiposity trajectories, 
vascular risk profile, and late-life cognitive 
decline. 
• Childhood intelligence may play an important 
underlying role. Intelligence strongly 
influences the maintenance of a healthy 
lifestyle throughout life, and may also confer 
advantages in brain structure (brain reserve) 
and function (cognitive reserve), that can buffer 
the impact of brain damage in late-life and 
delay the symptomatic onset of dementia. 
Conclusion
• The relationship between fats and the brain 
is extremely complex. Fats may be harmful 
in mid-life if in excess, but could also be an 
important energy reserve that could improve 
resilience to the effects of dementia-related 
neuropathology and comorbidities in later 
life. The same factors that influence the 
accumulation of adiposity across the life 
course be implicated in the development and 
decline of cognitive function.
• More research is needed to elucidate the 
complex relationship between adiposity and 
cognitive function, cognitive impairment and 
dementia. The use of a life course approach in 
future studies is imperative. 
3 Nutritional factors and 
dementia prevention
• Dementia prevention is an urgent priority, both 
to reduce incidence and slow the progression 
of the condition. We need to identify important 
modifiable risk factors, particularly in the 
absence of any treatments that modify the 
course of dementia after its onset. 
• Epidemiologic evidence can inform dietary 
recommendations to reduce dementia 
risk, when associations are consistent and 
biologically plausible. However, the design and 
interpretation of such studies is complicated 
by the impact of dementia on dietary habits 
(reverse causality) and the link between general 
good health and healthier diets (confounding). 
Long-term longitudinal (cohort) studies are 
required to clarify possible causal links. 
• Experimental evidence from randomised 
controlled trials provides the best basis for 
guiding treatment and prevention strategies. 
However, given the long latent period between 
the beginning of complex pathophysiological 
mechanisms and the clinical, detectable onset 
of symptoms, definitive trials may be difficult 
8
to conduct particularly when treatment or 
prevention may need to be implemented in 
mid-life to delay or prevent dementia onset in 
late-life.
B vitamins 
• B vitamins, which play key roles in cell 
metabolism, cannot be synthesised in 
sufficient quantities and have to be acquired 
through diet. Vitamins B6 (pyridoxine), B9 
(folate) and B12 (cobalamin) have all been 
proposed to have protective effects on 
cognitive ageing.
• When folate or vitamin B12 are deficient, 
homocysteine levels rise, which predisposes 
to cardiovascular disease, and may contribute 
to amyloid and tau protein accumulation and 
neuronal death. Deficiencies in B12 and in folate 
increase with age. 
• The association between B vitamins and 
cognition has been the subject of several 
recent systematic reviews with further new 
studies published since then. 
• There is insufficient evidence, despite a large 
number of cohort studies, for an association 
between vitamin B6, folate or vitamin B12 
and cognitive decline or dementia. There is, 
however, consistent evidence that high levels 
of homocysteine are associated with cognitive 
decline. 
• Randomised controlled trials targeting 
elevated homocysteine levels have shown that 
supplementation with B vitamins (B6, B12 and 
folate alone or in combination) consistently 
reduces homocysteine levels, but without any 
significant effect on cognitive function. There 
is a suggestion from some studies that those 
with higher homocysteine levels at baseline, 
or clear and defined vitamin deficiencies may 
benefit from supplementation. However, this 
has not been clearly demonstrated, and more 
research is required.
Antioxidants
• Neural inflammation and oxidative damage 
are thought to be key mechanisms in the 
development of dementia. Oxidative stress 
directly damages cell components, resulting 
in damage to synapses and nerve cell death. 
Antioxidants are thought to act against 
neurodegeneration by limiting the production 
of toxic substances and reducing damage by 
free radicals. 
• Nutrients with antioxidant properties 
include vitamins C and E and flavonoids. 
Most research has focused on the potential 
protective effect of vitamin E.
• There is currently insufficient evidence from 
either longitudinal epidemiological studies or 
randomised controlled trials to support a role 
for antioxidants in cognition. 
• The only consistent associations were 
reported in epidemiological cohort studies 
that have assessed vitamin E status 
using food frequency questionnaires, 
rather than biochemical measures. Three 
randomised controlled trials failed to show 
any clear or consistent benefit of vitamin 
E supplementation on cognitive decline or 
dementia incidence among those with mild 
cognitive impairment. 
• One recent cohort study indicated a possible 
relationship between flavonoid consumption 
and cognitive decline, and one randomised 
controlled trial indicated possible benefits of 
flavonoid supplementation.
• No clinical trials were specifically limited 
to people with low levels of vitamin E/C or 
flavonoids. 
Omega-3 polyunsaturated fatty 
acids (PUFA)
• Omega-3 PUFA (polyunsaturated fatty acids) 
cannot be synthesised in the human body 
but are an essential dietary constituent, 
particularly for the brain. Over 22% of both 
the cerebral cortex and the white matter are 
made of phospholipids, and the function of 
neuronal cell membranes is modulated by 
their fatty acid composition. Dietary omega-3 
PUFA are also implicated in neuronal growth 
and influence synapse formations. Omega-3 
PUFA may be implicated in the vascular, 
inflammatory and also the amyloid pathways 
of dementia, and are therefore potentially 
important in vascular dementia, Alzheimer’s 
disease and mixed forms.
• The main food sources of omega-3 PUFA are 
‘oily fish’ such as salmon, mackerel, herring, 
sardines, fresh tuna, and swordfish.
• The evidence from epidemiological studies 
on the beneficial effects of fish consumption 
to prevent dementia incidence is conflicting, 
with no clear evidence for a protective effect. 
Confounding by healthy lifestyles and life 
circumstances (including socio-economic and 
educational level) that are associated both with 
higher fish consumption and lower dementia 
risk may explain positive results found in some 
studies.
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Conclusion
• Overall, there is currently insufficient evidence 
to confirm a relationship between the micro- 
and macronutrients described above (vitamin 
B6, vitamin B12, folate, vitamin C, vitamin E, 
flavonoids, omega-3, Mediterranean diet) and 
cognitive function. Although some studies have 
shown positive results, particularly those using 
cross-sectional designs, the findings have not 
been consistently supported in prospective 
cohort studies, and preventive interventions 
have generally failed the critical test of 
randomised controlled trials.
• The strongest and most consistent evidence to 
date is for the potential benefits of adherence 
to a Mediterranean diet. Implementing 
such an intervention on a large scale, and 
in a sustainable way, would be difficult. 
More intervention studies are needed to 
further understand the preventive role of the 
Mediterranean diet, and the active ingredients 
for improving cognitive function and reducing 
dementia risk. 
• A general limitation is that very few randomised 
controlled trials to date have targeted 
supplementation upon those who are deficient 
in the relevant micronutrient. 
4 Undernutrition in dementia
• Undernutrition and underweight are common 
problems in older people. Weight loss is 
associated with increased morbidity and 
mortality, and it also worsens the prognosis for 
several chronic diseases. 
Mechanisms
• Progressive malnutrition and weight loss 
are observed almost inexorably in dementia 
patients, resulting from an imbalance between 
nutrient/energy intake and needs. There are 
numerous potential mechanisms, divided into 
those that may cause a reduction in energy 
intake and those that may cause an increase 
in energy expenditure, which may act from 
as early as the pre-clinical and asymptomatic 
phase of the disease to the most advanced 
stages. 
• Evidence suggests that dementia-related 
brain atrophy may impact on brain regions 
implicated in appetite control and energy 
balance, with metabolism in these regions 
significantly reduced in dementia.
• Dietary habits are influenced by diverse 
factors, from food availability and preparation, 
to appetite, taste and feeding problems. 
• Evidence from experimental studies on 
the beneficial effects of omega-3 PUFA 
supplementation is insufficient to recommend 
their use in populations either for the 
prevention, or treatment of dementia. However, 
dietary recommendations to increase the 
amount intake of omega-3 PUFA from foods 
and the use of supplements in those who are 
deficient in these fatty acids is indicated for 
other reasons.
• There are some limitations in experimental 
studies conducted to date. Longer follow-ups 
may be needed to observe significant changes 
in cognitive function in primary prevention 
trials because changes in cognitive function 
were small in both the treated and placebo 
arms of existing trials. Inability to control fish 
consumption as part of the experimental 
design may have diminished the difference in 
total dietary omega-3 PUFA intake between 
those who were given the supplement and 
those who receive placebo. 
Mediterranean diet
• A Mediterranean diet (with high intake of 
cereals, fruits, fish, legumes, and vegetables) 
has been associated in some studies with 
reduced risk for cardiovascular disease, type 
2 diabetes, some forms of cancer and overall 
mortality. 
• Mediterranean diet could reduce the risk 
of dementia through its effects on the 
vascular system, reducing cardiovascular 
disease, by increasing the concentration of 
plasma neutrophins, which protect neurons 
against oxidative stress, or by limiting pro-
inflammatory cascades. 
• Moderate evidence from epidemiological 
studies suggests an association between 
adherence to the Mediterranean diet and 
reduced dementia risk. Not all the studies did, 
however, report positive findings, in particular 
regarding cognitive decline. 
• Only one study, the PREDIMED-NAVARRA 
randomised trial has attempted to test this 
association in an experimental design, by 
comparing a nutritional Mediterranean diet 
intervention supplemented with either extra-
virgin olive oil (EVOO) or mixed nuts, with a 
low-fat control diet. The intervention, lasting 
6.5 years showed encouraging results; 
participants that supplemented Mediterranean 
diet with EVOO but not with mixed nuts, had 
better cognitive function, and less incident mild 
cognitive impairment (MCI) than the control 
group (OR for MCI = 0.34, 95% CI 0.12–0.97). 
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• Close monitoring of body weight is very 
important in people with dementia, and should 
guide strategies to prevent and treat weight 
loss. 
5 Improving nutrition for 
people with dementia
• In considering strategies to improve the 
nutrition of people living with dementia it 
is important to consider care homes and 
hospitals, as well as the home setting. 
• There may be benefits from systems level 
interventions; for example a hospital or care 
home introducing staff training or changes 
to the environment, ambience and context in 
which food is provided; as well as individual 
approaches. 
• Studies have been conducted to assess 
the effect of four main types of intervention; 
training and education programmes for 
caregivers; mealtime environment or routine 
modification; nutritional supplements; and 
provision of feeding assistance.
• A structured assessment of the problem is the 
first step. Nutritional support (simple dietary 
advice, with assessment and management 
of risk factors, and attention to needs for 
feeding assistance) may suffice. If this fails, 
or in the case of more severe undernutrition, 
high-energy and/or high-protein oral nutritional 
supplements (ONS) may be a quick, reliable 
and generally well-tolerated way of improving 
nutritional status.
Nutritional assessment for people 
with dementia
• The continuous monitoring and surveillance 
of nutritional status is critical to plan, and 
evaluate the efficacy of nutritional interventions 
for people with dementia. The main types 
of nutritional assessment are: 1) dietary 
assessment, 2) weight history, 3) physical 
anthropometry, 4) screening questionnaires 
for nutritional status, 5) nutritional biomarkers 
and 6) eating and feeding behaviour. 
Anthropometric measures and screening 
questionnaires are most widely used. 
• Dietary assessment of food intake can be 
prospective or retrospective. Commonly used 
methods include 24-hour dietary recall, food 
frequency questionnaires and food records. 
Prospective methods require the diarised 
recording of foods and fluids consumed over 
a specified period of time, and can be carried 
out by a family member or care assistant.
Brain damage in general, and the cognitive 
and behavioural symptoms of dementia in 
particular, influence these factors and hence 
may impact on dietary habits in different ways 
at different stages of dementia.
• Aversive feeding behaviours are common, 
severely disrupting dietary intake, and making 
assistance at mealtimes indispensible and 
progressively more problematic. They also 
are, understandably, a source of considerable 
anxiety and strain for family caregivers.
Occurrence and dynamic of 
dementia-related undernutrition
• Numerous studies have investigated the 
association of dementia, or dementia severity 
with weight loss. 
• Evidence on the association between dementia 
and weight loss is compelling. Several 
epidemiological studies have confirmed 
that people with dementia experience a 
significantly more marked decline in body 
weight in older age, across high income 
countries and LMIC. This weight loss likely 
starts sometimes in late mid-life, and may even 
represent an early marker of disease.
• Several mechanisms may be implicated and 
are not fully understood. It is likely that causal 
pathways vary from the pre-clinical phase, to 
the clinical onset and through the severity of 
dementia. 
• Future studies should also investigate 
whether faster cognitive ageing in mid-life is 
associated with any weight loss before older 
age. Monitoring of weight change is highly 
recommended in people with dementia, and 
in older people. Further research is needed to 
determine whether monitoring in mid-life may 
also be beneficial for prevention.
Consequences of dementia-related 
undernutrition and weight loss 
• The consequences of weight loss and 
undernutrition in people with dementia are 
well characterised. Overall weight loss and 
undernutrition have a significant impact on 
the course of the disease, on both cognitive 
and functional symptoms, and on the overall 
clinical prognosis. 
• Weight loss may be part of the clinical 
expression of dementia, worsens the 
clinical course of dementia, leads to greater 
functional impairment and dependence, and 
increases the risk of morbidity, hospitalisation, 
institutionalisation, and ultimately mortality. 
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Education and training interventions
• Most caregivers understand that nutrition is 
an important component of the care that they 
provide. New skills must be learnt, and roles 
assumed, particularly for male caregivers who 
plan meals, shop for food and cook. 
• Spouse caregivers gradually assume decision-
making responsibility for what to eat, and 
when to eat it, where this may have previously 
been a shared activity. This can weigh heavily. 
Weight loss, and how to prevent or treat it 
is a preoccupation for many caregivers. As 
dementia evolves it is increasingly likely that 
aversive feeding behaviours develop, and 
that the person with dementia may need 
feeding assistance. Managing such problems 
is demanding of caregiver time, and requires 
patience, empathy and skill. 
• People living in care homes are more likely 
to have advanced dementia, and feeding 
dependence and aversive feeding behaviours 
are therefore more prevalent. Residents with 
dementia take longer to eat, require prompting 
and encouragement, and may have problems 
with coordination and swallowing. Mealtimes 
are a busy time for care assistants. Feeding 
a person with dementia can take up to 40 
minutes per resident.
• In a large US study of care home residents 
with dementia, 54% had low food intake, and 
51% had low fluid intake. In another study in 
up to a quarter of cases of advanced dementia 
with feeding difficulties the family was not 
satisfied with the assistance provided.
• There is no reason to assume that family 
caregivers, or indeed care assistants in 
care homes are naturally equipped with 
the knowledge and skills to assess and 
manage the often complex nutritional needs 
of a person with dementia. Education and 
training interventions targeting caregivers may 
therefore have an important part to play in 
decreasing negative outcomes and increasing 
quality of life.
• There are many excellent practical guides 
and sources of information for caregivers of 
people with dementia, one of which is the 
factsheet prepared by the UK Alzheimer’s 
Society ‘Eating and Drinking’ (http://www.
alzheimers.org.uk/site/scripts/download_info.
php?fileID=1799). This explains the importance 
of a healthy balanced diet, and the risks of 
weight loss in people with dementia. The 
contributions of cognitive problems, sensory 
deficits and aversive feeding behaviours are 
described, and strategies proposed to address 
them.
• A detailed weight history should be obtained 
along with current weight (a history of weight 
loss, whether intentional or unintentional, and 
over what period). Weight loss exceeding 5 kg 
(10lb) over six months is a red flag for further 
assessment.
• Body weight and height are the essential 
physical parameters. Body Mass Index (BMI) 
is the ratio of weight to height-squared (kg/m2) 
and is widely used to assess nutritional status. 
A BMI cut off of <18.5 kg/m2 defines adult 
chronic dietary energy deficiency. Overweight 
is defined as a BMI between 25 and 29.9 kg/m2 
and obesity as BMI ≥30 kg/m2. 
• Other simple physical assessments used to 
monitor nutritional status include triceps and 
truncal skinfold thickness, and mid-upper arm 
or calf muscle circumference. 
• Nutritional screening aims to identify 
those who are malnourished or ‘at risk’ of 
malnutrition, and composite screening tools 
have been developed, e.g. the widely used 
Malnutrition Universal Screening Tool (MUST) 
(http://www.health.gov.il/download/ng/
N500-19.pdf) and the six item mini nutritional 
assessment (MNA-SF®) http://www.mna-
elderly.com/
• Nutritional biomarkers are part of a 
comprehensive assessment of nutritional 
status of frail older persons. An initial screen 
might comprise haematology (full blood count 
with differential) and biochemistry (electrolytes, 
urea and creatinine, fasting glucose, albumin, 
and ferritin).
• Eating and feeding behaviour assessments are 
usually observer rated, and assess aversive 
feeding behaviours and feeding dependency 
(need for assistance). The most widely used 
and best validated measure is the 10 item 
Edinburgh Feeding Evaluation in Dementia 
Scale (EdFED), developed for those with 
moderate to late-stage dementia, and brief 
and simple enough to be used in routine care. 
It establishes the level and type of feeding 
disability and can be used to plan effective 
interventions.
• Measurements of energy expenditure 
(resting, physical activity and dietary) and 
body composition (fat and lean body mass) 
do not form a part of current routine clinical 
assessment. However, assessments are 
becoming cheaper and easier to perform, and 
such evaluations, in research, may help to 
identify mechanisms explaining weight loss in 
dementia. 
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• Training and education on diet and nutrition 
is generally appreciated by caregivers, and 
there is a clear need for support particularly 
when aversive feeding behaviours and 
feeding difficulties occur. It may be that 
basic information should be provided to all 
families, while more concentrated training 
and dietician services should be focused 
upon those developing feeding difficulties or 
undernutrition. 
Modifications to mealtime 
environment and routine
• In terms of experimental evidence, according 
to a recent systematic review applying 
standard criteria, ‘insufficient evidence’ 
exists to make clear recommendations 
regarding mealtime environment and routine 
modifications given the poor quality and limited 
quantity of trials (mostly small time-series 
comparisons).
• While poorly researched, this is currently a 
fertile area for innovation with successful 
advocacy driving forward change based to a 
large extent upon core principles, supported 
by some evidence and expert opinion. 
• The last 30 years have seen a gradual 
transition to flexible, individualised and 
person-centred care in care settings that more 
resemble households or homes. The four 
core design principles relate to their scale, 
the nature and use of space, the relationships 
between living areas, and creation of spaces 
that support the autonomy and independence 
of residents. Kitchen and dining areas are 
an important part of this broader design 
framework.
• ‘Households’ typically comprise 8–12 
residents, and the Life Safety Code Task 
Force has recommended 24 as the maximum 
feasible number. Household designs seek to 
replicate the living areas of houses, comprising 
resident rooms with bathrooms, a kitchen and 
dining area, and a living room or activity space.
• Large communal dining areas should be 
avoided, in particular for residents with 
dementia. It takes time to assemble residents, 
meaning that some will be left waiting for long 
periods for the meal to begin. Large dining 
spaces can be noisy and confusing, with too 
much sensory distraction, and do not provide 
the sensory cues that orientate a person with 
dementia to mealtime. 
• Smaller dining rooms can have a more intimate 
and familiar ambience, and reduce confusion 
as to the function of the room. Smaller dining 
rooms, ‘bright and welcoming’ colours, 
• We identified seven studies of education and 
training interventions. 
• In two Taiwanese studies, training was 
provided to people with dementia who were 
resident in care homes in an attempt to modify 
their feeding behaviours. Montessori-based 
activities (practicing hand-eye coordination, 
scooping, pouring, and squeezing, and 
distinguishing food from non-food items) 
were associated with a significant reduction 
in feeding difficulties with some evidence 
for reduced need for feeding assistance. In 
neither study was the intervention associated 
with improvements in weight, BMI or overall 
nutritional status.
• In two other studies, the intervention 
comprised education and training of 
professional caregivers in nursing homes or 
other long-term care facilities for people with 
dementia. While improvements were noted in 
staff knowledge, attitudes and behaviour, there 
was no increase in food intake in one study, 
while in the other study an improvement in 
intake was not associated with improvement 
in nutritional status of the residents with 
dementia.
• Education programmes for informal caregivers 
were evaluated in three studies, two 
randomised controlled trials, and a controlled 
non-randomised study. The format of the 
training programmes was similar, comprising 
group sessions conducted by a dietician or 
other health professional. Topics covered 
included; the importance of a healthy balanced 
diet; dietary challenges in dementia; monitoring 
food intake, weight and nutritional status; 
advice on enriching dietary protein and energy 
content; and strategies to manage aversive 
eating behaviours. The largest trial indicated a 
moderate positive benefit for overall nutritional 
status, but no change in weight. The other trial 
did indicate statistically significant weight gain, 
but with a smaller effect size than for another 
arm of the same trial that was randomised to 
oral nutritional supplement. 
• There is currently little or no evidence 
to suggest that training and education 
interventions, whether for paid care assistants 
in care homes, or for family caregivers of 
people with dementia, result in clinically 
meaningful improvements in the nutritional 
status of people with dementia. That is not to 
say that there may not be benefits. Surprisingly 
little research has been conducted in care 
homes, and evidence regarding training and 
education for family caregivers is dominated by 
one large well-conducted cluster-randomised 
controlled trial.
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• Residents should sit in chairs with arms that 
slide under the table, so that they can be close 
enough to focus their attention on eating. 
Tables should be high and broad enough to 
allow wheel chairs to be accommodated, and 
with no central columns or support structures 
to restrict access. 
• The creation of a ‘family-style’ eating 
environment with food served at table, more 
staff involvement and less distraction was 
associated with impressive improvements 
in energy intake, body weight, quality of life 
and physical performance in a large cluster-
randomised controlled trial in Dutch nursing 
home residents without dementia. A much 
smaller study of a similar intervention in 
cognitive impairment nursing home units 
in Canada showed similar results, and the 
greatest nutritional benefit was gained by the 
most cognitively impaired residents. 
Macronutrient oral nutritional 
supplementation (ONS)
• Oral protein and energy supplements are 
widely used in older people with undernutrition, 
or at risk of undernutrition, among whom their 
use is associated with significant weight gain, 
and a reduction in mortality for those who are 
undernourished.
• The main concerns associated with their 
use are problems with the willingness and 
ability of older people to consume them, the 
potential for gastrointestinal adverse effects, 
and the risk that the additional calories from 
the supplement may be more than offset by a 
compensatory reduction in customary diet.
• We conducted a review of studies identified 
in three previous systematic reviews, 
supplemented by a recently completed and 
unpublished systematic review of nutritional 
interventions for frail dependent older people 
(personal communication AT Jotheeswaran). 
Our objective was to identify all randomised 
controlled trials and controlled studies of 
oral nutritional supplements for people with 
dementia. 
• We identified six randomised controlled 
trials (RCTs) of ONS, one crossover trial, a 
controlled trial, and an RCT of micronutrient 
supplementation in which both arms received 
macronutrient ONS. All of the studies were 
small ranging from 33 to 99 participants. In all 
440 participants with dementia were included 
in placebo or other controlled comparisons 
of ONS, and pre-post within group data was 
available for 246 individuals receiving ONS. 
and other residential features (sideboards, 
paintings, objets d’art, use of a bulk re-
thermalization system in place of tray service) 
seem to be associated with increased food 
intake. Low food intake is less common in 
smaller assisted living and residential care 
facilities, in facilities with ‘non-institutional’ 
dining rooms, and where residents take their 
meals in public dining rooms.
• As a design principle for care homes, ideally, 
each room should have just one activity 
associated with it. For people with dementia 
it may be particularly important to have a 
dedicated dining room, the use of which is 
limited to meals and food. This should look like 
a dining room in a home, with recognisable 
furniture such as dining tables and sideboards. 
• The room can be a social hub throughout 
the day; for having coffee with friends after 
breakfast, inviting visitors to share food snacks 
from the kitchen between meals, and having 
afternoon tea with staff and residents. 
• ‘Eat-in-kitchens’ linked to dining areas help to 
involve residents in meal preparation. Kitchens 
evoke feelings of warmth, comfort and 
security. Linking the eating area with a kitchen 
stimulates all of the senses with the smell and 
sound of cooking, cueing that a meal is about 
to take place. Diffusion of food-preparation 
smells has been suggested to stimulate the 
appetite of people with dementia and to 
remind them of meal times. 
• Meals should be relaxed, unhurried and free 
from distraction. People with dementia find 
it difficult to concentrate on meals, and are 
sensitive to excessive noise and stimulation. 
Staff activities and other intrusions should be 
kept to a minimum and services areas (for food 
preparation and plating) should be outside the 
dining area. On the other hand, staff dining 
with residents may normalise the activity and 
foster person-centred care. For those with 
eating difficulties, quiet spaces free from 
distracting views can be helpful. 
• While distracting noise should be reduced, 
familiar background music may increase 
calorie consumption. 
• Good quality lighting is essential in dining 
areas so that older people with visual 
impairment can identify food and cutlery. In a 
study conducted in US care homes, increasing 
the light levels at table level led to an increase 
in food intake and feeding independence. A 
lighting intensity of 50 foot candles (540 lux) 
has been recommended for dining areas. Food 
consumption also increases when there is high 
contrast between the plate and table.
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this finding requires replication. While the 
standard recommendation from systematic 
reviews is that there is insufficient evidence to 
conclude either way on the possible benefits 
or harms of supplementation the evidence on 
cognitive impairment does seem conclusively 
null. 
• Two multi-centre RCTs conducted in the USA 
indicate some possible benefits of vitamin E 
supplementation in slowing clinical progression 
and/or functional decline in Alzheimer’s 
disease of mild to moderate severity. In the 
most recent trial all-cause mortality and safety 
analyses did not suggest increased rates of 
adverse outcomes in the vitamin E group. 
Medical foods
• Medical foods are defined as a special 
category of products that are intended for the 
dietary management of a disease or condition 
with distinctive nutritional requirements. 
Three medical foods have claimed to have 
benefits for people with dementia and are 
available in the USA and/or Europe: Axona® 
(AC-1202, Accera, Inc., CO, USA), Souvenaid® 
(Danone Research, France) and CerefolinNAC® 
(LA, USA). Randomised controlled trials of 
Souvenaid and Axona do not support any 
consistent or clinically significant cognitive 
benefit, and no studies have been reported 
regarding the efficacy of CerefolinNAC. 
Conclusion
• There is consistent evidence that 
macronutrient oral nutritional supplementation 
(ONS) is effective in maintaining or improving 
weight among people with dementia. 
Supplements are well tolerated, with high 
levels of adherence under controlled clinical 
trial conditions. 
• Nutritional benefit from ONS is proportionate 
to its intensity and duration, but benefits 
gained from short term supplementation, over 
weeks or months, is retained in the short to 
medium term. Hence brief cycles of ONS may 
be as effective as long-term supplementation.
• Most trials focused mainly on those who were 
at risk of undernutrition, or normally nourished. 
There is therefore an important outstanding 
question as to the effectiveness of ONS 
among people with dementia who are already 
undernourished. 
• Given the health hazards of undernutrition, 
particularly when this involves protein 
catabolism and loss of lean body mass, one 
might expect maintenance of nutritional status 
• Six of the studies were conducted in care 
homes or other long-stay accommodation, and 
three in the community. 
• Oral nutritional supplements provided were 
between 125 and 680 kcal per day, and 
were generally offered between meals and 
mainly in the morning to maximize adherence 
and reduce substitution. Duration of the 
intervention varied between three weeks and 
one year. Total calorie supplementation varied 
between 5,418 and 91,350 kcal. 
• There was strong evidence that ONS was 
effective in increasing weight (pooled mean 
difference in % weight gain across five studies 
= 3.43%, 95% CI 2.08–4.78) and body mass 
index (pooled mean difference across four 
studies 1.15 kg/m2, 95% CI 0.48–1.82).
• The % gain in body weight was proportional 
both to the daily calorie supplementation, and 
to the duration of ONS. 
• ONS was generally well tolerated, and the 
calorie value of supplements was not offset 
by a reduction in the usual diet from regular 
meals. 
• There was insufficient evidence to judge the 
impact of ONS on mortality among people 
with dementia (RR 0.69, 95% CI 0.00–1.46). 
No effect of ONS on cognitive function 
was observed in three RCTs, while in one 
non-randomised controlled study cognitive 
deterioration was more marked in the ONS 
intervention group. No benefit of ONS on 
activities of daily living was observed in five 
studies.
Micronutrient supplementation 
• Micronutrient deficiencies are relatively 
common among older people, due to 
insufficient dietary intake, inefficient 
absorption, or both. Low levels of vitamin 
B12 and folate (folic acid) are associated with 
high blood levels of homocysteine which has 
been linked with the risk of arterial disease, 
dementia and Alzheimer’s disease (AD). 
Evidence that free radicals may contribute 
to the pathological processes of Alzheimer’s 
disease has led to interest in the use of vitamin 
E, which has antioxidant properties, in its 
treatment. 
• There was no evidence, from several RCTs that 
supplementation with either folate or vitamin 
B12, alone or in combination has any beneficial 
effects on cognitive function in people with 
dementia. In one trial, those randomised to 
folate were much more likely to be considered 
as ‘treatment responders’ to cholinesterase 
inhibitors (OR 4.06, 95% CI 1.22–13.53), but 
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then watched the videos with the staff and 
explained what was happening. 
• Dr Acosta provided caregivers with tools to 
assess cognitive and functional impairment, 
and identify and classify feeding behaviours 
and needs for feeding assistance. ‘In other 
words, I went with them, the staff, through a 
process of informal education about dementia, 
the course of dementia, and feeding and eating 
problems through the illness’. In private homes, 
both the paid caregiver and the main family 
caregiver were involved in the same education 
process. 
• Dr Acosta then worked with nursing home 
staff and home caregivers to find approaches 
to help improve ‘eating time’ without incurring 
additional expense. The lessons learnt from 
this programme were that:
 − The enthusiasm and active involvement of the 
staff in the process was crucial. They began 
to give ideas as to how to improve each 
patient’s behaviour and were very creative in 
their suggestions. 
 − Categorising the behaviour was an essential 
first step in order to plan and implement 
measures to help it. 
 − The measures can be very simple, not costly, 
and some of them were quite effective (see 
Chapter 5 for details). 
 − The education and the positive attitude of 
the feeder were crucial in determining the 
success of the intervention. The education 
of those involved, about eating and feeding 
in patients with AD, helped to reduce the 
neglect of this essential aspect of care. 
 − Not all people with dementia would have 
equal needs for calorie intake - think of 
hunger as a possible explanation for those 
residents who screamed or otherwise 
vocalised distress. 
 − As well as calorie intake, staff needed to 
be taught about the importance of offering 
liquids often, and to avoid fluid restriction 
with the intention of avoiding incontinence or 
frequent diaper changes. 
Assistive tableware
• Research by a Royal College of Art design 
team revealed that assistive tableware was 
not used as much as it might have been in UK 
care homes. Some care home managers opted 
not to use it because of a lack of aesthetic 
appeal. Since residents had different needs 
and abilities, and assistive tableware stood out 
from standard items, users of assistive table 
settings felt different, and stigmatised. 
with ONS to be associated with wider health 
benefits than those identified in the studies 
reviewed. This may be due to the short period 
of nutritional support and follow-up (disability, 
mortality), and the failure to assess relevant 
outcomes (quality of life, depression, physical 
functioning).
• There is, as yet, no evidence to recommend 
the use of micronutrient supplementation 
at any stage of dementia. The possible 
exception to this advice is that of vitamin E 
supplementation given two positive trials with 
respect to cognitive and functional decline 
outcomes, although the balance of risks and 
benefits need to be more clearly established. 
• There is currently no evidence to support 
the widespread screening for folate and 
B12 deficiency enshrined in many good-
practice post-diagnostic recommendations. 
Supplementation does not seem to 
affect cognitive function, and the cost-
effectiveness of these non-evidence based 
recommendations needs to be established in 
RCTs. 
• There is currently insufficient evidence to 
recommend the use of any medical foods 
currently marketed for the treatment of 
Alzheimer’s disease, and some evidence 
to suggest that they do not confer clinically 
significant cognitive benefit. 
• Given the strong theoretical basis for 
micronutrient supplementation, it is under 
researched, with relatively few trials, most of 
which are small and underpowered, do not 
focus upon those with proven micronutrient 
deficiency, and have relatively short follow-up 
periods. 
Feeding Assistance – managing 
aversive feeding behaviours in 
advanced dementia
• A case study from the Dominican Republic 
demonstrates the importance, and the 
feasibility of managing aversive feeding 
behaviours, through training paid caregivers 
of people with dementia, whether domestic 
workers (hired originally to clean the house 
and prepare food), or care assistants in 
nursing homes. Neither the behaviours, nor the 
consequent weight loss were recognised as 
part of the illness.
• Dr Daisy Acosta obtained consent to videotape 
several settings; private homes, nursing 
homes and state nursing homes; identifying 
the different types of eating behaviours and 
how the staff reacted and handled them. She 
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and attempts to remove the tubes, which may 
lead to sedation being given.
• Advanced eating and swallowing problems 
need to be seen more in the context of holistic 
palliative end-of-life care. Communication and 
shared decision-making are key factors, and 
having trust in doctors and surrounding staff is 
essential for patients and caregivers. However, 
many nurses and care home staff do not feel 
confident with issues related to end-of-life and 
dying with dementia, and there is a need to 
improve training.
Summary and conclusion
• Micronutrient and macronutrient (protein and 
energy) deficiency are common in dementia 
and Alzheimer’s disease, and it is clear that 
undernutrition has important consequences 
for health, quality of life and survival. Loss of 
body weight seems on the one hand to be a 
natural part of the condition, with complex 
multifactorial determinants, and yet to be 
amenable to intervention. 
• Standard recommendations for dietary 
management in dementia emphasise the role 
of dietary advice including fortification of 
existing diet to boost the protein and energy 
content, before resorting to oral nutritional 
supplements (ONS). Boosting calorie intake 
should improve nutritional status, and doing 
this through natural foods is likely to be more 
appealing than supplements, which can be 
costly. However, the evidence to support 
the efficacy, safety and tolerability of ONS is 
particularly strong, and this may be the most 
reliable means of restoring nutritional balance.
• Therefore, while dietary advice and food 
fortification can be tried first, ONS should be 
implemented without delay if this approach 
fails to improve nutritional status. This is 
particularly the case for those with established 
undernutrition.
• Given the relative lack of large definitive long-
term trials in this area, there are still some 
important questions to be resolved:
 − Should those with undernutrition receive 
continuous ONS (and is this feasible and 
acceptable), or is short interval ONS equally 
effective and more acceptable?
 − Is ONS as effective for those with 
undernutrition as for those at risk of 
undernutrition? 
 − Is long-term ONS associated with net benefits 
for cognition, functional status, depression, 
quality of life, and survival?
• The aim of the design team was to create a 
range of matching tableware that formed a 
complete set, could be used by people of all 
abilities, and resembled standard domestic 
tableware. 
• Colour contrasts help to distinguish food from 
the plate upon which it is placed, and from the 
table covering. The same approach can be 
used to highlight the handle of a cup and its 
rim. 
• Special plates with high lips were designed to 
assist those eating pureed or diced food with 
just a plate and spoon. 
• The ‘care cup’ is one of the most disliked 
assistive tableware items, because of its 
similarity in appearance to a baby product 
(made from plastic with two handles and a 
nippled lid). The design team normalised this 
product by crafting it in ceramic but with a 
double skin to insulate the heat and prevent 
burning. The lid minimises the association to 
the nipple of a baby cup by elongating the form 
around the rim.
• The tableware includes items designed 
specifically for use with assisted feeding, 
including a plate, a bowl and lids for cups. The 
items are reduced in weight, and designed so 
that they can be easily and securely grasped 
by the carer, with one hand. The plate allows 
the carer to orientate it in an ‘offering position’ 
(in the sensory range of the person being fed 
so that they can see and smell what they are 
eating). 
Managing oropharyngeal dysphagia 
in advanced dementia through 
enteral tube feeding
• Problems with swallowing are common in 
advanced dementia. However, the use of 
nasogastric or percutaneous endoscopic 
gastrostomy (PEG) feeding tubes, while 
widespread, is controversial, and needs to be 
evaluated carefully with respect to patient and 
caregiver preferences, and the balance of risks 
and benefits for individual patients. 
• A Cochrane systematic review suggests that 
tube feeding for people with dementia does 
not confer any benefit regarding nutritional 
status, reduction of pressure sores, mortality 
risk or survival time. 
• Families and health professionals often have 
unrealistic expectations of the outcomes of 
tube feeding. Potential for harm exists from an 
increase in urinary and faecal incontinence, 
leading to pressure sores; from discomfort, 
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feeding behaviours, and the benefits of 
focused support and training interventions 
needs to be evaluated in this group. 
• Dietary advice should remain a standard 
recommendation. There is a clear demand 
from caregivers for advice and support, 
particularly with aversive feeding behaviours. 
There has been remarkably little research 
into nutritional training and education of care 
assistants in long-term care facilities, with 
many anecdotal examples of potential benefit.
• While many people with dementia use 
micronutrient supplements, there is little 
or no evidence of any benefit as regards 
progression of the condition. On the current 
evidence, the recommendation would be that 
these supplements should not be used for 
the treatment of Alzheimer’s disease or other 
forms of dementia. B12 or folate deficiency, 
if identified, should be corrected. However, 
the overall cost-benefits of screening for 
these deficiencies in all patients with newly 
diagnosed dementia are not established, and 
current recommendations are not based on 
evidence. 
• Very few older people are deficient in vitamin 
E. However, hypersupplementation of this 
vitamin (2000 IU total daily) does seem to be 
associated, in two randomised controlled 
trials, with slower progression of the cognitive 
and functional impairment of Alzheimer’s 
disease. However, these doses are 100 times 
higher than the recommended daily allowance 
to maintain vitamin E levels and exceed the 
tolerable upper intake level. Excess intake of 
vitamin E, particularly over the longer term may 
be associated with bleeding and haemorrhagic 
stroke. Therefore the use of this agent cannot 
be recommended until more data is available 
on the balance of risks and benefits. 
• There is strong evidence, although not from 
randomised controlled trials, that systems 
level interventions, for example small scale 
household level dining, ‘family style’ eating 
arrangements, and use of appropriate 
tableware and lighting levels may be 
associated with increased calorie consumption 
and increases in weight. Much more work 
needs to be carried out into the effectiveness 
of assistive feeding interventions to address 
aversive feeding behaviours.
• Although much of the work on nutritional 
interventions has been carried out in long-
term care facilities, many of the findings are 
generalisable to home care by informal carers. 
This would include the benefits of ONS (and 
the relative inefficacy of dietary advice alone), 
the importance of a home dining environment, 
and including the person with dementia as 
part of the family social dining activity. Many 
informal caregivers struggle with aversive 
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Chapter 1 Background
The world’s population is ageing. Improvements in 
health care in the past century have contributed to 
people living longer and healthier lives. However, this 
has also resulted in an increase in the number of people 
with non-communicable diseases, including dementia. 
There is lack of awareness and understanding of 
dementia, at some level, in most countries, resulting 
in stigmatisation, barriers to diagnosis and care. 
The condition impacts upon caregivers, families and 
societies physically, psychologically and economically. 
Dementia can no longer be neglected and should 
be considered an important part of the public health 
agenda in all countries.
lesions present in the brain and the severity 
or the symptoms of dementia is not clear. The 
co-existence of other conditions, especially 
cerebrovascular disease, may be important. 
Dementia and cognitive impairment are by far 
the most important contributors, among chronic 
diseases, to disability, dependence, and, in 
high income countries, transition into residential 
and nursing home care1. The behavioural and 
psychological symptoms (BPSD) linked to 
dementia, typically occurring later in the course of 
the disease, also have an impact on the quality of 
life of the old person and are an important cause 
of caregiver strain. Dementia is overwhelming 
not only for the people who have it, but also for 
their caregivers and families. Around half of all 
people with dementia need personal care (and 
the others will develop such needs over time)1. 
Compared with other chronic conditions, the need 
for care and supervision typically develop early 
in the course of the condition, and intensify over 
time, leaving those with more advanced dementia 
completely reliant on caregivers for their basic 
needs1.
Prevalence of dementia
The coming global epidemic of Alzheimer’s 
disease and other types of dementia is 
recognised by the World Health Organization 
as a public health priority 2,3. It is estimated in 
2013 that 44.35 million people worldwide live 
with dementia, with numbers affected doubling 
Dementia: numbers and burden
What are dementia and cognitive 
impairment? 
Dementia is a syndrome affecting memory, 
thinking, behaviour and the ability to perform 
everyday activities, usually chronic or progressive 
by nature, which is caused by a variety of 
brain illnesses. Cognitive impairment, which 
includes the more operationalised category of 
‘Mild Cognitive Impairment’ (MCI), describes 
measurable deficits in one or more cognitive 
abilities (e.g. memory, planning, language, 
attention or visuospatial skills) which may be 
noticeable to the older person or those around 
them, but do not yet interfere substantially with 
everyday living. When the impact on everyday 
abilities is significant, this may suggest dementia. 
Whilst dementia mainly affects older people, 
it is not a normal part of ageing. Although the 
prevalence is high among the “oldest-old”, most 
do not have dementia. At the same time, there 
is a growing awareness of ‘young onset’ cases 
starting before the age of 60 years.
Dementia is linked to several underlying brain 
pathologies, of which Alzheimer’s disease, 
vascular dementia, dementia with Lewy-Bodies, 
and frontotemporal dementia are the most 
common. The boundaries between the subtypes 
can be difficult to define, and mixed forms 
exist. The relation between the pathological 
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every 20 years, to reach 135.46 million by 20504. 
Much of the increase is attributable to increases 
in the number of people with dementia in low and 
middle income countries (LMIC); currently 62% of 
all people with dementia live in such regions, this 
proportion rising to 66% in 2030 and 71% in 2050.
The epidemic is driven mainly by population 
ageing, given the strong association with older 
age; consistently across regions, dementia 
prevalence increases exponentially with age, 
doubling with every five to six year increment3.
Incidence of dementia
The latest systematic review on the incidence of 
dementia included 34 studies, of which 16 had 
been conducted in Western Europe, five in North 
America, four in East Asia, six in Latin America 
and the Caribbean, one in Australasia, one in the 
Asia-Pacific region and one in West Sub Saharan 
Africa. Summarising the evidence from all studies, 
the incidence of dementia increases exponentially 
with increasing age, from 3.1 per 1000 person 
years at age 60–64 to 175.0 per 1000 person 
years at age 95+ 2. While the incidence appears 
to be somewhat higher in high income countries 
than in LMIC this effect is no longer apparent 
when the 10/66 Dementia Research Group’s* 
cross-culturally validated dementia diagnosis was 
applied to the studies that the group conducted 
in LMIC. It is estimated that there will be nearly 
7.7 million new cases of dementia each year 
worldwide, implying one new case every 4 
seconds. The majority of new cases will arise in 
LMIC: 3.6 million (46%) in Asia, 2.3 million (31%) in 
Europe, 1.2 million (16%) in the Americas, and 0.5 
million (7%) in Africa.
Costs of dementia
The total estimated worldwide cost of dementia 
in 2010 was US$ 604 billion, equivalent to around 
1% of global gross domestic product, of which 
about 70% was incurred in Western Europe 
and North America5. Costs of informal care 
(unpaid care provided by families and others) 
and the direct costs of social care (provided by 
community care professionals and in residential 
home settings) contribute similar proportions 
(42%) of total costs worldwide; while the direct 
costs of medical care are much lower (16%). 
However, in low and middle income countries 
where formal care services are not well developed 
direct social care costs are negligible and informal 
*  The 10/66 Dementia Research Group is a collective of 
researchers carrying out population-based research into 
dementia, non-communicable diseases and ageing in 
low and middle income countries. More information on: 
http://www.alz.co.uk/1066/
care costs predominate, accounting for up to two-
thirds of all costs. 
Malnutrition, undernutrition, and 
obesity: worldwide patterns of the 
‘double burden’
Diet and nutrition play an important role in 
maintaining health and wellbeing. You are, after 
all, what you eat. Diet can be defined as what 
we habitually eat and drink. Diet is thus best 
conceived as a lifestyle and plays a relevant role 
in both morbidity and mortality. This is because 
diet is critical for nutrition, although there are non-
nutritive compounds in foods, often referred to 
as phytochemicals, which are likely, beneficial to 
health too.
Nutrition can be simply defined as the use of 
foods that humans (and all living organisms) make 
in order to live and maintain their health. Nutrition 
encompasses the processes of ingesting and 
digesting foods, and absorbing and metabolising 
their nutrients. It is implicated in the provision of 
water, micronutrients (i.e., vitamins and minerals), 
macronutrients (i.e., carbohydrates, proteins and 
lipids), and energy. These components are used 
by the human body to build and maintain tissues, 
and to allow its optimal functioning, hence 
adequate nutrition is essential for healthy living.
Malnutrition comprises both overnutrition (excess 
food/calorie intake) and undernutrition, which is 
the depletion of body energy stores and loss of 
body mass (mainly lean mass). Malnutrition results 
mainly from eating an inadequate diet in which 
either or both quantity and/or quality of nutrients 
do not meet the needs of our body. Health 
status influences diet, and several diseases 
may concomitantly lead to excess losses of 
micronutrients and increased energy expenditure, 
which can also cause and exacerbate 
malnutrition.
Undernutrition (insufficient calories, protein or 
other nutrients needed for tissue maintenance and 
repair) is the most common nutritional problem, 
affecting up to 10% of older people living at home, 
30% of those living in care homes, and 70% of 
hospitalised older people. Evidence from studies 
conducted in low and middle income countries is 
more limited, but the prevalence of undernutrition 
in older people is likely to be even higher, 
probably linked to poverty and food insecurity. 
In studies conducted in sub-Saharan African 
countries between 11.5% and 40.0% of 65 years 
and over had a body mass index (BMI) <18.5, 
indicating undernutrition6–9. In the 10/66 Dementia 
Research Group studies in Latin America, India, 
China and Nigeria the prevalence of undernutrition 
indicated by low arm circumference (≤23.5cms) 
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ranged from 0.5% in China to 53.9% in rural India. 
Prevalence was higher in less developed and rural 
settings, and increased with age (Figure 1.1).
Consequences of undernutrition include frailty, 
reduced mobility, skin fragility, an increased 
risk of falls and fractures, exacerbation of 
health conditions, and increased mortality10,11. 
Risk factors include; the older person’s social, 
economic and environmental situation; problems 
with mouth, teeth and swallowing; mental, 
neurological and other chronic physical diseases; 
and side effects of long-term treatment with 
certain drugs12. Older people are also at risk of 
micronutrient deficiency (vitamins and minerals, 
needed in small quantities), often as part of a 
generally inadequate diet, but also seen in normal 
weight or obese people due to lack of meat, 
dairy products, or vegetables in the diet. Calorie 
requirements decrease with age but nutrient 
needs either remain the same or even increase 
in some cases. Thus, meeting the nutritional 
requirements of older adults is a challenge, even 
for those that eat what we would consider an 
adequate diet.
With globalisation and rapid social and 
economic development, many low and middle 
income countries are now facing a “double 
burden” of disease. While they continue to deal 
with the problems of infectious disease and 
undernutrition, they are experiencing a rapid 
upsurge in non-communicable disease risk 
factors including obesity, particularly in urban 
settings. Rapid societal and lifestyle changes 
are progressively modifying indigenous dietary 
and lifestyle habits, and driving the assimilation 
of westernised habits (e.g., increased physical 
inactivity and consumption of saturated fat, 
animal proteins and refined carbohydrates)13. 
It is not uncommon to find undernutrition and 
obesity existing side-by-side within the same 
country, the same community and the same 
household14. Overweight and obesity (abnormal 
or excessive fat accumulation that presents 
a risk to health) are major risk factors for 
several chronic diseases, including diabetes, 
cardiovascular diseases and cancer, and is the 
fifth leading modifiable risk determinant for global 
deaths14. The main cause of obesity is an energy 
imbalance between calories consumed and 
calories expended. Globally, there has been an 
increased intake of energy-dense foods that are 
high in fat and an increase in physical inactivity 
(increased sedentary nature of many forms of 
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Figure 1.1 
Prevalence of undernutrition (arm circumference ≤23.5cms) in the 10/66 studies, by age group
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work, changing modes of transportation, and 
increasing urbanisation). Obesity in the elderly will 
be an increasing problem in the coming decades. 
In Europe, several studies already reported a 
prevalence ranging from 18% in France15, 18–20% 
in the Netherlands16 and 35% in Spain17 among 
the old population (above 60/65 years) while the 
European Prospective Investigation into Cancer 
and Nutrition (EPIC), with participants aged 
40–65 years in 1996, predicted a prevalence 
of obesity of about 30% in 201518. In the US, it 
was estimated that the prevalence of obesity in 
older Americans aged 60 years and older, would 
increase from 32.0% in 2000 to 37.4% in 201019. 
Once considered a problem only in high income 
countries, overweight and obesity are also now 
rising dramatically in low and middle income 
countries, especially in urban settings.
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Key life course concepts: 
‘sensitive periods’ and 
‘accumulation’
The study of how risk and protective factors 
dynamically interact to influence later 
disease outcomes is referred to as life course 
epidemiology 1. Accumulating evidence suggests 
that dementia has a lifelong trajectory in a manner 
comparable to several other chronic diseases 
of late life, with risks clustering around specific 
developmental epochs and often accumulating 
in their effects, sometimes with relatively long 
latent periods before onset of clinical dementia 
syndromes 2.
For instance, it has been observed that while 
mid-life vascular risk factors, including high blood 
pressure and high adiposity may increase the 
risk of dementia in late life 3, declining values of 
blood pressure and body weight after midlife 
are also associated with dementia, possibly 
in relation to underlying disease processes. 
Because dementia-related neuropathology likely 
begins decades prior the symptomatic onset of 
the disease 4, issues related to directionality are 
not easily disentangled and the age at which 
exposure to a putative risk factor is measured 
is clearly crucial. A life course approach to late-
onset dementia may improve our understanding 
of the disease 5, 6, and create evidence on 
potential additive effects of exposures over time 
Chapter 2 Nutrition and dementia 
across the life course
Nutrition can influence our risk of developing dementia, 
and our chances of ‘living well with dementia’ if we 
develop the disease. 
•  Good nutrition contributes to healthy brain 
development, which may protect against the onset of 
dementia in late life.
•  Obesity in midlife and diets rich in saturated fat, which 
predispose to cardiovascular disease, may increase the 
risk of developing dementia in late life.
•  The onset of dementia is associated with a decade-
long gradual decline in body mass. 
• Maintaining an adequate diet is challenging for people 
with dementia, leading to a particularly high prevalence 
of undernutrition.
This chapter explores the latest evidence on the 
complex relationship between nutrition and dementia 
across the life course.
(‘accumulation’), and on ‘sensitive periods’ of life 
during which exposure to a risk factor may be 
more detrimental for dementia risk. This could 
have a considerable impact on prevention. At 
present there are significant design and analytical 
challenges that limit the feasibility of life course 
epidemiological studies of dementia and cognitive 
decline. Besides, controversial conceptual 
and methodological issues exist in life course 
epidemiology relevant to the causal inference 
debate in epidemiology 7, 8. As far as dementia 
is concerned, these issues are the contentions 
that prevention should begin early in life and be 
concerned not only with the onset of dementia 
and its progression, but also with trajectories of 
cognitive ageing from mid-life, when impairment 
likely begins 9.
Nutrition for optimal brain/
cognitive development
Micronutrients and fat stores accumulated during 
intra-uterine life, particularly between the 35th 
and 40th weeks of gestation, are chiefly important 
for brain and nervous system maturation and 
development that occur primarily up until age 
five 10. In turn brain development may influence 
risk of cognitive impairment and dementia in 
older age 11. Post-mortem studies have shown 
that people with evidence of the pathological 
hallmarks of Alzheimer’s disease in their brains 
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(i.e., amyloid plaques and fibrillary tangles) 
may yet have shown no signs of cognitive 
impairment or dementia up to the time of death 12. 
Hence, brain reserve, the number of neurons 
and synapses (for which brain size may be a 
marker), may buffer the effects of dementia-
related neuropathology and explain the observed 
variability in the expression and severity of the 
dementia syndrome in people with comparable 
levels of neuropathology. Brain reserve is likely to 
be influenced by a variety of factors, both genetic 
and environmental, including early life nutrition.
Evidence suggests that low birth weight, a 
marker of inadequate nutrition in uterus, may 
be associated with lower cognitive level in both 
childhood and adulthood 13. Persistent insufficient 
nutrient intake in early infancy slows growth 
and causes low height for age (stunting) that 
tracks through young adulthood and results in 
shorter legs for total height. Therefore having 
shorter legs relative to total height in adulthood is 
considered a valid proxy of early life inadequate 
nutritional level. Evidence from the 1946 British 
birth cohort study suggests that height in early 
life is positively associated with cognitive function 
in adolescence independently of birth weight 14. 
These associations may track across the life 
course and influence risk for dementia onset, as 
suggested by the finding in the 10/66 study that 
longer leg length and larger skull circumference 
were associated with lower dementia prevalence 
amongst over 15,000 older people studied in 
diverse geographic regions and cultures in Latin 
America, China and India 15.
While larger birth weight and high (optimal) body 
size in childhood may be associated with better 
cognition, overweight and obesity that result 
from an excess of nutrient/energy intake and/
or reduced physical activity level are notoriously 
harmful for health. Overweight and obesity 
are associated with higher mortality risk and 
reduced life expectancy 16, and may contribute 
to neurodegenerative and cerebrovascular 
changes underlying late-life dementia through 
both vascular and metabolic pathways 17. These 
issues are spreading worldwide to epidemic 
proportions 18, and if their link with dementia 
should be proved to be causal, the public health 
impact would be tremendous. Luchsinger and 
Gustafson have proposed several potential linking 
mechanisms, emphasising the continuum of high 
adiposity, hyperinsulinaemia, and non-insulin 
dependent diabetes (type 2 diabetes) 19 – Box 2.1. 
However, although the relationship between 
obesity and dementia-related brain damage is 
certainly biologically plausible, its complexity can 
be problematic, making mechanistic evidence 
hard to reconcile. For instance, prolonged 
exposure to high levels of pro-inflammatory 
molecules (i.e. Tumor Necrosis Factor-α and 
Intereleukin-6) produced by adipocytes (where 
body fat is stored) may affect the brain directly. 
Nevertheless, high levels of leptin, an important 
cytokine produced in the adipose tissue, seem 
to enhance cognitive function 20, 21 and may 
have neuroprotective effects 22. The association 
between fat cell metabolism and brain damage is 
complex, and is further complicated by the fact 
that some neuropathologic changes in the brain 
that build up several years before the clinical 
onset of dementia may be associated with weight 
loss 23. 
In the next section of this chapter we focus 
on high adiposity before older age, and report 
Box 2.1
Links between adiposity and 
cognitive impairment
Mechanisms that may link adiposity to 
cognitive impairment and dementia, revised by 
Luchsinger and Gustafson17
Hyperinsulineamia – Insulin resistance and 
hyperinsulineamia are caused by high adiposity. 
Excess of insulin can have direct effects in the brain, 
for instance it may interfere with the clearance of 
amyloid and contribute to brain damage. 
Advanced glycosylation end products 
(AGEs) – AGEs are produced in excess in diabetes 
and are responsible for the end organ damage. 
AGEs have been found both in amyloid plaques 
and in fibrillary tangles; the glycation of amyloid 
oligomers enhances their aggregation into insoluble 
plaques seen in Alzheimer’s disease, and may 
facilitate neuronal damage.
Adipokines and cytokines – The adipose 
tissue produces inflammatory cytokines (which 
may increase the brain inflammatory state), and 
acts as an endocrine diffuse organ too. Adipokines 
(adiponectin, leptin, and resistin) have direct effects 
on brain regions implicated in dementia (e.g., the 
hippocampus), and may affect cognitive function. 
Vascular risk factors – Obesity is associated 
with several vascular risk factors including lower 
physical activity, poorer diet and higher blood 
pressure. These vascular risk factors are associated 
with dementia and may thus mediate the effect of 
adiposity.
Cerebrovascular diseases – Adiposity 
may increase dementia risk also through 
cerebrovascular disease (diffuse and focal vascular 
damage) and stroke, which are strongly associated 
with dementia. 
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the main conclusions of available systematic 
reviews and any new research in which the effect 
of mid-life adiposity as a potential risk factor 
for dementia was the question under study. In 
Chapter 4 we will address this association in the 
opposite direction, that is dementia-associated 
undernutrition, particularly weight loss; reviewing 
and commenting on studies that focused on 
adiposity in late-life, or investigated the natural 
history of weight or BMI changes from mid- to 
late-life as a function of a later dementia diagnosis 
(or of measures of brain damage). 
Role of high adiposity 
(overweight/obesity)
When energy ingested is greater than energy 
expended, fat is stored in adipose tissue. The 
term adiposity is used to indicate the total 
amount of adipose tissue, and adiposity is 
considered to be excessive when it adversely 
affects health. To measure the level of excess 
adiposity in populations, measures of body 
weight and height are combined using a simple 
formula to calculate body mass index (BMI, 
weight in kilograms divided by height in meters 
squared, i.e. kg/m2). Overweight and obesity 
are commonly used terms to refer to excess of 
adipose tissue. In adults, a BMI between 25 and 
29.9 kg/m2 indicates overweight, and BMI equal to 
or greater than 30 kg/m2, obesity 24. BMI is widely 
used as a reliable clinical measure of both global 
and central adiposity in population as well as in 
clinical settings 25. However, BMI cut points for 
overweight and obesity are less clear in older age 
due to physiologic changes in body composition 
with a progressive decrease of lean compared 
to fat mass 26. Waist circumference, a measure 
of central adiposity, is also commonly used to 
measure adiposity, and is a valid indicator of the 
associated metabolic changes. Cut-offs of waist 
circumference of 102 cm for men, and 88 cm for 
women predict adiposity-associated negative 
health consequences 27. Waist circumference 
measures are more prone to measurement error 
and cannot be self-reported (whereas height 
and weight are commonly known). In addition, 
waist circumference may underestimate the so-
called gynoid fat distribution characterised by a 
preferential accumulation of body fat in the limbs 
and lower body depots. 
The association between adiposity and ensuing 
dementia is biologically plausible, and of great 
potential public health relevance. The existence of 
a causal association is quite widely accepted; for 
example a recent review of modifiable risk factors 
for Alzheimer’s disease estimated the relative risk 
associated with mid-life obesity as 1.60 (95% 
CI 1.34–1.92), and the population attributable 
fraction (the proportion of incident cases of AD 
that might be prevented if the risk factor was 
completely removed from the population) as 
2.0% 28. Nevertheless, the literature is constantly 
developing, and a critical overview of the evidence 
accumulated to date is necessary. 
A significant number of prospective 
epidemiological studies have been conducted 
on the associations between BMI and/or waist 
circumference in mid-life and dementia. We 
have identified three reviews published in recent 
years. These reviews have slightly different 
main objectives and the included and excluded 
studies differ. Overall, evidence on the association 
between high adiposity in mid-life and higher 
dementia risk is weak and remains highly 
conflicting.
Gorospe and colleagues 29 included in their 
review seven studies that were published up 
until 2007 30- 36. The authors concluded that the 
evidence that high BMI increases dementia risk is 
compelling. However, of the seven primary studies 
included only four found a positive, significant 
association. In addition, amongst these, issues 
related to residual confounding may exist in two 
studies in which adjustment was limited to age 
and education 31, or did not include education 
level 34. BMI was measured in late-life in another 
of the studies reporting significant associations 30, 
making this difficult to compare with studies that 
focused on exposure to high adiposity in mid-life. 
Beydoun and colleagues conducted a systematic 
review and meta-analysis one year later 37 and 
were able to include three further published 
studies and one unpublished in addition to those 
found by Gorospe 38- 40. They concluded that 
current evidence shows that the association 
between obesity and the risks of dementia and 
Alzheimer’s disease is moderate. However, 
the findings from the primary studies were 
heterogeneous and results from the largest 
study included in the meta-analysis 35 strongly 
influenced the combined estimate.
Finally, Anstey et al. (2011) published the most 
recent available review on the association 
between adiposity and (any) dementia 41. Primary 
studies that used BMI or waist circumference 
measured either in mid-life or late-life were 
eligible, and were separately combined. Pooled 
effects were calculated for the association of 
overweight or obesity with Alzheimer’s disease, 
vascular dementia, and any dementia. The 
authors concluded that underweight, overweight 
and obesity in mid-life all increase dementia 
risk 41. The authors’ conclusions are based on 
results of their meta-analysis, in which the primary 
studies’ estimates are pooled. However, they 
comment on the large heterogeneity across the 
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dementia risk was found also in the Prospective 
Population Study of Women in Sweden (PPSW), 
in which BMI at the same age in mid-life was not 
associated with dementia (see above) 42. The fact 
that in the same cohort (i.e. PPSW) contrasting 
results emerged using two measures of adiposity 
is extremely interesting. Because central adiposity 
captures the associated-metabolic changes 
better than global adiposity (i.e. BMI), this finding 
supports the hypothesis that any link between 
adiposity and dementia may be best understood 
as a continuum through insulin resistance and 
type 2 diabetes 17. Conversely, the production 
by adipose tissue of substances with metabolic 
(adipokines) and inflammatory (cytokines) 
functions may be less important. 
Further research is warranted because an 
improved understanding of the critical pathways 
that may lead from high adiposity to greater 
dementia risk could have a significant impact on 
targeting of primary prevention strategies. 
Adiposity and cognitive function 
in mid-life
Dementia has an insidious onset. The latency 
period, defined as the time between initiation 
and detection of the disease, can be as long as 
20–30 years. Evidence on changes of cognitive 
function in adulthood suggests that cognitive 
impairment may begin in mid-life 9, 45. Modifiable 
factors across the life course may influence 
the achievement and maintenance of optimal 
cognitive function levels in mid-life, and higher 
levels of cognitive function before older age have 
been suggested to potentially act as a reserve 
to ward off the consequences of accumulated 
brain damage and reduce symptoms 46. A focus 
on progressive cognitive ageing from adulthood 
into older age rather than on dementia diagnosis 
in late-life seems very promising for prevention 47. 
Also, the metabolic changes associated with 
dementia and its symptoms (both cognitive and 
behavioural) can have a considerable impact 
on risk factor profiles, including declining blood 
pressure and weight loss. This complicates 
elucidation of the direction of causal relationships, 
and has led to an increasing interest in studies 
that track both exposure and outcome measures 
before older age.
Few studies have investigated the relationship 
between adiposity measured in young adulthood 
and cognitive function or cognitive decline in 
mid-life. Overall results are heterogeneous but 
seem to indicate that the potential detrimental 
effect of adiposity on cognitive function may 
be largely confounded. In the Vieillissement et 
Santé au Travail (ageing and health at work; 
VISAT) Study, higher BMI at baseline but no gain 
primary studies included in their review. The 
reported pooled relative risks (RR) of dementia 
(Alzheimer’s, vascular dementia or any dementia) 
for both overweight (see Table 3 in Anstey et al.’s 
paper 41) and obesity (see Table 4 in Anstey et al.’s 
paper 41) in mid-life compared to normal BMI were, 
again, all largely driven by results from the Kaiser 
Permanente study 35, and to a lesser extent by the 
Primary Prevention Study in Goteborg, Sweden 34. 
In the Kaiser Permanente study, generalisability 
of the finding may be limited by the fact that 
participants were part of the Kaiser Permanente 
medical care programme in northern California. 
In the Goteborg study 34 educational level was 
not controlled for; residual confounding seems 
likely, because education is strongly associated 
with both BMI and dementia risk. Moreover, in 
both studies, dementia diagnosis was largely 
or entirely based only upon available medical 
records, which may have introduced an important 
ascertainment bias. Since higher BMI predicts 
morbidity and hospitalisation, those who were 
leaner in mid-life may have been less likely to be 
diagnosed with dementia simply because they 
were not as frequently routinely assessed 35. 
In addition to these limitations, Anstey et al. 
did not include in their review two large and 
important epidemiological studies, the Finnish 
Cardiovascular Risk Factors, Aging and Dementia 
(CAIDE) study 32, and the Prospective Population 
Study of Women in Sweden (PPSW) 42 although 
both seem to meet the inclusion criteria. These 
Scandinavian studies reported no significant 
associations between overweight and obesity 
measured in mid-life and dementia in late life, and 
indicate that the association between mid-life 
BMI and dementia may be largely explained by 
confounding by socio-demographic, health and 
lifestyle characteristics. 
It has been recently suggested that the 
association between adiposity and dementia 
may be in fact explained by factors (both genetic 
and environmental) that may influence lifelong 
adiposity trajectories, vascular risk profile, 
and late-life cognitive decline too 43. Waist 
circumference is less often measured than BMI in 
prospective, longitudinal epidemiological studies 
of the association with onset of dementia in 
late-life. Nevertheless, in contrast with the highly 
conflicting evidence on BMI, the association 
between central obesity and dementia risk is 
more consistent. Results are unequivocal in the 
Kaiser Permanente study, in which those with 
highest central obesity in mid-life (as measured 
with sagittal abdominal diameter, SAD) were 
almost three times more likely to have been 
diagnosed with dementia three decades later 44. A 
positive, prospective association between a waist-
to-hip ratio (WHR) greater than 0.80 and greater 
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Taken together, evidence from these studies of 
younger adults suggests that BMI gain across the 
life course is not related to worse cognitive ageing 
before older age, and that childhood intelligence 
may in fact largely explain any associations 
between high adiposity and dementia observed 
in some epidemiologic studies (above). This is 
plausible, because intelligence strongly influences 
the maintenance of a healthy lifestyle throughout 
life, including lower adiposity, and may confer 
advantages in brain structure (brain reserve) and 
function (cognitive reserve), that can buffer the 
impact of brain damage in late-life and delay 
the symptomatic onset of dementia. A recent 
hypothesis posited by Corley et al. maintains 
that the association of adiposity with cognitive 
impairment is in fact confounded by genotype 
and life circumstances that may shape lifelong 
adiposity trajectories, and also cognitive ability 
and decline 43. 
Adiposity and brain measures
A further improvement in our understanding of 
the complex relationship between adiposity and 
dementia could come from studies that investigate 
associations with dementia-related brain damage. 
However to date evidence from longitudinal, 
prospective, population-based studies on this 
topic is scanty, to our knowledge no studies have 
explored the association of mid-life BMI with 
brain atrophy and vascular lesions (both focal 
and diffuse), the structural changes underlying 
dementia. The only evidence we could find was 
on BMI and changes in MRI (magnetic resonance 
imaging) structural measures, both measured in 
mid-life. Results were not significant after relevant 
potential confounders were controlled for 53. 
Conclusions
In conclusion, the available evidence from 
epidemiological studies on the association 
of overweight and obesity in mid-life, 
clinically measured with BMI, with dementia 
is still conflicting. Factors that may explain 
discrepancies across studies are summarised in 
Box 2.2.
Any associations between early life adiposity and 
cognitive function or impairment in mid-life seem 
to be accounted for by a strong confounding 
effect exerted by childhood intelligence and 
educational achievement. 
Central obesity in mid-life, as measured by 
waist circumference, waist hip ratio or other 
anthropometric measures, may be more 
consistently linked to the development of 
dementia in older age. This is consistent with the 
fact that waist circumference seems to capture 
obesity-related health problems better than BMI 27, 
in BMI in adulthood was associated with lower 
scores in memory and speed/attention tests, 
independently of relevant covariates and potential 
confounders 48. In the Whitehall II study, with the 
exception of executive function, compared to 
those who had a normal weight, those who were 
obese or overweight in young adulthood (mean 
age 25 years), and early mid-life (mean age 44 
years) did not have lower cognitive function levels 
in late mid-life (mean age 61 years). However, 
there was a significant cross-sectional association 
at age 61 years, such that both obese and 
underweight participants had lower scores, and 
being obese at all three assessments compared 
to never having been obese was significantly 
associated with a 1.6 point (out of 30) lower score 
on the Mini Mental State Examination in late 
mid-life 49. Further analysis showed that obesity 
was associated with a steeper 10-year cognitive 
decline in mid-life only in obese participants 
who were also ‘metabolically abnormal’ (having 
two or more of three metabolic syndrome 
factors; dyslipidaemia, high blood pressure, and 
diabetes) 50. In the 1946 British 51 birth cohort 
study the positive association between gain in 
BMI from adolescence (15 years) until mid-life (53 
years), with mid-life cognitive function and steeper 
cognitive decline in mid-life (from 43 to 53 years) 
was largely explained by educational level and 
childhood intelligence. Moreover, there were no 
significant associations in this cohort between 
BMI gain and crystallised intelligence (which 
captures the slippery concept of cognitive reserve 
beyond educational level). 
Finally, in the Coronary Artery Risk Development 
in Young Adults (CARDIA) study, Reis et al. 
investigated the relationship of cardiovascular 
health (defined according to the American Heart 
Association (AHA) criteria) in young adulthood and 
mid-life with cognitive function in mid-life (before 
age 60) 52. BMI is one of the seven cardiovascular 
health components indicated by AHA. Those 
with higher BMI in both young adulthood (i.e. 
before 30 years of age) and mid-life (i.e. before 
60 years of age) had significant lower scores in 
tests of executive functions, attention and speed 
but similar scores on memory tests administered 
in mid-life. Though statistically significant, 
differences in cognitive tests scores across BMI 
levels were very small, and of negligible clinical 
significance. These tests have been developed 
to assess cognitive performance in older people. 
A ceiling effect may exist when they are used 
in relatively young adults that makes it hard to 
detect objective cognitive impairment defined for 
example by a score that is more than 1.5 standard 
deviations lower than the mean score in the 
source population. 
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dementia. The use of a life course approach in 
future studies is imperative 56. 
and that central obesity is a strong predictor of 
insulin resistance and diabetes 54, which in turn 
may be harmful for the brain and are associated 
with dementia. However, there are different types 
of central obesity, and visceral fat rather than 
subcutaneous fat deposits seem to be most 
associated with harmful health outcomes 55. 
The relationship between fats and the brain is 
extremely complex. Fats are fundamental for brain 
and cognitive development, may be harmful (if 
in excess) in mid-life, and may be an important 
energy reserve that could improve resilience to the 
effects of dementia-related neuropathology and 
comorbidities in later life. The evidence we have 
presented seems to suggest that the same factors 
that influence the accumulation of adiposity 
across the life course may also be implicated in 
the development and decline of cognitive function. 
New studies are certainly needed to elucidate 
the complex relationship between adiposity and 
cognitive function, cognitive impairment and 
Box 2.2
Discrepancies in evidence
Reasons that may explain discrepancies across epidemiologic studies on the association between 
adiposity and dementia
Healthy average adiposity level in mid-life – When average adiposity in mid-life is below or around 
healthy levels in the cohort under study, detrimental effects cannot be observed simply because too few 
people are truly ‘at risk’. Descriptive data on average BMI in the sample under study should be carefully 
considered to interpret results.
Age of participants when the adiposity is measured with respect to ascertainment of cognitive 
status – The life course hypothesis in epidemiology posits that critical periods during which the effect of 
risk factors may have more impact may exist. Under this assumption, null findings in cohort studies with 
relatively few repeated observations across the life course may be explained by the lack of data in the 
supposed time window when high adiposity is truly detrimental. Evidence on the existence of such critical 
periods is best derived from birth cohort studies, in which participants sampled at birth are followed up 
and measured several times across the life course.
Reverse causality – Subtle weight loss may precede the symptomatic onset of dementia by several 
decades. Long follow-up intervals between adiposity measures at baseline and cognitive assessment in 
late-life reduce this possible nuisance, but it cannot be entirely excluded (see Chapter 4).
Variation of the validity of adiposity measures with age, and across populations – Age, gender 
and ethnicity influence the validity of the standard cut-points of BMI used to define overweight and 
obesity. Relationship of dementia to continuous BMI should be always explored before categorising BMI 
using thresholds for overweight and obesity.
Dementia diagnosis, cognitive assessments – It is very likely that dementia diagnosis and cognitive 
assessments vary significantly across epidemiologic studies. This clearly limits the appropriateness of 
direct comparisons. The 10/66 study is an example of how pre-validated diagnostic procedures and the 
use of standard study protocols in diverse world regions allow for comparison and contrasting of results in 
different cohorts.
Survival bias and competing risks – A true association between high adiposity and dementia may 
be difficult to observe because those who are obese in mid-life are less likely to survive to older age 
than those who are lean. This means that ‘mortality and dementia’ compete in people exposed to high 
adiposity. Indeed, very few studies have considered survival across levels of BMI in mid-life.
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With an estimated 7.7 million new cases each year1, 
dementia prevention is an urgent priority, both to reduce 
incidence and slow the progression of the condition. We 
need to identify important risk factors, particularly those 
that can be modified. Nutrition, brain development 
and adult brain health are linked together by complex 
pathways across the life course, suggesting multiple 
opportunities for prevention. This is important as a cure 
for dementia is still lacking. 
under study. When associations are biologically 
plausible, reported consistently across numerous 
studies, and independent of potential confounding 
factors, epidemiologic evidence can inform 
dietary recommendations to reduce risk of 
dementia in populations. 
Experimental evidence from randomised 
controlled trials always provides the best basis 
for guiding treatment and prevention strategies. 
However, dementia is a multifactorial chronic 
disease, with a long latent period between 
the beginning of complex pathophysiological 
mechanisms and the clinical, detectable onset 
of symptoms. Definitive trials may therefore be 
difficult to conduct, particularly when treatment or 
prevention may need to be implemented in mid-
life to delay or prevent dementia onset in late-life, 
and their feasibility to test the effect of diet on 
dementia risk may be limited.
In this chapter we will summarise and review 
the expanding epidemiological and clinical trial 
evidence assessing the relevance of nutrition 
to cognitive impairment and dementia. Nutrient 
deficiencies and their associations with cognitive 
decline will be described from cohort studies, and 
the evidence surrounding the benefits of nutrient 
supplementation will be derived from randomised 
controlled trials. Searches were carried out on 
Pubmed/Medline and the Cochrane Library using 
the search strategies included in Appendix 1. 
Reference lists to identify further studies were 
also hand-searched. 
Chapter 3 Nutritional factors and 
dementia prevention
Mechanistic evidence and animal models suggest that nutrients can be directly 
implicated in modifying brain damage. Micro- 
(vitamins) and macronutrients (fatty acids) are 
natural antioxidants that can reduce oxidative 
stress levels in the brain. Moreover, some 
micronutrients and fatty acids modulate the 
production and activity of neurotrophins (proteins 
implicated in the development, function, and 
survival of neurons), have vasoprotective effects, 
and favour the clearance of β amyloid. Sufficient 
intake of nutrients is also important to avoid 
micronutrient deficiencies that are potentially 
harmful to the brain. Therefore evidence on the 
association between nutrients and cognitive 
impairment spans treatment and prevention of 
micronutrient deficiencies, to investigations of 
the potential beneficial effects of healthy dietary 
patterns (e.g. the so-called Mediterranean diet) or 
supplements. 
The association of diet and nutrients with 
cognitive function, impairment and dementia 
has received much attention in past decades. 
Evidence from cross-sectional studies showed 
that compared to adults with dementia, healthy 
older people tend to have a healthier diet, richer 
in fruits and vegetables, rather than meat, 
processed carbohydrates and fats. Because 
dementia alters dietary habits, these initial studies 
have been useful in generating hypotheses but 
could not prove any causal link. Prospective 
cohort studies with long follow-up intervals are 
needed to clarify the direction of the association 
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B vitamins 
Introduction
Researchers have had a long interest in the link 
between neurological disorders and vitamin 
B complex, with first reports of a relationship 
between vitamin B12 and ‘subacute combined 
degeneration of the cord’ dating back to 18492. 
B vitamins are organic, water-soluble, chemical 
compounds that cannot be synthesised in 
sufficient quantities by an organism and have 
to be acquired through diet. B vitamins play key 
roles in cell metabolisms. There are eight different 
chemically distinct types of vitamin B, with B6, B9 
and B12 all being linked with protective roles in 
cognition (see Box 3.1).
Folate (vitamin B9) and vitamin B12 have related 
roles in the metabolism of DNA and protein 
synthesis. They are both essential for the 
remethylation of homocysteine to methionine by 
using 5-methyltetrahydrofolate (THF) as a methyl 
donor. When folate or vitamin B12 are deficient, 
homocysteine levels rise, which may contribute 
to amyloid and tau protein accumulation and 
neuronal death. Homocysteine stimulates 
apoptosis and neurotoxicity (leading to nerve 
cell death), and platelet activation (contributing 
to white matter lesions, vascular injury and 
ischaemic strokes3).
Deficiencies in B12 and in folate increase with age. 
In a UK study the prevalence of B12 deficiency 
was 5% in people aged 65–74, doubling to 10% 
in people aged 75 and over, with similar trends 
reported for folate deficiency4. 
Evidence from the latest reviews
The association between B vitamins and cognition 
has been the subject of several recent systematic 
reviews. 
O’Leary and colleagues identified 35 cohort 
studies (with a total population of 14,235 
participants and a mean sample size of 409 
subjects) that assessed the relationship between 
serum vitamin B12 or B12 biomarkers and 
dementia5. Only 21 studies were deemed to be 
of good quality, and among those only seven 
studies reported significant associations between 
B12 status and AD, dementia or cognitive decline, 
the conclusion being that there was insufficient 
evidence to reach a final verdict on this 
relationship. However, the subgroup of studies 
that assessed B12 status using a marker with 
greater specificity (e.g. methylmalonic acid (MMA), 
holotranscobalamin (holoTC)), reported consistent 
associations with cognition. 
There is also insufficient evidence to support an 
association between either folate or B6 deficiency 
and cognitive impairment or dementia with 
mixed findings reported in reviews of prospective 
studies6-8. An added problem, which may partially 
explain the heterogeneity of results, is the fact 
that few studies consider the underlying nutrient 
status of the populations studied; this issue 
is particularly important in the case of folate, 
because folic acid fortification in certain countries 
has led to an almost complete eradication of 
folate deficiency9. 
As mentioned in the introduction, deficiencies in 
B12 and folate can lead to an abnormal elevation 
of homocysteine (Hcy) blood levels, called 
hyperhomocysteinaemia (HHcy). Homocysteine 
levels have also been identified as a potential 
modifiable risk factor for dementia, and there 
seems to be more consistent evidence regarding 
the association between Hcy and dementia. One 
systematic review identified 12 retrospective 
studies assessing this relationship, and found 
that all studies apart from two found a significant 
relationship between Hcy levels and cognitive 
decline10. The consistent associations from 
Box 3.1
B vitamins
Vitamin B6, also known as pyridoxine, is 
involved in the synthesis of haemoglobin, 
neurotransmitters, and the production of 
vitamin B3. Pyridoxine is also involved in the 
metabolism of lipids and amino acids. 
Sources: bread, eggs, fish, milk, peanuts, 
potatoes, pork, poultry, soya beans, 
vegetables 
Guideline intake*: 1.7 mg a day for men, 
1.5 mg a day for women
Vitamin B9, also known as folate, is involved 
in the production of red blood cells, in the 
metabolism of amino acids and nucleic acids 
and in aiding normal cell division during 
pregnancy.  
Sources: asparagus, broccoli, brown rice, 
brussels sprouts, chickpeas, liver, peas, 
spinach 
Guideline intake*: 0.4 mg a day
Vitamin B12, also known as cobalamin, is 
essential in the production of red blood cells 
(together with folic acid) and nerve sheaths, 
and in the metabolism of carbohydrates, lipids 
and proteins. 
Sources: cheese, cod, eggs, meat, milk, 
salmon 
Guideline intake*: 0.0024 mg a day
*Guideline intakes are for adults aged 50 and over and 
are based on dietary reference intakes (DRI) issued by the 
Food and Nutrition Board of the Institute of Medicine.
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of vitamin B6, vitamin B12 and folic acid alone 
or in any combination. Dosage of vitamin B12 
ranged between 0.05–1 mg, vitamin B6 between 
3–50 mg and folic acid 0.75–15 mg. B vitamins 
supplementation, in any form, was found to be 
effective in reducing total homocysteine (tHcy) 
levels in older people with or without significant 
cognitive impairment. However, the pooled 
estimates of the meta-analyses suggested that 
these epidemiological studies have led to an 
increase in trials of interventions targeting 
homocysteine levels and their consequent effect 
on cognitive function. Nineteen English language 
trials of B vitamin supplementation targeting 
lowering of elevated homocysteine levels have 
been synthesised and meta-analysed11. The 
dosage and composition of the supplementation 
varied across studies, but mainly consisted 
Table 3.1 
Characteristics of included studies
APSYMAD (Asymptomatic and partially symptomatic Alzheimer’s disease). tHcy (total homocysteine), holoTC (holotranscobalin). 
a) population of people with previous stroke or transient ischaemic attack b) population of community-dwelling older people with 
depressive symptoms c) participants with MCI. $ participants with low B vitamin levels were selected/analysed
Study/ 
location/ 
reference
Population 
(sample size 
and baseline 
mean age)
Follow-
up
(years)
Exposure/
Intervention 
measure
Control 
group
Outcome 
measure Effect
Longitudinal/cohort studies
Morris et al. 2012
Framingham, USA
n=549
74.8
8 Vitamin B12, folate Cognitive 
decline
Protective
Hooshmand et al. 
2011
Kuopio, Finland
n=274
70.1
7.4 tHcy, holoTC, folate Cognitive 
decline
Direct effect between tHCy and 
some cognitive domains, mainly 
non-statistical associations 
between holoTC, folate and 
cognitive functions
Ford et al. 2012
Perth, Australia
n=4,227
77.9
5.8 tHcy Dementia 
risk
direct 
Zylberstein 2011, 
Gothenburg, 
Sweden
n=1,368
46.8
35 tHcy Dementia 
risk, AD risk
direct
Randomised controlled trials
Hankey et al. 
2013
20 countries
n=8,164a
63.5
2.8 B vitamin treatment 
(folic acid 2 mg, 
vitamin B6 25 mg, 
vitamin B12 0.5 mg)
placebo tHcy, 
cognitive 
decline, 
cognitive 
impairment
No effect on cognitive 
impairment or decline but 
lowering of tHcy
Douaud et al. 
2013
Oxford, UK
n=156
76.5$
2 B vitamin treatment 
(folic acid 0.8 mg, 
vitamin B6 20 mg, 
vitamin B12 0.5 mg)
placebo Cerebral 
atrophy in 
grey matter 
regions
Grey matter regions athropy 
slowed down in individuals with 
high homocysteine levels
Walker et al. 
2013
3 cities, Australia
n=900b
65.9
2 B vitamin treatment 
(folic acid 0.4 mg, 
vitamin B12 0.1 mg)
placebo Cognitive 
function
Improvement in cognitive 
function (in particular in 
immediate and delayed memory 
performance), but not in other 
domains 
De Jager et al. 
2011
Oxford, UK
n=226c
76.7$
2 B vitamin treatment 
(folic acid 0.8 mg, 
vitamin B6 20 mg, 
vitamin B12 0.5 mg)
placebo 
(vitamin-
free 
tablets)
Cognitive 
decline 
Lowering of tHcy. Improvement 
in global cognition, episodic 
memory and semantic memory 
but only in participants with 
baseline homocysteine levels 
above the median
Kwok et al. 2011
Hong Kong
n=140
78.15$
2 Folic acid 5 mg, 
methylcobalamin 
1 mg
placebo 
(capsules 
containing 
starch)
tHcy, 
cognitive 
decline
Lowering of tHcy. No effect 
on cognitive decline, with the 
exception of the group with 
elevated plasma tHcy 
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Conclusions
So far, cohort studies have produced inconclusive 
evidence on the association between vitamin-B 
deficiency and cognitive decline, but have seemed 
to confirm that high levels of homocysteine are 
associated with poorer cognition. 
Randomised controlled trials have shown that 
supplementation with B vitamins can consistently 
reduce levels of homocysteine, but that this does 
not necessarily translate into slower cognitive 
decline, improvement in cognitive function or 
reduction in dementia incidence. It is important to 
note that more encouraging findings have been 
reported in individuals with higher homocysteine 
levels at baseline, suggesting that those with 
clear and defined deficiencies may be the 
ones who could actually benefit from vitamin 
supplementation. 
Antioxidants
Introduction
Neural inflammation and oxidative damage are 
thought to be key mechanisms in the development 
of dementia, and in particular of Alzheimer’s 
disease (AD) and Dementia with Lewy bodies 
(DLB). Oxidative stress directly damages cell 
components, resulting in damage to synapses 
and nerve cell death. Antioxidants (Box 3.2) are 
thought to act against neurodegeneration by 
limiting the production of toxic substances and 
by reducing damage by free radicals19. There are 
relatively fewer antioxidant enzymes specifically 
focused on neuronal protection, suggesting that 
antioxidant nutrients may have a more prominent 
role in older and ageing brains than in other organ 
systems20. 
Evidence from the latest reviews
Most of the research that has investigated the 
relationship between antioxidants and cognitive 
function has focused on vitamin E. Most of the 
longitudinal studies that have investigated this 
relationship using a food frequency questionnaire 
have reported an inverse association between 
vitamin E levels and the incidence of cognitive 
decline or dementia21. The evidence is not as 
conclusive and consistent in the studies that have 
assessed vitamin E status using biochemical 
levels (concentrations of individual tocopherols). 
It has been suggested that this may be due 
to the fact that total tocopherols levels, rather 
than the individual components, may be more 
important for neuroprotection21. This seems to 
be supported by studies that have reported a 
significant relationship between low levels of 
total tocopherols, cognitive decline and incident 
dementia22,23. 
supplementation with B vitamins did not improve 
cognitive function either in cognitively impaired 
or healthy individuals, irrespective of study size, 
study duration and whether the countries from 
which participants were recruited had instituted 
folate fortification procedures. 
New studies
Since the latest reviews, a number of new studies 
have been published (Table 3.1). The role of B 
vitamins/homocysteine in cognitive decline has 
been explored in four cohort studies. In the 
Framingham study, participants with plasma 
vitamin B12 concentrations of 257 pmol/L or less 
had a significantly faster cognitive decline than 
individuals with higher concentrations, and the 
cognitive disadvantages linked to low vitamin B12 
were increased at high folate levels9, suggesting 
that there may be an interaction between vitamin 
B12 and folate on cognition status. The other 
three cohort studies investigated the relationship 
between homocysteine and cognitive decline 
or dementia risk12-14. All the studies identified a 
direct relationship between high homocysteine 
levels and poor cognitive function, strengthening 
the findings from previous studies. The Australian 
“Health in Men Study” reported that tHcy was 
related with an increased risk of dementia and 
cognitive impairment after a follow up of almost 
6 years. Similar findings were also reported by 
two Scandinavian cohorts12,14, backing up the 
evidence of the systematic review. 
Several new randomised controlled trials have 
also been published in the past couple of years 
with mixed results (Table 3.1). One of the largest 
studies was carried out across 20 countries in 
8,164 people who previously had a stroke or a 
transient ischaemic attack15. Although mean 
tHcy levels were reduced after B vitamins 
supplementation, there was no significant effect 
on cognitive decline. Lowering of tHcy levels was 
also seen in two other trials, neither of which 
reported a significant effect of homocysteine 
lowering treatment on the reduction of cognitive 
decline16,17. However, clinical benefits in cognition 
were seen in the groups that already had elevated 
homocysteine levels. In a similar fashion, a UK 
study18 identified that B-vitamin supplementation 
was associated with a decline of cerebral atrophy 
in the grey matter regions of the brain that are 
vulnerable to Alzheimer’s disease, but that this 
beneficial effect was limited to participants with 
high homocysteine levels (above 11µmol/L). 
No studies specifically recruited only those 
participants who were B12/folate deficient or 
who had hyperhomocysteinemia, however 
some studies, as described above, considered 
baseline levels in their analyses. These studies are 
identified with a small $ sign in the table.
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report any significant improvement in cognitive 
performance in people with multiple sclerosis, 
after the 12 week intervention34. Similarly, the 
5 year ginkgo biloba intervention on a group of 
2,854 French participants did not slow down 
conversion to Alzheimer’s disease35. Finally, one 
of the largest and longest multivitamin trials did 
not report any differences in mean cognitive 
change between the intervention and the control 
The role of flavonoids and vitamin C has also 
been scrutinised21,24,25, but the evidence from 
cohort studies is once again very mixed and 
inconclusive, with highly heterogeneous studies 
(e.g. deficiency definition, populations, follow-
up time, investigated outcomes, etc.) showing 
inconsistent results for both types of antioxidants. 
A recent Cochrane systematic review did not 
find any supportive evidence that vitamin E 
supplementation is beneficial to cognition26. This 
review identified three randomised controlled 
trials. Only one study found vitamin E to have 
some beneficial effects27, with the two other 
studies showing no significant changes in 
cognitive decline and no slower conversion 
from mild cognitive impairment to Alzheimer’s 
disease28,29. Further details are given in Chapter 
5. Similar inconsistent results have been reported 
by Mecocci and colleagues who have reviewed 
clinical trials of antioxidants, not focusing 
solely on vitamin-E but also considering other 
nutrients with antioxidant properties30. One of 
the potential explanations to support the lack of 
positive findings is the low permeability of the 
blood brain barrier to the type of antioxidants that 
are currently used, which suggests the need to 
identify new delivery systems. 
New studies
The Nurses’ Health study, which followed up 
16,010 older participants for an average 6.4 
years, has recently published on the association 
between antioxidants and cognition (Table 3.2). 
Vitamin C and E were assessed using a semi-
quantitative food frequency questionnaire, but no 
consistent associations between vitamin C and E 
intake and cognitive decline were identified31. In 
the same study, with regard to flavonoids (berries 
in particular), a higher intake of strawberries and 
blueberries was associated with slower cognitive 
decline at follow up32.
There are four recently published trials of 
antioxidant supplementation (Table 3.2), not 
included in recent reviews. Using a double-
blinded, parallel arm study, an Italian group 
randomised 90 adults with mild cognitive 
impairment to consume a drink containing 
either 900 mg (high), 520 mg (intermediate) or 
45 mg (low) levels of flavanols for 8 weeks33. 
Participants consuming drinks with high levels 
or intermediate levels of flavanols had better 
scores in some cognitive domains at the end of 
the trial, compared to the control group, but there 
were no overall differences in general cognition. 
Two studies, one in Washington State (USA) and 
one in France, assessed the effect of a daily 
dose of 120 mg of a ginkgo biloba extract, a 
potent antioxidant, on cognition, both reporting 
negative findings. The American study did not 
Box 3.2
Antioxidants
Antioxidants include several different nutrients, 
such as vitamin C, vitamin E and flavonoids.
Vitamin E belongs to a group of eight fat-
soluble complexes, which include tocopherols 
and tocotrienols. vitamin E has important 
antioxidant functions, but it is also involved in 
gene expression and cell signalling, enzymatic 
activities and neurological functions. 
Sources: nuts and seeds, plant oils (corn, 
olive and soya oil), wheat germ 
Guideline intake*: 15 mg a day
Vitamin C also known as ascorbic acid 
or ascorbate, is a water-soluble vitamin, 
which cannot be stored in the body, and is 
a co-factor for several enzymatic reactions. 
vitamin C is essential for connective tissue 
maintenance, helps protect cells and has 
important roles in wound healing. vitamin C 
also has antioxidant properties. 
Sources: blackcurrants, broccoli, brussel 
sprouts, oranges and orange juice, red and 
green peppers, potatoes, and strawberries 
Guideline intake*: 90 mg a day for men, 
75 mg a day for women.
Flavonoids are a class of plant secondary 
metabolites, responsible for many plant 
colours. The term “flavonoids” include 
several different chemical structures, 
including flavanones, flavanonols, flavans, 
anthocyanidins and anthoxanthins. Flavonoids 
have antioxidant properties, but also support 
vitamin C, help with inflammation control, and 
in some cases have antibiotic properties. 
Sources: dark chocolate, dry beans, fruit 
(citrus, grapes, apples, berries), grains, herbs 
(thyme, parsley, celery, hot peppers), soy 
foods, tea, vegetables (broccoli, kale, onions, 
scallions [spring onions]) and wine. 
Guideline intake: no current guidelines
*Guideline intakes are for adults aged 50 and over and 
are based on dietary reference intakes (DRI) issued by the 
Food and Nutrition Board of the Institute of Medicine
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Omega-3 
Introduction
Alpha linolenic acid (ALA), eicosapentanoic 
acid (EPA), and docosahexanoic acid (DHA) are 
omega-3 polyunsaturated fatty acids (PUFA), 
which means that in the long carbon chain of 
which they are made, there is a double bond at 
the third carbon atom from the end (or w-3). 
Omega-3 PUFA cannot be synthesised in the 
human body but are very important, particularly 
for the brain – therefore they are an essential 
dietary constituent. Brain tissue is made primarily 
by lipids and DHA is the most abundant structural 
omega-3 PUFA in the brain. Over 22% of both 
the cerebral cortex and the white matter are 
made of phospholipids, and their fatty acids 
composition is heavily influenced by diet, which 
affects in particular cell membranes. The function 
of cell membranes is modulated by their fatty 
acid composition. Dietary omega-3 PUFA are 
group36. This study was once again not limited to 
undernourished or vitamin deficient individuals, 
and the vitamin dosage may have been too low 
to have an effect on this population, potentially 
explaining the negative findings. No clinical trials 
were specifically limited to people with low levels 
of vitamin E/C or flavonoids. 
Conclusions
There is currently insufficient evidence from either 
longitudinal studies or randomised controlled 
trials to support a role for antioxidants in 
cognition. The only consistent associations were 
reported in studies that have assessed vitamin E 
status using food frequency questionnaires, rather 
than biochemical measures, suggesting that 
more work is needed to better understand these 
nutrients and their relationship with dementia. 
Table 3.2 
Characteristics of included studies investigating antioxidants and cognition
a) participants with mild cognitive impairment b) participants with multiple sclerosis
Study/ 
location/ 
reference
Population 
(sample size 
and baseline 
mean age)
Follow-
up
(years)
Exposure/
Intervention 
measure Control
Outcome 
measure Effect
Longitudinal/cohort studies
Devore et al. 
2012/2013
United States
n=16,101
74.2
6.4 Vitamin C (diary)
Vitamin E (diary)
Flavonoids (diary)
Cognitive 
decline 
Vitamin C and E were not 
consistently related to 
cognition. Higher intake of 
flavonoids reduced rates of 
cognitive decline
Randomised controlled trials
Desideri et al. 2012
Italy
n=90a
71.1
8 weeks Cocoa Flavanols 
drink (990 mg 
high/520 mg 
intermediate)
Cocoa Low 
flavanol drink 
(45 mg low)
Cognitive 
function
Improvement in some 
cognitive domains (verbal 
fluency, visual attention/task 
switching) but not in overall 
cognition 
Grodstein et al. 2013
Unites States
n=5947
71.6
12 years Supplementation of 
β-carotene(lurotin, 
50 mg), vitamin 
E (α-tocopherol, 
400IU), ascorbic 
acid (500 mg) 
and multivitamin 
(centrum silver)
Placebo Cognitive 
function
No difference in mean 
cognitive function changes 
between intervention and 
placebo group
Lovera et al. 2012
United States
n=120b
52.1
12 
weeks
Ginkgo biloba 
supplement 
(120- mg)
Placebo Cognitive 
function
No improvement in cognitive 
function in the intervention 
group
Vellas et al. 2012
France
n=2854
76.3
5 years Ginkgo biloba 
supplement 
(120- mg)
Placebo 
(containing 
quinine 
hydrochloride)
AD risk No reduction of AD risk in the 
intervention group
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related with dietary consumption of omega-3 
PUFA in the Women’s Health Study45.
Negative results have been reported in 
studies that used the plasma concentration of 
omega-3 PUFA as exposure rather than dietary 
consumption of fats in relation to subsequent 
dementia risk. In the Canadian Study of Health 
and Aging, higher plasma concentration of 
omega-3 PUFA at baseline were found in those 
who developed dementia at the 5-year follow-up 
compared to those who did not46. In the Uppsala 
Longitudinal Study of Adult Men, after more 
than 30 years follow-up dementia incidence did 
not vary by baseline measurements of plasma 
concentration of omega-3 PUFA47. However, 
lower DHA concentration in red blood cells was 
also implicated in neuronal growth and influence 
synapse formations, thus impacting also on the 
interaction between neurons. Dietary omega-3 
PUFA are important throughout life, from before 
birth (particularly during the third trimester of 
pregnancy), to older age when diets poor in 
omega-3 PUFA accelerate the physiological 
reduction of their concentration in cell membranes 
in the nervous system.
The main food sources of omega-3 PUFA are ‘oily 
fish’ such as salmon, mackerel, herring, sardines, 
fresh tuna, and swordfish. Eggs and meat may 
contain DHA and EPA if animals are fed with diet 
rich in ALA. In humans the conversion of ALA in 
DHA and EPA is not efficient, thus foods rich in 
ALA, like soybean, black currant, and nuts are 
minor sources of omega-3 PUFA.
There are several potential mechanisms for a 
protective effect of dietary omega-3 PUFA in 
dementia (Box 3.3). Omega-3 PUFA may be 
implicated in the vascular, inflammatory and 
also the amyloid pathways of dementia, and 
are therefore potentially important in vascular 
dementia, Alzheimer’s disease and mixed forms. 
Evidence from latest reviews
The relationship of omega-3 PUFA with cognitive 
impairment and dementia has been investigated 
in cross-sectional and cohort studies, and in 
randomised controlled trials. 
Cross-sectional studies have shown that older 
people with dementia consume significantly 
less fish and more meat than those without 
dementia37, and that people who consume more 
fish have better cognitive function in mid-life38. 
However, evidence from longitudinal studies 
is conflicting. In a recent meta-analysis, Lin et 
al. have demonstrated that the concentration 
of omega-3 PUFA (EPA, DHA) is significantly 
reduced in older people with dementia compared 
to those without the disease. Whether this 
reduction is a consequence of the disease and 
particularly of brain damage is unknown39.
There was a lower risk of incident dementia in 
the Rotterdam study in the short-term40 but not 
in the long-term follow-up41. Risk of dementia 
was reduced also in the Three-City cohort study 
in France42, and in older people in the Chicago 
Health and Aging Project (CHAP)43 amongst 
those who consumed more fish and whose diets 
were richer in omega-3 PUFA content compared 
to their counterparts. However, the association 
between higher fish consumption and lower 
dementia risk was apparently confounded by 
educational level and healthy lifestyle in another 
French PAQUID cohort study44. Furthermore, 
serial cognitive testing over 4 years was not 
Box 3.3
Omega-3 PUFA
Postulated mechanisms for the protective role 
of omega-3 PUFA in dementia. 
1 Cardiovascular and cerebrovascular 
protection – omega-3 PUFA have 
antiarrhythmic and antithrombotic effects 
that reduce the risk of both stroke and 
diffuse microinfarcts. Omega-3 PUFA also 
have antiatherogenic effects, and may 
improve endothelial function benefiting the 
integrity and health of arteries. Moreover, 
omega-3 PUFA lower blood pressure levels 
and improve serum lipid profiles, both of 
which are implicated in dementia risk.
2 Omega-3 PUFA directly reduce the 
synthesis of cytokines that have pro-
inflammatory functions (like interleukin 1 
and 6), which in turn can reduce the brain 
inflammation that accompanies brain 
damage.
3 Omega-3 PUFA, particularly DHA, are key 
components of the phospholipids that form 
cell membranes and preserve the integrity 
and the function of neuronal membranes.
4 Omega-3 PUFA modulate the metabolism 
of the amyloid precursor protein and 
may reduce the formation and favour the 
clearance of β amyloid, the main component 
of the extracellular plaques deposited in 
Alzheimer’s disease. 
Guideline intake*: 1.6g a day per men, and 
1.1g a day per women
*Guideline intakes are for adults aged 50 and over and 
are based on dietary reference intakes (DRI) issued by the 
Food and Nutrition Board of the Institute of Medicine.
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New studies
Three new randomised controlled trials have 
recently been published testing the effect of 
omega-3 supplementation on cognitive decline 
(Table 3.3). Cognitive function was tested after 
a 90-day supplementation with the Omega-3 
essential fatty acid docosahexaenoic acid 
(DHA) in a group of 74 healthy participants55. No 
significant effects of the intervention on cognitive 
function were reported. Similar non-significant 
results were reported by an Australian group, who 
carried out a 6-month double-blind trial of n-3 
PUFA, DHA and EPA in a group of people with 
mild cognitive impairment. Cognitive functions did 
not improve in the intervention groups compared 
to the control group, with the exception of verbal 
fluency in the DHA group. However, depressive 
symptoms scores were reduced in both groups 
that received supplementation (DHA or EPA) 
compared with the control group56. Participants 
with mild cognitive impairment were also the 
subject of another intervention trial that was 
conducted in a small group of 25 adults57. 
The intervention, lasting for 12 weeks, was a 
supplementation with an oily emulsion of DHA. 
Several domains of cognitive function were 
reported to be improved in the intervention group, 
compared to placebo, including overall cognitive 
function, measured using the Mini-Mental State 
Examination (MMSE). These results should 
however be interpreted with caution because of 
the small sample size. Moreover the results were 
not adjusted for multiple comparisons and MMSE 
cross-sectionally associated with smaller brain 
volume and worse cognitive performance in the 
Framingham study48.
Evidence on the potential enhancing effect 
of omega-3 PUFA on cognitive function from 
childhood to older age has been recently 
reviewed49. Luchtman and colleagues concluded 
that there is strong evidence of a beneficial 
effect of omega-3 PUFA to improve cognitive 
impairment in those who have an insufficient 
intake, particularly of DHA through diet. However, 
epidemiologic and experimental evidence on the 
potential protective effect of omega-3 PUFA to 
prevent dementia or slow cognitive decline was 
considered to be weak.
Similar conclusions were reached in a recent 
Cochrane systematic review of randomised 
controlled trials that tested the efficacy of 
omega-3 PUFA supplementation to prevent 
cognitive impairment in cognitive healthy people. 
Though only three studies could be included in 
the meta-analysis50,51,52, their results consistently 
showed no beneficial effects of omega-3 PUFA 
supplementation for the prevention of cognitive 
decline53. In a further review that included 
additional trials on the effect of omega-3 PUFA 
supplementation also in participants with 
cognitive impairment or dementia, Dangour et 
al. similarly concluded that the use of omega-3 
PUFA supplements for prevention or treatment 
of cognitive impairment in older age cannot 
be recommended on the basis of the available 
experimental evidence, regardless of level of 
cognitive function when supplementation starts54.
Table 3.3 
Characteristics of included studies
PUFA (total polyunsaturated), DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), MNA (Mini Nutritional Assessment). 
a) participants with MCI. $ participants were excluded if they ate fish more than once per month and if they had taken fish oil 
supplements in the previous 3 months
Study/ 
location/ 
reference
Population 
(sample size 
and baseline 
mean age)
Follow-
up
(years)
Exposure/
Intervention measure Control
Outcome 
measure Effect
Randomised controlled trials
Stough et al. 
2012
Australia
n=50
71.1
3 
months
HiDHA® (1000 mg of tuna oil 
comprising of 252 mg DHA, 
60 mg EPA, 10 mg vitamin E).
1000 mg of 
tuna oil
Cognitive 
function
No significant effect of DHA 
on cognitive functioning 
Sinn et al. 
2012
Australia
n=78a
74.1$
6 
months
Either EPA-rich fish oil (1670 mg 
EPA +160 mg DHA) or DHA-rich 
fish oil (1550 mg DHA +400 mg 
EPA)
Safflower oil 
(containing 
2.2.g of n-6 
PUFA linoleic 
acid)
Cognitive 
function
No significant effect of 
supplementation and 
cognitive domains. 
Reduction in depressive 
symptoms in treatment 
groups
Rondanelli et 
al. 2012
Italy
n=25a
85.7
12 
weeks
Oily emulsion (DHA 720 mg, EPA 
280 mg, vitamin E 16 mg, soy 
phospholipids 160 mg, tryptophan 
95 mg, melatonin 5 mg)
Non-fish oil 
placebo
Cognitive 
function
Improvement in cognitive 
function, and also 
improvement in MNA scores
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Scarmeas and colleagues59 who have shown 
that the association between Alzheimer’s disease 
and the Mediterranean diet is not mediated by 
vascular co-morbidity. 
Oxidative stress has also been suggested as a 
potential mechanism to explain an association 
between the Mediterranean diet and dementia. 
Cognitively impaired brains show evidence of 
injury mediated by highly unstable reactive oxygen 
and nitrogen species. Some of the components 
of the Mediterranean diet (e.g. vegetables, olive 
oil, wine and fruits) are rich in antioxidants. 
Neutrophins, which are basic proteins, usually 
protect neurons against oxidative stress, and 
some have proposed that the Mediterranean 
diet could increase the concentration of plasma 
neutrophins60. 
Finally, the Mediterranean diet could reduce the 
risk of dementia by limiting pro-inflammatory 
cascades, reducing C-reactive protein levels and 
inflammatory cytokines such as IL-661,62
What is the evidence?
The effect of the Mediterranean diet on cognitive 
decline and dementia risk has been assessed 
in nine longitudinal studies (Table 3.4). Six were 
conducted in the United States, one in Australia, 
one in France and one in Greece. Five studies 
investigated cognitive decline, four dementia 
risk (three specifically risk of AD), and three Mild 
Cognitive Impairment (MCI) risk. The average 
sample size was 1,715 individuals (SD=888). The 
follow-up period ranged between 2.2 and 8 years. 
Non adherence to a Mediterranean diet was 
associated with cognitive decline in three studies 
63 64,65, but no significant associations were 
reported by Psaltopoulou66 and by Cherbuin67. 
Higher Mediterranean dietary pattern scores 
using the MedDiet assessment were related to 
slower rates of cognitive decline after adjustment 
for age, sex, education, race, energy, and 
participation in cognitive activities in a study in 
the Chicago Health and Aging Project (CHAP)64. 
Similar findings were reported in the Washington 
Heights Inwood and Columbia Aging Project 
(WHICAP)65 and the French “Three-City Cohort”68. 
In the latter, higher adherence to a Mediterranean 
diet was associated with slower cognitive 
decline, measured using the Mini Mental State 
Examination (MMSE), but was not associated 
with a lowered risk of incident dementia. Two 
other cohort studies 65,69,70 investigated the 
association between Mediterranean diet and 
incident Alzheimer’s disease, both reporting 
lower risks for AD among people who had better 
adherence to Mediterranean diet. The WHICAP 
study also reported that higher adherence to this 
diet was linked to a reduced risk of converting 
from Mild Cognitive Impairment to Alzheimer’s 
was one of several endpoints, suggesting that 
these findings may be explained by chance.
Conclusions
The evidence on the beneficial effects of fish 
consumption to prevent dementia incidence is 
overall conflicting, but a protective role does 
not seem to exist. Healthy lifestyles and life 
circumstances (including socio-economic and 
educational level) that are associated both to 
higher fish consumption and lower dementia risk 
may explain the positive results found by some 
studies.
Evidence from experimental studies on 
the beneficial effects of omega-3 PUFA 
supplementation is insufficient to recommend 
their use in populations either for the prevention, 
or treatment or amelioration of dementia. But 
dietary recommendations to increase the amount 
of the intake of omega-3 PUFA from foods and 
the use of supplements in those who be deficient 
in these fatty acids, particularly of DHA, seems 
indicated for other reasons.
Some issues related to experimental studies may 
exist that could explain the weak results reported 
so far. Longer follow-ups may be needed to 
observe significant changes in cognitive function 
in primary prevention trials because changes 
in cognitive function were somewhat minimal in 
both the treated and placebo arms of existing 
trials. An additional concern exists regarding the 
experimental integrity of these trials, because the 
absence of limitations in fish consumption may 
have diminished the difference in total dietary 
omega-3 PUFA intake between those who were 
given the supplement and those who receive 
placebo. 
Mediterranean diet
Introduction
Several studies have reported that a 
Mediterranean diet (Box 4) is associated with 
reduced risk for a number of outcomes, including 
cardiovascular disease, type 2 diabetes, some 
forms of cancer and overall mortality58. More 
recently, there has been an increased interest in 
understanding the potential protective role of such 
diet against dementia risk and cognitive decline. 
Three main biological mechanisms, relating to 
impact on the vascular system, oxidative stress 
and attenuation of the inflammatory pathway, have 
been proposed to support these associations. 
The Mediterranean diet could reduce the risk 
of dementia by affecting the vascular system, 
reducing cardiovascular disease, which in itself 
is a risk factor for dementia. However, this 
hypothesis does not seem to be supported by 
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disease (HR 0.55, 95% CI 0.34–0.90)71, but with 
no reduced risk of developing MCI (HR 0.72, 95% 
CI 0.62–1.12). MCI a finding (i.e. no reduced risk 
of MCI) shared by Cherbuin and colleagues67. A 
recent meta-analysis of four longitudinal cohort 
studies reported that people who had a high 
adherence to the Mediterranean diet had a 40% 
reduced risk of incident cognitive impairment 
(RR 0.72, 95% CI 0.58-0.88).
To date, only one study, the PREDIMED-
NAVARRA randomised trial72 has attempted to 
test this association in an experimental design, 
by comparing a nutritional Mediterranean diet 
intervention supplemented with either extra-virgin 
olive oil (EVOO) or mixed nuts, with a low-fat 
control diet. The intervention that lasted 6.5 years 
showed encouraging results, where participants 
that supplemented Mediterranean diet with EVOO 
Table 3.4 
Characteristics of included studies
FFQ (Food Frequency Questionnaire), SFFQ (Semi-quantitative Food Frequency Questionnaire), CDR (Clinical Dementia Rating), 
MCD (Mild Cognitive Disorder), MCI (Mild Cognitive Impairment), AD (Alzheimer’s disease). a) median age
Study/  
location/  
reference
Population (sample 
size and baseline 
mean age)
Follow-up
(years)
Exposure/
Intervention 
measure
Outcome 
measure Effect
Longitudinal/cohort studies
Cherbuin et al. 2012
Canberra, Australia
n=1,528 
62.5 
4 FFQ/MeDi score Cognitive decline, 
MCD risk
Non-significant
Tagney et al. 2012
Chicago, USA
n=3,790
75.4
7.6 FFQ/MedDiet 
score
Cognitive decline Protective
Roberts et al., 2010
Minnesota, USA
n=1,233
79.6a
2.2 FFQ/MeDi score MCI risk Protective
Gu et al. 2010
New York, USA
n=1,219
76.7
3.8 SFFQ/MeDi score AD risk Protective
Scarmeas et al. 2009b
New York, USA
n=1,393
76.9
4.5 SFFQ/MeDi score MCI risk, 
conversion to AD
Protective 
Scarmeas et al. 2009a
New York, USA
n=1,880
77.2
5.4 SFFQ/MeDi score AD risk Protective
Feart et al. 2009
Bordeaux, France
n=1,410
75.9
5 FFQ/MeDi score Cognitive decline, 
dementia risk
Protective for cognitive 
decline, but non-significant 
for dementia risk
Psaltopoulou, 2008
Athens, Greece
n=732
60+
8 FFQ/MeDi score Cognitive decline Non-significant
Scarmeas et al. 2006
New York, USA
n=2,258
77.2
4 SFFQ/MeDi Cognitive decline, 
AD risk
Protective
Randomised controlled trials
Martinez et al. 2013
Navarra, Spain
n=285
74.1
6.5 MedDiet 
intervention
Cognitive decline, 
MCI risk, dementia 
risk
Protective
Box 3.4
What constitutes a 
Mediterranean diet?
A diet with a high intake of cereals, fruits, fish, 
legumes, and vegetables. This diet is often 
rich in unsaturated fatty acids, its main source 
being olive oil, and low intake of meat, poultry 
and saturated fatty acids. Dairy products 
intake, especially yogurt and cheese, tend 
to be low to moderate and meals are often 
accompanied by a moderate amount of 
alcohol (particularly wine). This type of diet is 
particular common across Greece, Southern 
Italy, Spain and Morocco. 
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A review conducted for the 2011 World Alzheimer 
Report looking at treatment of established 
dementia concluded ‘There is, as yet, no evidence 
to recommend the use of (micro) nutritional 
supplementation at any stage of dementia’, and 
we believe that the statement is also currently 
applicable for prevention. Yet, supplementation for 
cognitive problems is a large market, with a recent 
survey of adults in the United States, reporting 
that 15 million Americans specifically consumed 
supplements to “prevent” or “treat” cognitive 
problems73, with little empirical evidence. 
In this chapter we have shown that there is, 
however, a strong theoretical basis for implicating 
deficiencies in these micronutrients in the 
known mechanisms of neurodegeneration, and 
that the negative results may be the result of 
methodological issues with current study designs, 
rather than with a lack of relationship per se. 
The main limitation is that trials have been few in 
number, and often small and underpowered. The 
duration of supplementation may have been too 
short to demonstrate an effect. It has also been 
suggested that simultaneous supplementation 
with multiple micronutrients (fatty acids, 
phospholipids, vitamins E, C, B6 and B12, and 
folic acid) might be required synergistically 
to increase brain levels of molecules that are 
essential building blocks of brain synapses. 
However, results from RCTs of such ‘medical 
foods’ are mixed, with preliminary data showing 
some improvement in specific cognitive tasks 
but not in overall cognition, clinical status, or 
functioning74. Moreover the majority of the studies 
have not focused on those with deficiencies of 
the supplemented micronutrient. It has been 
postulated that vitamin supplementation may 
but not with mixed nuts, had better cognitive 
function, and significantly less incident MCI 
than the control group (OR for MCI = 0.34, 95% 
CI 0.12–0.97). 
Conclusions
There is currently moderate evidence suggesting 
a positive link between adherence to the 
Mediterranean diet and dementia risk. Not 
all the studies did, however, report positive 
findings, in particular regarding cognitive decline. 
Unfortunately, there is very little evidence from 
clinical trials, with only one study that has used 
the Mediterranean diet as an intervention. 
This is potentially due to intrinsic difficulties of 
implementing such an intervention on a large 
scale, and in a sustainable way. More intervention 
studies are needed to further understand the 
preventive role of the Mediterranean diet, and the 
active ingredients for improving cognitive function 
and reducing dementia risk. 
Overall conclusions 
There is currently insufficient evidence to 
confirm a relationship between the micro- 
and macronutrients described above (vitamin 
B6, vitamin B12, folate, vitamin C, vitamin E, 
flavonoids, omega-3, Mediterranean diet) and 
cognitive function. Although some studies have 
shown positive results, particularly those using 
cross-sectional designs, the findings have not 
been consistently supported in prospective 
cohort studies, and preventive interventions have 
generally failed the critical test of randomised 
controlled trials (Table 5). 
Table 3.5 
Summary of evidence for each nutrient
 signifies decreased risk with higher levels of nutrient  signifies increased risk
Nutrient
Type of 
association Evidence for Cohort Studies
Evidence from Randomised Controlled 
Trials
Vitamin B6, B12, folate Insufficient conflicting evidence
Insufficient evidence (but encouraging for 
participants with high homocysteine levels)
Homocysteine levels Good evidence
Vitamin C Conflicting, insufficient evidence Insufficient evidence
Vitamin E Conflicting evidence (good evidence using 
frequency questionnaire, but not with 
biochemical levels)
Insufficient evidence
Flavonoids Insufficient evidence Insufficient evidence
Omega-3 Insufficient evidence Insufficient evidence
Mediterranean diet Moderate evidence Insufficient evidence
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Chapter 4 Undernutrition in dementia
3 Revise the evidence on the consequences of 
undernutrition in people with dementia. 
We used PubMed and the Cochrane Library to 
retrieve publications of observational studies on 
dementia, dementia severity, dementia-related 
neuropathology and measures of undernutrition 
(i.e., low body weight, weight loss, changes in 
body composition). We further hand-searched 
references lists of relevant studies. We focused on 
existing reviews, which were integrated with new 
evidence when available.
Mechanisms
Introduction
Undernutrition results from an imbalance between 
nutrient/energy intake and needs. This is usually 
due to an inadequate diet, but can also be 
the result of altered digestion, absorption and 
metabolism of nutrients and energy from foods. 
Complex endocrine, nervous, cognitive and 
sensory signals and information are processed 
in the central nervous system in order to regulate 
energy homeostasis, mainly through modulation 
of food intake. Both pathways are likely to be 
implicated in dementia-related weight loss. 
Evidence suggests that dementia-related brain 
atrophy may impact on brain regions implicated in 
appetite control and energy balance including the 
mesial temporal cortex14, the hypothalamus15, and 
the cingulate gyrus16, with metabolism in these 
Undernutrition and underweight are common 
problems in older people. Weight loss is associated 
with increased morbidity and mortality, and it also 
worsens the prognosis for several chronic diseases1,2. 
Maintaining body mass seems to have a greater 
protective effect on health with increasing age3, 
probably because the health risks associated with 
excess body weight (and fat) seem to be reduced 
in older people. A moderate excess of body fat may 
provide a ‘reserve to the individual in times of stress, such 
as illness’3. In older people weight loss is considered 
to be clinically significant or potentially harmful, when 
it amounts to 5% of total body weight or more over 
one year. A weight loss of 10 lb (4.5 kg) or more over 
few months is easily detected because of loose-fitting 
clothes or other obvious changes. 
Weight loss occurs in part as a result of the ageing process itself, but underlying 
diseases often contribute4, of which dementia, 
along with cancer and cardiovascular disease, 
is a well-recognised cause. In 1906 Alois 
Alzheimer recorded Ms August D’s progressive 
weight loss in his celebrated case report5. This 
observation remained long neglected in research, 
and relatively few clinical studies followed6. 
However, nearly half of all patients with dementia 
experience clinically significant weight loss7, and 
weight loss is now considered a characteristic 
feature of Alzheimer’s disease8. 
Weight loss seems to precede the symptomatic 
onset of dementia by several decades9–11, and 
accrues as the disease progresses9,12. Evidence 
from the 10/66 study confirms that the association 
between dementia and weight loss strengthens 
through the stages of dementia severity, and that 
geographical variations across diverse world 
regions are essentially negligible13. This may 
support a causal role of dementia on weight loss, 
with diverse underpinning mechanisms acting 
during the course of the disease. 
In this chapter we aim to:
1 Provide an overview of the mechanisms that 
may underline dementia-related undernutrition / 
weight loss. 
2 Systematically review the evidence on 
dementia-related undernutrition / weight loss.
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regions (a marker of brain activity) significantly 
reduced in dementia17,18. The existence of a 
hypermetabolic state has been demonstrated in 
animal models of AD, in mice that overexpress 
amyloid-precursor protein, but not as yet in 
humans19. 
Dietary habits are influenced by diverse factors, 
from food availability and preparation, to 
appetite, taste and feeding problems. Brain 
damage in general, and the cognitive and 
behavioural symptoms of dementia in particular 
influence these factors and hence may impact 
on dietary habits in different ways at different 
stages of dementia; in the pre-clinical phase, 
as neuropathology subtly builds up; in the early 
stages of dementia, when mild cognitive and 
psychological symptoms progressively appear 
along with impairments in complex activities of 
daily living; and finally in advanced dementia, 
when the impact of neurological and behavioural 
impairments are most evident. Feeding problems 
are extremely common in advanced dementia. 
Some degree of feeding supervision or assistance 
is almost always required. Aversive feeding 
behaviours are common, swallowing is slow and 
poorly coordinated, and oropharyngeal dysphagia 
(distinct from the laryngeal or oesophageal forms 
that are more usually encountered) can cause 
choking and food avoidance. The multifactorial 
and stage-specific nature of weight loss in 
dementia is corroborated by evidence on the 
natural history; weight loss starts decades 
before symptomatic onset and then accrues 
progressively from mild, to moderate and severe 
dementia9–11,13.
Evidence from latest reviews
The various mechanisms that may explain 
weight loss in people with dementia have been 
comprehensively reviewed20. Mechanisms are 
illustrated in Table 4.1, along with examples of 
how the different pathologies and symptoms of 
dementia may interfere with dietary habit, and 
energy balance. Mechanisms can be broadly 
divided into those that may cause a reduction 
in energy intake, and those that may cause an 
increase in energy expenditure. The proposed 
mechanisms may act at different stages of the 
development of dementia syndrome (Table 4.1). 
Some may interfere with nutrition during the 
asymptomatic phase, as brain damage slowly 
progresses. Others are more prominent through 
the early (mild to moderate) stages of dementia 
(characterised by impairment of memory, changes 
in personality, and psychological symptoms 
including apathy, irritability and depression), 
which, along with the related difficulties in 
carrying out complex, instrumental activities of 
daily living (like shopping, and preparing meals) 
alter dietary habits more broadly. 
Finally, aversive feeding behaviours and loss of 
interest in eating develop progressively in the 
advanced stages of the disease. A classification 
of these behaviours has been proposed by 
Blandford et al.21 as summarised in Table 4.2. 
The underlying mechanisms are largely 
neurological, resulting from advanced cortical 
brain damage. Agnosia (loss of ability to recognise 
or comprehend the meaning of objects even with 
intact sensation), means that food may not be 
distinguished from non-food, and that feeding 
utensils are not recognised for what they are. 
Dyspraxia (loss of higher order control of complex 
motor functions) can lead to loss of feeding 
skills, for example normal use of plates, cups and 
cutlery. Oropharyngeal dysphagia is a prominent 
end stage feature of both AD and frontotemporal 
dementia, and can result from cortical (premotor, 
primary motor, primary somatosensory, insula) 
or sub-cortical neurodegeneration. Aversive 
feeding behaviours are, understandably, a 
source of considerable anxiety and strain for 
family caregivers – there is also evidence from 
one longitudinal study that such behaviours are 
more likely to present when caregivers have high 
baseline levels of strain22.
Conclusions
Progressive undernutrition and weight loss are 
observed almost inexorably in dementia patients 
(see also below). There are numerous potential 
mechanisms, which may act from as early as 
the pre-clinical and asymptomatic phase of the 
disease to the most advanced stages, when 
aversive feeding behaviours are common, severely 
disrupting dietary intake, and making assistance 
at mealtimes indispensible and progressively 
more problematic. 
Occurrence and dynamic of 
dementia-related undernutrition
Introduction
Numerous studies have investigated the 
association of dementia, or dementia severity with 
weight loss. Dementia-related weight loss can be 
conceived as the study of the natural history of 
body weight in those with dementia.
Evidence from latest reviews
A comprehensive review on weight loss and 
Alzheimer’s disease, focussing upon prospective 
studies, was carried out in 2007 under the 
auspices of the International Academy of Nutrition 
and Aging (IANA)21. The first epidemiologic studies 
on the topic were carried out in the mid-nineties32. 
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Table 4.1 
Possible mechanisms of undernutrition (i.e. weight loss) in dementia from pre-clinical to advanced stages of the 
disease
Reduced energy intake Example
Stage of the natural history of dementia 
when the mechanism is more relevant
Brain damage Damage of brain regions implicated in appetite control and 
food intake (i.e. the hypothalamus, and mesial temporal 
cortex) causes anorexia
From the pre-clinical phase of the disease 
onwards
Cognitive impairment Forgetfulness may lead to skipping meals 
Apraxia and impaired executive function may reduce the 
ability to use utensils and to prepare meals
Aphasia and communication problems affect the ability to 
ask for food and communicate hunger
Impaired decision-making ability may slow food choice and 
reduce intake
May prevail in the early stages of the disease, 
when severity is mild to moderate
Psychological symptoms Apathy is associated with decreased interest in food
Sadness, depressive symptoms are associated with 
anorexia
Mild to moderate stages of disease progression
Behavioural symptoms Agitation/aggression/hostility lead to aversive feeding 
behaviours and interfere with family members and carers 
who may not be able or willing to provide meals or food
Personality changes can alter attitude towards food and 
change dietary preferences in ways that may be difficult to 
understand and meet
More likely when the disease is severe
Personality changes may occur very early in the 
course of the disease, even before the clinical 
diagnosis
Sensory functions Olfactory dysfunction (reduced sense of small), common in 
AD, affects taste and can reduce appetite
Progressive sensory dysfunction (loss of taste 
and smell) is part of normal ageing, but loss of 
smell is more marked in AD and may be present 
already in the pre-clinical stage and worsen 
with disease severity
Oral and dental health (see 
also Box 4.1 for more details 
on bidirectional associations 
with cognition)
Tooth loss, dental or gum disease, ill-fitting dentures, 
ulcers and infections impact on chewing and may cause 
pain that interferes with eating
These issues are a normal part of ageing, and 
may worsen when dental care is compromised 
as dementia symptoms progress
Motor disturbances Wandering may lead to skipped or interrupted meals and 
may significantly reduce eating time
Moderate to severe stages of dementia
Social factors In most cultures, eating is a social activity, from which 
people with dementia may be excluded, particularly when 
they develop feeding dependence (needing to be fed)
Isolation, poverty and low socio-economic circumstances 
impact on food availability and on its nutritional quality
Depending on the social context, social 
factors can be prominent at any stage of the 
disease, including the pre-clinical phase when 
subtle personality changes may alter social 
relationships and mild cognitive impairment may 
impact on the socio-economic circumstances
Increased energy 
expenditure (EE) Example Stage when more relevant
Increased resting metabolic 
rate (RMR) (the energy 
required for basic metabolic 
functions at rest)
Central hypermetabolism Pathology of the hypothalamus and mesial temporal cortex 
can re-set RMR higher
All phases of dementia natural history, starting 
already at the pre-clinical phase
Inflammation Increased systemic levels of pro-inflammatory molecules 
(interleukin 1, and 6, TNF-alpha) promote a catabolic state 
leading to loss of muscle mass
Pre-clinical phase, getting worse with the 
accruing of the inflammatory response in 
damaged brain regions
Physical activity EE Example Stage when more relevant
Motor disturbances Wandering increases the average physical activity level Severe stage
Sleep disturbance Increase in waking hours means less resting time and 
higher EE 
Mild to moderate, and exacerbates in the severe 
stage
Behavioural symptoms Overexcitement / over activity may increase EE through 
increased body movements 
From mild to severe stage
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Box 4.1 
Oral health and cognition
Oral health has an important but complex relationship with cognition (Figure 4.1). Poor oral health is most 
often thought of as an outcome driven by lack of access to routine oral care and inattention to oral hygiene 
among people with dementia. However, it may also be an underlying risk factor for cognitive impairment.
A recent review indicates relationships between poor oral hygiene, caries and dementia23. For example, 
a study conducted in Finland identified that people with AD had poorer oral hygiene (OR 12.2: 95% CI 
1.9–77.0) and worse denture hygiene (OR 2.9, 95% CI 1.1–7.8), than people without AD24. This relationship 
has been reported to worsen with time; in a one year prospective study oral health deteriorated faster in 
people with dementia, including worsening caries25. 
Caries and poor oral hygiene can lead to periodontitis (a chronic infection affecting the tissues surrounding 
the teeth), which has been associated with tooth loss and also with poor cognitive performance in older 
people23,26. Several prospective studies have found a relationship between tooth loss and cognitive 
decline27 or incident dementia28. 
Tooth loss leads to inadequate chewing capacity. This, in turn, can force people to adopt a diet low 
in fibres and micronutrients29, and high in saturated fats and cholesterol, often easier to chew than 
foods rich in fibres30, which, in the long term, can lead to micronutrient deficiencies (B12 and thiamine), 
undernutrition31 and exacerbation of cognitive impairment.
Figure 4.1 
The complex and multi-directional relationship between oral health and cognitive function, with potential 
mediators and confounders
Inadequate
chewing capacity
Poor
oral health
Caries
Tooth loss
Periodontitis
Systematic
inflammation
Diet low in fibre
/micronutrients
and high in
saturated fat/
cholesterol
Micronutrient
deficiencies
Undernutrition
Cognitive
function
Table 4.2  
Aversive feeding behaviours (adapted from Gillette-Guyonette et al.21)
Dyspraxia/agnosia Resistance
Oral neuromuscular 
incoordination 
(oropharyngeal dysphagia)
Selective feeding 
behaviours
Cannot use utensils properly
Does not recognise food or eats 
non edible items present on the 
table
Requires coaxing 
Wanders away from the table 
during meals
Turns head away from food or 
pushes food away
Holds hands in front of mouth/ 
clenches teeth and lips
Grabs, hits or bites feeding 
assistant
Spits or throws food
Problems with mouth and 
tongue control e.g. does not 
open mouth; chews without 
swallowing; cannot form food 
bolus
Problems passing bolus from 
mouth to pharynx
Change in preference for 
quality (e.g. taste or texture) or 
quantity of food
Requests specific foods, which 
will complain about and refuse 
to eat
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4.5 kg or more experienced in the three months 
preceding the interview. This information was 
recalled by participants and was corroborated 
by an informant in all dubious cases. There was 
a strong, linear association between dementia 
and reported weight loss, resistant to adjustment 
for a variety of socio-demographic, lifestyle 
and health characteristics. Compared to older 
people who were cognitively healthy, those with 
dementia were two, four and five times more likely 
to have lost weight in the previous 3 months, if 
the severity of the disease was mild (CDR=0.5), 
moderate (CDR=1), or severe (CDR=2/3), 
respectively. This is illustrated in Figure 4.2. 
The observed associations were very similar 
across eight very diverse low and middle-income 
countries in Latin America and Asia. The validated 
and highly standardised procedures applied in 
the 10/66 study allowed to directly compare the 
significance and magnitude of the association 
between dementia severity and weight loss in 
very diverse settings. Because these differences 
encompass lifestyle, culture, social structure and 
a number of other circumstances, the fact that 
weight loss was a consistent feature amongst 
patients with dementia, and that the likelihood of 
its occurrence increased linearly with the severity 
of the disease, supports the hypothesis that 
dementia causes weight loss.
The association between dementia and weight 
loss is indirectly supported by studies that found, 
contrary to prior hypotheses, that higher BMI in 
older age seems to protect against the onset of 
Since then consistent evidence has accumulated 
on the association of dementia, dementia severity 
and subsequent weight loss12,33. In a two year 
prospective study comparing those with mild to 
moderate dementia with controls, dementia was 
the sole factor independently associated with 
clinically significant weight loss of 5% of body 
mass or greater (OR 2.54, 95% CI 1.76–3.78). In 
another five year prospective study, controlling 
for age and gender, those with AD lost an average 
of 0.52 kg/m² compared with 0.14 in healthy 
controls12,33. In three French cohorts of those with 
mild to moderate Alzheimer’s disease, clinically 
significant weight loss (4% or more of body 
mass over one year) was observed in 45% of 
patients (cohort size, n=76)34, 33.4% (n=395)35, 
and 20% (n=486)36. In a large north American 
cohort study, 666 patients with dementia were 
followed up for up to six years, allowing the 
natural course of disease progression and weight 
loss to be monitored beyond the mild to moderate 
stages observed in other studies12. The loss 
of weight tended to increase with the severity 
and progression of the disease; each one stage 
progression in Clinical Dementia Rating severity 
(from mild to moderate to severe) was associated 
with a loss of approximately one kilogram in 
weight. 
The 10/66 study of dementia and ageing is 
the largest cross-sectional survey to date on 
dementia severity, quantified with the Clinical 
Dementia Rating scale, and reported weight 
loss13. We enquired about any weight loss of 
Figure 4.2  
Increase in weight loss risk by dementia severity calculated combining country-specific estimates 
From Albanese et al. 201313
CDR 0.5
CDR 1
CDR 2/3
*Meta-analytic prevalence ratios from Poisson models: CDR = Clinical Dementia Rating scale
2.19 (1.98 to 2.41)
3.81 (3.35 to 4.33)
5.18 (4.41 to 6.10)
O 1 2 3 4 5 6
p for trend <0.001
Weight loss risk (PRs)*
49CHAPTER 4: UNDERNUTRITION IN DEMENTIA
ALZHEIMER’S DISEASE INTERNATIONAL · NUTRITION AND DEMENTIA
loss of lean body mass, increasing risk of falls 
(and therefore fractures), pressure sores and 
infection. An increase in disability and needs for 
care is therefore explained both by worsening 
of physical health and functioning, as well as by 
the more rapid progression of dementia itself. 
Undernourished people with dementia may need 
earlier institutionalisation, and longer and more 
frequent periods of hospitalisation. Ultimately, 
survival is significantly shorter in people with 
dementia who experience marked weight loss and 
who are severely malnourished.
Evidence
Available studies in this field typically follow-up 
clinical samples of patients with dementia to 
allow close monitoring of weight change and 
assessment of its impact on dementia severity 
and other clinical outcomes. Evidence from 
epidemiologic studies on the consequences 
of weight loss in dementia patients is limited. 
According to a recent review conducted by 
members of the International Academy on 
Nutrition and Aging (IANA), the evidence of 
the detrimental effects of weight loss and 
undernutrition in clinical samples is compelling. 
Weight loss was strongly associated with 
dementia severity, more rapid progression of 
cognitive impairment12, and with subsequent 
mortality12,42. Undernutrition is also prospectively 
associated with the clinical progression of 
dementia and with institutionalisation43,44. Weight 
loss and feeding difficulties are also strongly 
predictive of mortality in advanced dementia; in a 
cohort of nursing home residents the combination 
of advanced dementia and feeding difficulties was 
associated with a 27% nine month mortality, and 
weight loss at baseline was the only significant 
predictor of mortality45. 
Such findings are certainly not unique to 
dementia. In population-based studies of 
older people in general, weight loss increases 
risk of mortality46–49, and is associated with 
a steeper decline in activities of daily living or 
physical function50,51. The association with 
mortality is particularly marked among frail older 
people52. Underweight, rather than obesity is 
associated with increased cardiovascular and 
all cause mortality among those with coronary 
artery disease1. There is some evidence that 
improvement of nutritional status through, for 
example, the use of oral nutritional supplements 
for older people may be associated with a 
reduction in subsequent mortality (RR 0.79; 
95% CI 0.64–0.97) at least among those that are 
frankly undernourished53. However, evidence for 
improvement in functional status or other relevant 
health outcomes is lacking. 
cognitive decline and dementia37–40. Weight loss 
in those with incipient dementia likely explains 
the apparent paradox of a beneficial effect for 
dementia risk of higher adiposity in older age, 
since when trajectories of body weight or BMI 
from mid- to late-life in those with and without 
dementia in late-life are compared, those who 
had gone on to develop dementia had tended to 
lose weight more rapidly from mid-life onwards, a 
trend that may begin up to two decades prior the 
clinical diagnosis9–11. 
Weight loss in the pre-clinical phase of the 
disease is certainly not explained by the 
symptoms of dementia (either cognitive or 
behavioural), nor by impaired instrumental 
activities of daily living including shopping 
and cooking. During the pre-clinical phase 
of dementia, which may last decades, 
neuropathology is thought to build up 
progressively and slowly. Brain damage may 
therefore cause a decrease in appetite and 
may impair the central regulation of energy. 
This hypothesised mechanism is in line with 
research that shows that Alzheimer’s disease 
neuropathology is associated with a steeper 
decline in BMI prior to death also amongst those 
that were not diagnosed with dementia before 
death41.
Conclusions
Evidence on the association between dementia 
and weight loss is compelling. Several 
epidemiological studies have confirmed that 
people with dementia experience a significantly 
more marked decline in body weight in older 
age. This weight loss likely starts sometimes in 
late mid-life already, and may even represent an 
early marker of disease. Future studies should 
also investigate whether faster cognitive ageing 
in mid-life is associated with any weight loss 
before older age. Monitoring of weight change is 
highly recommended in people with dementia, 
and in older people. Further research is needed to 
determine whether monitoring in mid-life may also 
be beneficial for prevention.
Consequences of dementia-
related undernutrition and weight 
loss 
Introduction
The consequences of weight loss and 
undernutrition in people with dementia are 
well characterised. Overall weight loss and 
undernutrition have a significant impact on the 
course of the disease, on both cognitive and 
functional symptoms. Moreover, the overall 
clinical prognosis is profoundly worsened by the 
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Nutritional assessment for people 
with dementia
Introduction
The continuous monitoring and surveillance 
of nutritional status during lifestyle is critical 
to plan, and evaluate the efficacy of nutritional 
interventions for people with dementia. A number 
of anthropometric and body composition, 
biochemical, haematological, and dietary 
indicators are commonly used in the assessment 
of nutrition status1. Nutritional assessment in 
older people with dementia is similar to the 
generic approach used for frail older people2. 
Here, we focus specifically of the use of physical 
and biochemical indicators of nutritional status 
to provide a systematic and evidence-based 
approach for the assessment of nutritional status 
in older people with dementia. The main areas of 
nutritional assessment are: 1) dietary assessment, 
2) weight history, 3) physical anthropometry, 
4) screening questionnaires for nutritional status, 
5) nutritional biomarkers and 6) eating and feeding 
behaviour. In the context of dementia-related 
malnutrition, anthropometric techniques and 
screening questionnaires are by and large the 
preferred approach both in epidemiologic studies 
and in clinical settings. Assessment of energy 
expenditure and body composition do not yet 
have a part to play in routine clinical assessment, 
but are important for research to gain further 
understanding of the origins of weight loss in 
In this chapter, we review strategies to improve the 
nutrition of people living with dementia, with a particular 
focus on evidence to support their effectiveness. It 
is important to consider the special contexts of care 
homes and hospitals, as well as the prevention and 
management of undernutrition in the home setting. As 
well as individual approaches, we highlight case studies 
of systems level interventions, where for example a 
hospital or care home seeks to change the way that 
staff are trained, clients with dementia are assessed, 
and the environment, ambience and context in which 
food is provided.
Chapter 5 Improving nutrition for people 
with dementia
Studies have been conducted to assess the effect of four main types of intervention:
1 Training and education programmes for 
caregivers
2 Mealtime environment or routine modification 
3 Nutritional supplements
4 Provision of feeding assistance
A simple structured assessment of the problem 
should always be the first step. This should 
include the degree of undernutrition, dietary 
intake and habits, risk factors and potential 
causes, aversive feeding behaviours, and needs 
for assistance with feeding. Suitable assessments 
and scales are highlighted, with evidence for their 
validity. 
Nutritional support (simple dietary advice, 
coupled with assessment and management of 
risk factors, and attention to needs for feeding 
assistance) may be enough to address the 
problem. Current guidelines for older people 
suggest two to three servings a day of protein 
(meat, fish or eggs), three or four servings a day of 
milk and dairy products, and at least five portions 
of fruit and vegetable per day. If this fails, or in the 
case of more severe undernutrition, high-energy 
and/or high-protein oral nutritional supplements 
(ONS), usually provided in liquid form, may be a 
quick, reliable and generally well-tolerated way of 
improving nutritional status.
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be applied to those with cognitive impairment as 
dietary records could to be completed by carers 
at home or in residential care homes2. A high 
compliance is needed to record all consumed 
food items and their weight (or approximate 
portion size). Technological advancement can 
again enhance compliance and improve accuracy 
of the dietary estimates4. 
Weight history
A detailed weight history should be obtained 
along with current weight. Detailed history 
should include a history of weight loss, whether 
the weight loss was intentional or unintentional, 
and during what period. A considerable and 
unexplained weight loss (>5 kg) during a 6-month 
period, whether intentional or unintentional, is a 
critical indicator for further assessment.
Physical anthropometry
Body weight and height are essential physical 
parameters for the evaluation of nutritional 
status in older people. Body Mass Index (BMI) 
is calculated as the ratio of weight to height-
squared (kg/m2) and is a widely used tool to 
assess nutritional status. A BMI cut off of <18.5 
kg/m2 has been recommended to define adult 
chronic dietary energy deficiency. Overweight is 
defined as a BMI between 25 and 29.9 kg/m2 and 
obesity as BMI ≥30 kg/m2. The validity of BMI as a 
measure of excess fat may decline in older people 
because of height loss5 and increases in fat mass6 
occurring with age even in the absence of weight 
gain. Waist circumference is a better predictor 
than BMI of cardio-metabolic risk7. Other simple 
physical assessments can be used to monitor 
nutritional status. These include triceps and 
truncal skinfold thickness, and mid-upper arm or 
calf muscle circumference. The former is a rough 
indicator of fat and the latter two indicators of lean 
body mass. These measurements can be easily 
performed using standardised protocols and they 
do not require costly and specialised equipment.
Screening tools for nutritional status
Nutritional screening aims to identify those who 
are malnourished or ‘at risk’ of malnutrition. 
There is a wide variety of signs and symptoms 
associated with nutritional problems. Body 
measurements and biochemical tests may be 
used but they could be difficult or expensive 
to measure in bed-bound or disabled people. 
To address this problem composite screening 
tools have been developed. Two have been most 
commonly applied in older people with and 
without dementia and a brief description of their 
characteristics is provided below.
dementia, and may have clinical applications as 
assessments become simpler and cheaper to 
perform.
Dietary assessment
Dietary assessment only measures intake and 
is not a measure of ‘status’, which ultimately 
depends on the balance between absorption and 
losses of nutrients1. Assessment of food intake 
can be prospective or retrospective. Commonly 
used methods include 24-hour dietary recall, food 
frequency questionnaires and food records. The 
element that is common to all dietary methods is 
that they all rely on the respondent remembering 
and recalling information regarding their diet. 
Retrospective methods (food frequency 
questionnaire (FFQ) and 24-hour dietary 
recall)
Retrospective methods are based on the 
recollection of food and drinks eaten in the past 
over a certain period of time. For the FFQ, this 
period is usually extended since the main aim is 
to capture typical dietary habits. Respondents 
are usually prompted in the questionnaire with 
pictures representing different food types and 
average portion sizes. The 24-hour dietary recall 
involves the recollection of all foods and fluids 
consumed the day prior the interview1. Multiple-
pass dietary recall, with repeated re-assessments 
of dietary intake in the previous 24 hours may help 
to improve accuracy of assessment of habitual 
intake over FFQ3. For people with dementia, such 
questionnaires would typically be administered 
to family carers or care home staff. The validity 
of the FFQ and 24-hour dietary recall has not 
been assessed under these circumstances 
and the adoption of one method over the other 
cannot be scientifically justified. The choice of 
the most appropriate dietary method depends 
on clinical and cognitive factors as well as on the 
information that is required for scientific and/or 
clinical purposes. The development of portable 
technologies (online platforms, tablets) have 
increased the reliability of these methods as well 
as decreasing errors relating to dietary coding 
and extraction of dietary information4. 
Prospective methods (food records)
Prospective methods require the recording by 
each participant of foods and fluids consumed 
over a specified period of time; this usually varies 
from four days to one week and includes at least 
one weekend day1. This method is considered the 
gold-standard method for dietary assessment but 
there has been debate around the intrusiveness 
of the method, its complexity in dietary coding 
and the possibility of influencing eating behaviour 
during the recording period day1. This method can 
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Step 2. Note percentage unplanned weight loss 
and score using tables provided.
Step 3. Establish acute disease effect and score.
Step 4. Add scores from steps 1, 2 and 3 together 
to obtain overall risk of malnutrition.
Step 5. Use management guidelines and/or local 
policy to develop a care plan.
Nutritional biomarkers
Nutritional biomarkers are essential for a 
comprehensive assessment of nutritional status 
of frail older persons, and is included in most 
good practice guidelines for dementia care. An 
initial screen might comprise haematology (full 
blood count with differential) and biochemistry 
(electrolytes, urea and creatinine, fasting glucose, 
albumin, and ferritin). Full blood count may 
indicate possible B12, folate or iron deficiency, or 
systemic inflammation (raised WBC count or C 
reactive protein). Serum albumin is not considered 
to be a sensitive enough biomarker to predict 
declining nutritional status, undernourishment, 
protein malnutrition or improved nutrient stores 
following nutrition interventions. Low serum 
albumin most likely reflects the presence of 
inflammatory stress. Individuals with marasmus-
type malnutrition experience weight loss as the 
result of decreasing fat and muscle mass while 
maintaining a normal serum albumin. The need for 
assessment of vitamin status should be guided by 
the clinical picture; assessment of folate, B6 and 
B12 is often performed, and any deficiency should 
be corrected, not least to moderate the increased 
cardiovascular risk from hyperhomocysteinaemia 
(see Chapter 3). 
Eating and feeding behaviour
Semi-structured assessment tools of problematic 
eating and feeding behaviours are mainly 
observational and semi-structured in nature. 
Existing measures were recently systematically 
reviewed for content, validity and clinical 
relevance13. The work of Blandford was formative 
and influential, in developing a taxonomy of 
24 adversive feeding behaviours (AFB) in four 
domains; oropharyngeal dysphagia (seven items), 
selective feeding behaviours (six items), resistive 
behaviours (five items) and dyspraxia/agnosia 
(six items)14. Blandford also proposed a four level 
‘feeding dependency scale’; normal feeder (self 
feeds with no AFB); aversive self-feeder (exhibits 
at least one AFB but self feeds); intermittently 
dependent (needs to be fed intermittently); and 
dependent (eats only when fed). Inter-rater 
reliability was demonstrated, and a two factor 
solution (active and passive aversive behaviours) 
identified on exploratory factor analysis. The most 
widely used and best validated measure is the 
Mini Nutritional Assessment (MNA®)8 *
The MNA test is composed of simple 
measurements and brief questions in four 
sections that can be completed in less than 
10 minutes: 
1 Anthropometric measurements (weight, height, 
and weight loss)
2 Global assessment (six questions related to 
lifestyle, medication, and mobility)
3 Dietary questionnaire (eight questions, related 
to number of meals, food and fluid intake, and 
autonomy of feeding)
4 Subjective assessment (self-perception of 
health and nutrition)
The maximum score is 30 points. The MNA 
classifies respondents as well-nourished (a score 
of 24–30), at risk for malnutrition (a score of 17–
23.5), or malnourished (a score of <17). Sensitivity 
is 74 % and specificity is 95% in a community 
population against a gold-standard based on 
clinical assessment.8
The Mini Nutritional Assessment short-form 
(MNA-SF®) is a short version of the original 18 
item MNA full version, comprising six items that 
best discriminated between malnourished, at risk, 
and normal older people9; decline in food intake; 
weight loss in the last three months; mobility 
limitation; psychological stress or acute diseases 
in the past three months; neurological problems 
(dementia and depression); and body mass index 
(BMI). BMI, requiring accurate assessment of 
height and weight, is time-consuming and difficult 
to measure in the community, particularly in bed 
or chair-bound older people. In the revised MNA, 
calf-circumference was substituted for BMI, 
with good criterion10 and predictive validity11. 
The MNA short form has a maximum score of 
14 points, with risk of malnutrition increasing 
with lower scores. Respondents are classified 
as well-nourished (a score of 12–14), at-risk for 
malnutrition (8–11), or malnourished (0–7). 
Malnutrition Universal Screening Tool 
(MUST)12 †
The MUST is a five-step screening tool to identify 
adults at risk of malnutrition (undernutrition). It 
also includes management guidelines, which can 
be used to develop a care plan. It is for use in 
hospitals, community and other care settings and 
can be used by all care workers.
Step 1. Measure height and weight to get a BMI 
score using chart provided. If unable to obtain 
height and weight, use the alternative procedures 
shown in the guide.
* http://www.mna-elderly.com/ 
† http://www.health.gov.il/download/ng/N500-19.pdf
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Body composition
The human body can be considered to 
comprise fat mass (FM) and lean body mass 
(LBM – muscle, bone). Ageing is associated 
with progressive changes in body composition 
including reciprocal changes in fat mass and 
lean body mass, influenced by gender, degree of 
adiposity and age-related hormonal changes6. 
Muscle mass declines by 1% per year from 
the third decade of life, and older people, even 
those with stable normal weight or overweight 
have difficulties in maintaining muscle mass; an 
accelerated decline in LBM may have important 
clinical consequences19. Several models have 
been proposed for measuring body composition 
varying from two compartment models (fat mass, 
fat free mass) to more complex models sub-
dividing the body into mineral mass, total body 
water, fat mass, and protein and carbohydrate 
mass20. These assessments require relatively 
complex techniques such as whole body 
scanning with Dual X Ray Absorptiometry (DXA), 
or Air Displacement Phlethysmography (ADP). 
Bioelectrical impedance is a non-invasive, user-
friendly, portable technique which could be more 
routinely applied in research and clinical practice 
for people with dementia. A careful monitoring of 
muscle mass may be particularly important for 
people with dementia, and nutritional interventions 
that succeed in maintaining or improving lean 
muscle mass (as opposed to adiposity) may have 
more beneficial impact on physical and overall 
functioning. 
Education and training 
interventions
Background and rationale
Most caregivers understand that maintaining the 
nutrition of the cared for person with dementia 
is an important component of the care that 
they provide, even seeing this as part of the 
treatment for the condition. From the early stages 
of dementia, new skills must be learnt, and new 
roles assumed21;22. This is particularly the case 
for male caregivers who may not previously 
have been much involved in meal planning, food 
shopping or cooking21. All spouse caregivers must 
gradually assume decision-making responsibility 
for what to eat, and when to eat it, where this 
may have previously been a shared activity. This 
responsibility can weigh heavily, occasioning 
anxiety as to whether the ambiguous food 
preferences of the person with dementia are 
being correctly interpreted, and whether their 
diet is adequate21–23. Weight loss, and how to 
prevent or treat it is a preoccupation for many 
caregivers. In a study in Sweden, for example, 
Edinburgh Feeding Evaluation in Dementia Scale 
(EdFED), developed for those with moderate to 
late-stage dementia15. The EdFED assesses 10 
items: is the person with dementia refusing to 
eat, refusing to swallow, refusing to open their 
mouth, turning their head away, spitting food, or 
leaving mouth open; and does the person require 
supervision, physical help with feeding, leaving 
food on the plate at the end of the meal, and is 
there spillage while feeding? The items are scored 
with 0 (never), 1 (sometimes) or 2 (often) based 
on the frequency of the problem behaviour. An 
11th item scores the person’s level of assistance: 
‘supportive-educative, partly compensatory or 
wholly compensatory’. The EdFED has been 
subject to extensive psychometric testing 
demonstrating internal consistency, hierarchical 
scaling properties (items 5–10), confirmatory 
factor analysis, construct, convergent and 
discriminant validity, inter-rater and test-retest 
reliability13. The EdFED is brief and simple enough 
to be used in routine clinical practice in care 
homes and hospitals, and might in principle be 
used to interview caregiver informants in the 
community. It establishes the level and type 
of disability and can be used to plan effective 
interventions.
Energy expenditure
The prevention of weight loss is critical for people 
with dementia, and matching energy intake 
to expenditure can help to achieve this. Total 
energy expenditure can be divided into three 
main components: 1) resting energy expenditure, 
2) physical activity energy expenditure and 3) 
energy expenditure induced by diet. All three 
components contribute to the progressive decline 
in total energy expenditure with ageing, which 
is predominantly a function of reduced physical 
activity and muscle mass16. There appears to 
be no difference in total energy expenditure in 
older people with and without dementia17. The 
component of total energy expenditure that 
may specifically contribute to unintentional 
weight loss in people with dementia is currently 
an under-explored area of research. Better 
understanding may help to tailor nutritional and 
lifestyle treatments. Several methods can be used 
to measure total energy consumption and its 
components. In clinical practice, simple methods 
such as portable calorimeters (i.e., MedGem) or 
prediction equations (i.e., Harris Benedict, Fredrix, 
Mifflin-St Jeor) can be used to calculate resting 
energy expenditure; total energy expenditure can 
then be obtained by applying specific coefficients 
to an estimated physical activity level (low, 
moderate, high)18. 
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Early intervention to improve awareness of the 
importance of a balanced diet, strategies to 
boost protein and energy content of the diet, 
and advice and support with managing aversive 
feeding behaviours may help to prevent or delay 
the complications of long-term inadequate food 
intake. Education and training interventions on 
mealtime difficulties in older adults with dementia 
targeting caregivers (e.g., family members, 
nursing staff) may therefore have an important 
part to play in decreasing negative outcomes and 
increasing quality of life.
There are many excellent practical guides and 
sources of information for caregivers of people 
with dementia, one of which is the factsheet 
prepared by the UK Alzheimer’s Society ‘Eating 
and Drinking’.*
This explains very clearly the importance of a 
healthy balanced diet, and the risks of weight 
loss in people with dementia. The contributions of 
cognitive problems, sensory deficits and aversive 
feeding behaviours are described, and strategies 
proposed to address them. Key points are that:
• Poor appetite may arise from depression, 
intercurrent physical illness, difficulty in 
communicating their needs, lack of activity, 
pain, oral or dental problems, side effects 
of medication, or constipation. Medical 
assessment may be required to identify and 
treat these problems, particularly if weight loss 
is recent and marked.
• Appetite may be stimulated by
 − Regular snacks and small meals
 − Experimentation – try food they like, food 
they have not tried before, stronger flavours, 
different times of day
 − Naturally soft food
 − Keeping food hot 
 − A relaxed atmosphere
 − Eat with the person with dementia, using 
it as an opportunity for activity and social 
stimulation 
 − Getting them to help with meal preparation
• It is important not to assume that a person who 
does not eat, does not want to eat. They may 
not recognize food (agnosia) or not be able to 
feed themselves independently (apraxia)
• Do not assume that a person has finished if 
they stop eating. They may find it difficult to 
concentrate on the task. Gentle encouragement 
and persistence may allow them to finish the 
meal
* http://www.alzheimers.org.uk/site/scripts/download_info.
php?fileID=1799
carers worried about the health risks of increasing 
the amount of fat in their partner’s diet in an effort 
to achieve weight gain21. As dementia evolves it is 
increasingly likely that aversive feeding behaviours 
develop, and that the person with dementia may 
need some feeding assistance. In a French study 
conducted among 224 home-dwelling people 
with dementia (mean MMSE score 15), 3.6% 
would only eat when fed, and 23.7% needed to 
be fed intermittently24. A further 31.8% had at 
least one aversive feeding behaviour, but fed 
themselves. Thus only 40% were completely free 
of feeding difficulties. Managing such problems 
is demanding of caregiver time, and requires 
patience, empathy and skill. While one might 
imagine that the emergence of feeding problems 
might cause caregiver strain, evidence is stronger 
for an effect in the opposite direction – that is that 
feeding problems are more likely to arise when 
the caregiver experiences strain24. There is also 
evidence that caregiver strain is an independent 
predictor for weight loss in patients with 
Alzheimer’s disease25. 
People living in care homes are more likely to have 
advanced dementia, and feeding dependence and 
aversive feeding behaviours are therefore more 
prevalent. Residents with dementia take longer 
to eat, require prompting and encouragement, 
and may have problems with coordination and 
swallowing. Some residents are bed-bound and 
need food to be brought to them. Therefore, 
mealtimes are a busy time for care assistants. 
Feeding a person with dementia can take up to 40 
minutes per resident to ensure that the experience 
is a calm and enjoyable one. A detailed 
observational study suggests that the quality 
of the interaction between the nurse providing 
feeding assistance and the patient with dementia 
is positively associated with the quantity of food 
consumed26. However, as staff-to-resident ratios 
are low in many homes, care workers report that 
meal times can be one of the most stressful parts 
of their day27. In a large US study of 407 residents 
with dementia in 45 assisted living facilities and 
nursing homes, overall, 54% of residents had 
low food intake, and 51% had low fluid intake28. 
In another study in 24 US nursing homes, in up 
to a quarter of cases of advanced dementia with 
feeding difficulties the family was not satisfied 
with the assistance provided for the person with 
dementia29.
There is no reason to assume that family 
caregivers, or indeed care assistants in care 
homes are naturally equipped with the knowledge 
and skills to assess and manage the often 
complex nutritional needs of a person with 
dementia. Undernutrition, and mealtime difficulties 
can have physical, cognitive, behavioural, social, 
environmental and cultural determinants30. 
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The Montessori approach uses rehabilitation 
principles including guided repetition and task 
breakdown, progressing from simple to complex 
tasks. Activities practiced were hand-eye 
coordination, scooping, pouring, and squeezing, 
and distinguishing food from non-food items. 
Spaced retrieval training focused upon eating 
procedures and behaviours with progressively 
lengthening intervals for repetition of the learnt 
material (from one to 32 minutes). In both studies, 
the Montessori-based activity intervention was 
associated with a significant net reduction 
in feeding difficulties with some evidence for 
reduced need for feeding assistance. In neither 
study was the intervention associated with 
improvements in weight, BMI or overall nutritional 
status. 
Training care assistants in care homes
In two studies, the intervention comprised 
education and training of professional caregivers 
in nursing homes or other long-term care 
facilities for people with dementia33;34. In a study 
conducted in Taiwanese nursing homes33, two 
facilities were allocated either to feeding skills 
training programme including three hours of in-
service classes (31 nursing assistants) and one 
hour of hands-on training, or a control group with 
no training (36 nursing assistants). Knowledge, 
attitudes and observed behaviours were more 
positive among the trained nursing assistants. 
However, there was no significant difference 
in food intake between the two groups, and 
feeding difficulties worsened in the intervention 
group. In a Finnish study34 28 nurses and food 
service attendants attended six half-day training 
sessions delivered by a dietician with the aim of 
assessing and monitoring nutritional status of 
residents using the Mini Nutritional Assessment 
and detailed food diaries, and then implementing 
planned adjustments to their diet. Pre- and post-
intervention assessments were made of energy 
and nutrient intake (21 residents) and nutritional 
status (19 residents). After one year, residents’ 
mean daily energy intake had increased by 
21% from 1230 to 1487 kcal, but there was no 
significant change in residents’ nutritional status 
according to the MNA. 
Training family caregivers
Education programmes for informal caregivers 
were evaluated in three studies, two randomised 
controlled trials, and a controlled non-randomised 
study35–37. The format of the training programmes 
was similar in each of the studies, comprising 
group sessions conducted by a dietician or other 
health professional. Topics covered included; 
the importance of a healthy balanced diet; 
dietary challenges in dementia; techniques 
to monitor food intake, weight and nutritional 
• Problems with coordination, and difficulty using 
cutlery can be managed by 
 − Chopping up the food, so that they can use a 
spoon
 − Providing nutritious ‘finger food’ – for example 
sandwiches, fruit, slices of quiche
• In advanced dementia, loss of feeding skills, 
and aversive feeding behaviours can mean that 
the person with dementia needs to be fed by 
the caregiver. Caregivers are reminded
 − Aversive feeding behaviours are not a 
deliberate attempt to be ‘difficult’, or a 
personal attack.
 − Try not to rush the person with dementia, and 
help them maintain as much independence 
as possible. 
 − Look for non-verbal clues such as body 
language and eye contact as a means of 
communication. 
 − If a person is agitated or distressed, do not 
put pressure on them to eat or drink. Wait 
until the person is calm and less anxious 
before offering food and drink.
 − Difficulties in swallowing (oropharyngeal 
dysphagia) can lead to risk of aspiration. It is 
important that the person with dementia is 
alert, comfortable, and sitting up in a good 
position before feeding is attempted. The 
advice of an appropriate specialist (speech 
and language therapist, occupational or 
physiotherapist) may be needed.
The evidence
In a recent systematic review, there was 
considered to be moderate evidence for efficacy 
of education and training interventions in reducing 
feeding difficulty and increasing eating time of 
older people with dementia30. However, just five 
studies were identified, and these tested quite 
different types of intervention, applied in different 
contexts.
Training people with dementia
In two Taiwanese studies, training was provided 
to people with dementia who were resident in 
long-term care settings in an attempt to modify 
their feeding behaviours31;32. While described 
as randomised controlled trials, the unit of 
randomisation was the long-term care facility; in 
one study (n=85 participants) three facilities were 
randomised to spaced retrieval, Montessori-based 
activities or usual care32, and in the other study 
(n=29 participants) two facilities were randomised 
to receive Montessori-based activities in the first 
or second phase of a crossover trial31. These are 
therefore quasi-experimental studies, lacking the 
usual benefits associated with randomization. 
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family caregivers of people with dementia, 
result in clinically meaningful improvements in 
the nutritional status of people with dementia. 
That is not to say that there may not be benefits 
associated with such interventions. Surprisingly 
little research has been conducted in care home 
settings. The evidence base regarding training 
and education for family caregivers is dominated 
by one large well conducted cluster-randomised 
controlled trial35. However, fewer training sessions 
(four) were provided for family caregivers in this 
trial than in two other smaller studies that did 
show positive benefits36;37. Training and education 
on diet and nutrition is generally appreciated by 
caregivers35, and there is a clear need for support 
particularly when aversive feeding behaviours 
and feeding difficulties occur (see case study 
on page 73). It may be that while basic 
information should be provided to all families, 
more concentrated training and dietician services 
should be focused upon those developing feeding 
difficulties or undernutrition35. 
Modifications to mealtime 
environment and routine
Background and rationale
In terms of experimental evidence, according to 
a recent systematic review applying standard 
criteria, ‘insufficient evidence’ exists to make 
clear recommendations regarding mealtime 
environment and routine modifications given 
the poor quality and limited quantity of trials 
(mostly small time-series comparisons)30. This 
may therefore be a case of ‘absence of evidence’ 
rather than ‘evidence of absence’ of effective 
interventions. Indeed, while poorly researched, 
this is currently a fertile area for innovation with 
successful advocacy driving forward change 
based to a large extent upon core principles, 
supported by some evidence and expert opinion. 
Available evidence on the effect of design 
innovation on dementia care has been helpfully 
collated at the Dementia Design Info website 
maintained by the University of Wisconsin Institute 
of Aging and Environment, I.D.E.A.S inc, and the 
Polisher Research Institute.*
The last 30 years has seen a gradual transition 
away from institutional models of long-term 
care for older people. Typically, these prioritize 
efficiencies of scale and the convenience of 
staff, over the rights of residents to flexible, 
individualised and person-centred care in settings 
that more resemble households or homes. 
This ‘household’ philosophy has been strongly 
advocated by the Culture Change movement, 
* https://www4.uwm.edu/dementiadesigninfo/
status; advice on enriching dietary protein 
and energy content; and strategies to manage 
aversive eating behaviours. The largest study 
by far was the Spanish, multi-centre cluster-
randomised controlled trial of the NutriAlz health 
and nutrition promotion programme35. Eleven 
outpatient clinics or day centres (n=946 home-
dwelling people with mild to moderate dementia 
and their caregivers) were randomised to an 
education and training intervention, or usual care. 
Over a third of participants did not complete 
outcome assessments at one year. No effect of 
the intervention was noted upon ADL (activities 
of daily living) score (the main outcome), weight, 
BMI, MMSE, dementia severity or behavioural 
symptoms. Nutritional status improved in the 
intervention group, but deteriorated in the control 
group, with a mean difference in MNA score 
of +1.12, 95% CI +0.65 to +1.59. This converts 
to a standardised mean difference of +0.33 
(95% CI +0.19 to +0.47), hence suggesting a 
small to moderate effect size of doubtful clinical 
significance. There was also no effect of the 
intervention on caregiver burden. The other 
randomised controlled trial, conducted in Brazil, 
included 90 people with AD randomised to 
oral nutritional supplementation, a nutritional 
education group, or treatment as usual control. 
After six months of follow-up weight increased in 
the education group and declined in the control 
group, with a MD for % weight change of 5.65% 
(+0.22 to +11.08) SE 2.77. However, weight 
gain was much greater in the oral nutritional 
supplementation group than in the education 
group (6.7 kg vs 1.2 kg). The non-randomised 
study was conducted in three European cities, 
in which 151 people with Alzheimer’s disease 
and their main informal caregiver were recruited 
from day centres or Alzheimer associations into 
an educational programme, while 74 patient/
caregiver dyads recruited from the same facilities 
and receiving normal clinical care acted as a 
control group. The mean difference for percentage 
weight change over one year was +1.93% (95% CI 
-0.34 to +4.20 SE 1.16) after adjusting for baseline 
covariates. There was no difference in overall 
nutritional status (MNA score mean difference = 
+0.60, 95% CI -0.11 to +1.31). Cognition declined 
in both groups, but to a greater extent in the 
control group MD = +1.1 (0.0 to +2.2). Combining 
the results across the three community-based 
studies suggests no effect of nutritional education 
interventions on weight (pooled MD for % weight 
gain +1.14%, 95% CI -0.22% to 2.50%). 
Conclusion
There is currently little or no evidence to suggest 
that training and education interventions, whether 
for paid care assistants in care homes, or for 
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residential features (sideboards, paintings, objets 
d’art, use of a bulk re-thermalization system 
in place of tray service) has been evaluated43. 
Food intake significantly increased with the 
environmental changes alone, and increased 
again (but not significantly) when combined with 
staff training. In a large US study of predictors 
of low food and fluid intake in care homes, such 
problems were less common in smaller assisted 
living and residential care facilities, in facilities 
with ‘non-institutional’ dining rooms, and where 
residents took their meals in public dining rooms 
as opposed to in their bedrooms28.
Dining rooms for dining
Disorientation in people with dementia, arising 
from problems with memory and gnosis, can 
be reduced by providing clear visual and other 
sensory cues as to the function of spaces. 
In this way, information is embedded in the 
design environment, rather than having to be 
remembered39. Generic multi-purpose living 
spaces where food is provided on trays to 
residents in the chairs where they sit for much 
of the day are a feature of many institutionalised 
care settings – there is a burden on residents 
to interact with each other, and studies suggest 
that this both leads to withdrawal and increases 
the likelihood of conflict. As a design principle 
for care homes, ideally, each room should have 
just one activity associated with it. For people 
with dementia it may be particularly important to 
have a dedicated dining room, the use of which is 
limited to meals and food. Hence, a dining room 
should look, as far as possible, like a dining room 
in a home, with recognisable furniture such as 
dining tables and sideboards. Thus, residents 
can develop a familiarity with its purpose over 
time, evoking positive and useful associations 
and cueing appropriate eating behaviours39. 
As with a dining room or kitchen in a home, the 
room can be a social hub throughout the day; for 
having coffee with friends after breakfast, inviting 
visitors to share food snacks from the kitchen 
between meals, and having afternoon tea with 
staff and residents. In non purpose-built care 
homes it may be difficult to reserve a room for 
dining times only. In such instances it is important 
to provide clear cues for when dining and non-
dining activities are taking place, for example by 
changing the layout of the room, and involving the 
residents in preparatory activities such as laying 
the tables. Noise levels and visual stimuli cannot 
be controlled. 
Kitchens next to dining areas
In homes, kitchens are generally next to dining 
rooms, or one room serves both functions. 
Across cultures, in the rituals surrounding food, 
there is a strong link between its preparation 
whose work has been influential in the USA and 
internationally38. Design has an important part 
to play. The aim is to create layouts and facilities 
that support residents’ residual abilities and limit 
the impact of their disabilities, while improving 
working conditions and providing a better care 
culture for staff, residents and visitors39. The four 
core design principles that distinguish the newer 
household and neighbourhood care settings 
relate to their scale, the nature and use of space, 
the relationships between living areas, and 
creation of spaces that support the autonomy and 
independence of residents40. Kitchen and dining 
areas form an important part of this broader 
design framework39.
The evidence
Downscaling
There is no clear threshold of size or scale 
that distinguishes a home from an institution, 
but clearly it would be very difficult for a 
single building with 60 residents or more to be 
‘homelike’. ‘Households’ typically comprise 
8–12 residents, and the Life Safety Code Task 
Force has recommended 24 as the maximum 
feasible number. Smaller, low-density homes 
facilitate social interactions among residents and 
with staff members, and reduce environmental 
over-stimulation. There is evidence that moving 
from high-density to low-density care settings 
is associated with a reduction in disruptive 
behaviours41. However, it is important to note that 
there is no simple relationship between the size of 
a home and the quality or outcomes of the care 
provided42. Household designs seek to replicate 
the living areas of houses, comprising resident 
rooms with bathrooms, a kitchen and dining area, 
and a living room or activity space. Care provider 
organisations can still achieve economies of scale 
by clustering households into ‘neighbourhoods’ 
of 30 to 50 residents with shared group leisure 
and social activities, and opportunities for staff 
training and support. These shared areas should, 
ideally, be separate from where residents live, 
respecting the normal distinction between 
home and community space. Large communal 
dining areas should be avoided, in particular for 
residents with dementia. It takes time to assemble 
residents in a central facility, meaning that some 
will be left waiting for long periods for the meal 
to begin. Large dining spaces can be noisy and 
confusing, with too much sensory distraction. 
Furthermore, such anonymous spaces fail to 
provide the sensory cues that orientate a person 
with dementia to mealtime. Smaller dining rooms 
can have a more intimate and familiar ambience, 
and reduce confusion as to the function of the 
room. The effect of reduced size dining rooms, 
‘bright and welcoming’ colours, and other 
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elements that detract from a resident’s residual 
abilities or make the environment feel institutional. 
Three key design issues to be addressed are 
controlling distracting stimuli, making tables 
accessible and safe, and deploying good quality 
lighting39.
Meals should be relaxed, unhurried and free from 
distraction. People with dementia find it difficult 
to concentrate on meals, and are sensitive to 
excessive noise and stimulation. Extraneous 
background noise should be reduced, for example 
by removing television sets. Large dining areas 
with many residents are intrinsically noisy and 
distracting; spaces can be broken up using 
moveable dividers and curtains and other soft 
materials can also reduce noise in the dining 
area39. Staff activities and other intrusions should 
be kept to a minimum, for example the circulation 
of a medication trolley during mealtimes should 
be avoided. On the other hand, staff dining 
with residents may normalise the activity and 
foster person-centred care. For those with 
prominent eating difficulties, quiet spaces free 
from distracting views can be helpful. As a 
design feature, moving services areas (for food 
preparation and plating) outside of the dining 
area may again help residents to focus on their 
eating. In the prototype design from the Royal 
College of Art project, the service hatch opens 
into the corridor to avoid staff having to distribute 
food from the dining area where residents are 
concentrating on their meals. While distracting 
noise should be reduced, another approach that 
has been trialled is to play music during mealtime. 
In the USA, an intervention study, investigating 
the effect of music during lunchtime on the caloric 
consumption of residents of nursing homes with 
middle-stage AD, showed a 20% increase in 
calories consumption when familiar background 
music was played45. Weekly average caloric 
consumption increased each week that music 
was played. 
Good quality lighting is essential in dining areas 
so that older people with visual impairment can 
identify food and cutlery. In a study conducted 
in US care homes increasing the light levels 
at table level led to an increase in food intake 
and independent feeding among residents46. 
Due to age-related changes to the pupil, lens 
and retina, older people may need as much as 
three times as much light as younger persons, 
and a lighting intensity of 50 foot candles (540 
lux) has been recommended for dining areas46. 
The Royal College of Art design team proposed 
overhanging lights for each table that could be 
individually adjusted, from 400 to 1200 lux, to the 
needs of the people sitting at it39. Decreased pupil 
reaction time and lens elasticity limits ability to 
adapt quickly to changes in lighting level, leading 
and consumption, and a prominent social 
component to these activities as evidenced by 
the importance of food to family and community 
celebrations. However, as highlighted in a recent 
collaborative research project between the Helen 
Hamlyn Centre at the Royal College of Art and 
Bupa, in many care homes design features and 
food management procedures make it difficult 
or impossible for residents to participate in these 
processes39. This is particularly the case when 
food is prepared in a central kitchen apart from 
the residential area, and then delivered either 
already plated on trays or from a heated trolley. 
Food service areas only include basic amenities 
for washing and serving and residents are not 
allowed into these areas for reasons of health and 
safety. One of the key recommendations of the 
research project was for ‘eat-in-kitchens’ to be 
included in the design of dining environments in 
care homes39. This could be achieved by splitting 
the kitchen into two sections; one equipped 
with everything necessary for the operation of 
a large-scale catering system, and the other 
a therapeutic ‘activity kitchen’ for residents in 
which everything is geared towards orientation, 
engagement and safety. The kitchen is homely in 
appearance, has a large cooker with unobtrusive 
safety features, and appliances that trigger 
memories of cooking activities. Residents can 
congregate at a large family-style table for leisure 
and supervised group activities including baking 
and other food preparation. Kitchen spaces 
evoke ideas and feelings of warmth, comfort and 
security. Associating the eating area with a space 
that looks and feels like a kitchen stimulates all of 
the senses with the smell and sound of cooking, 
evoking positive memories and cueing that a meal 
is about to take place in a much more direct and 
powerful way than words, signs or instructions 
could do. The diffusion of food-preparation smells 
has been suggested to stimulate the appetite of 
older people with dementia and to remind them 
of meal times. Suggestions include the ambient 
smell of fresh baked bread during meal times 
(i.e. the use of bread machine)44, and a Design 
Council technical innovation called ODE (www.
myode.org), a small device releasing up to three 
food-fragrances per day just before meal-times to 
stimulate appetite. ODE has been piloted tested in 
some care homes, with suggestions of increased 
interest in eating, requests for extra food, and 
weight gain among people with dementia. 
However, no formal experimental evaluations have 
been carried out to date.
Dining environment – family-style eating 
Having dedicated dining areas allows layouts and 
decor to be customised to reflect the specific 
function of the room. Dining areas should have a 
comfortable and appealing atmosphere avoiding 
61CHAPTER 5: IMPROvING NUTRITION FOR PEOPLE WITH DEMENTIA
ALZHEIMER’S DISEASE INTERNATIONAL · NUTRITION AND DEMENTIA
Oral nutritional supplementation 
for people with dementia
Background – macronutrient 
supplementation
Oral protein and energy supplements are widely 
used in older people, for undernutrition is more 
common than overnutrition, particularly in the 
context of chronic illness and hospitalisation. The 
supplements, usually in the form of commercially 
available liquid sip feeds, are safer and easier 
to administer than nasogastric feeds. The main 
concerns associated with their use are problems 
with the willingness and ability of older people to 
consume them, the potential for gastrointestinal 
adverse effects, and the risk that the additional 
calories from the supplement may be more than 
offset by a compensatory reduction in customary 
diet51. A Cochrane review of 62 trials of protein 
and energy supplementation in older people at 
risk from malnutrition indicated that their use 
was associated with a significant increase in 
weight (Mean difference +2.2%, 95% CI +1.8% to 
+2.5%) and a significant reduction in mortality risk 
among those who were undernourished (Relative 
Risk 0.79, 95% CI 0.64 to 0.97)51. We identified 
two further relevant systematic reviews, one of 
oral feeding options for people with dementia52, 
one of interventions on mealtime difficulties in 
older adults with dementia30. Evidence from 
these reviews were cross-referenced with those 
from a recently completed systematic review 
of nutritional interventions for frail dependent 
older people (personal communication AT 
Jotheeswaran). None of the reviews was 
completely satisfactory for our purposes. The 
review of oral feeding options for people with 
dementia52 included five trials which either 
focused upon cognitive impairment, or included 
frail or dependent older people not all of whom 
were affected by dementia. Some details of 
trial design and results seemed to have been 
incorrectly transcribed. No quantitative meta-
analysis was attempted. The review of mealtime 
interventions30 did focus upon studies recruiting 
people with dementia, and included seven trials, 
two of which were of micronutrient rather than 
protein/energy macronutrient supplementation, 
and one of which was a trial of whole formula 
diet replacement for normal dietary intake, rather 
than supplementation. Again details of trial design 
were incorrectly described. No quantitative data 
was presented, and no meta-analysis attempted. 
The Cochrane review51 included 62 randomised 
and quasi-experimental controlled trials, of which 
just five recruited only people with dementia; 
one of these was the trial of whole formula diet 
replacement. Quantitative meta-analysis was 
to sensitivity to glare. This can be managed by 
combining direct and indirect light sources to 
provide even lighting throughout the room. All 
light sources should be shaded with diffusers, 
including semi-sheer curtains for windows on 
bright days. Lights that cast shadows should be 
avoided because people with dementia may have 
trouble interpreting them. The place setting should 
contrast in colour with the table top to improve 
visibility. Food consumption increases when there 
is high contrast between the plate and table46. 
The table surface can also be contrasted at its 
edges to help those with low vision.
Square tables seating up to four residents may 
be optimal for communication and interaction 
among diners47, although for safety reasons 
corners should be curved to avoid sharp edges. 
Such tables can be grouped together for larger 
group activities or special occasions. Residents 
should sit in chairs with arms which need to slide 
under the table, so that the resident can be close 
enough to focus their attention on eating. Tables 
should also be high enough (74 cms, or 19 inches) 
and broad enough (107 cms or 42 inches) to allow 
wheel chairs to be accommodated, and with no 
central columns or support structures to prevent 
chair arms from clearing the underside of the 
table. The seat height of the chair should be 43 to 
48 cms (17 to 19 inches) enabling residents to sit 
with their feet firmly on the floor.
The various elements described above constitute 
a ‘complex’ (multicomponent) intervention, which 
has been described as the creation of a ‘family-
style’ eating environment. This does away with 
the practice of pre-plated meal delivery on trays 
and replaced it with a more informal ‘family style’ 
eating environment with bulk delivery of food to 
be served individually at the table. Staff are more 
involved in the process, but distractions are kept 
to a minimum. In a large and well conducted 
cluster randomised controlled trial in five nursing 
homes in the Netherlands, for 178 residents 
without dementia, the introduction of family-
style eating was associated with impressive 
improvements in energy intake, body weight, 
quality of life and physical performance48;49. A 
much smaller quasi-experimental study of a 
similar intervention (changes to foodservice and 
physical environment from institutional to more 
home-like environment in cognitive impairment 
nursing home units in Canada) has shown similar 
results50. Increases in energy, carbohydrate, and 
protein intake, but not fat intake were noted. 
Importantly, the greatest nutritional benefit 
seemed to be gained by the most cognitively 
impaired residents, and among those with lower 
body mass indexes (BMIs)50. 
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with analysis and reporting of findings, which, 
other than the same two higher quality studies, 
did not include effect sizes (mean differences) 
with standard errors or confidence intervals. One 
of the trials (Pivi et al37) could not be included in 
the meta-analysis because of lack of clarity of 
the reported effect sizes, and inconsistencies 
between effect sizes for weight and BMI (Table 
3 in the published paper). We have not yet been 
able to clarify these in correspondence with the 
authors of the report, but hope to update future 
published versions of this review.
Data synthesis
Given the small size of the studies, we attempted 
to calculate or estimate between group mean 
differences based upon change scores from 
baseline. Percentage weight gain was estimated 
as the change in weight divided by the baseline 
weight expressed as a percentage. Where 
baseline weight was not given this was estimated, 
conservatively, as 60 kg51. Where standard 
deviations of change scores were not provided 
these were imputed from baseline and follow-up 
SD, applying a between time point correlation 
derived from Laque et al55. If insufficient data 
was provided, then SD of change in % weight 
was imputed, conservatively, as 10% and SD of 
change in BMI was imputed as 1.5 kg/m2 (higher 
than those observed in any other study).
Results
Effect of ONS on weight / body mass
There was strong evidence that oral nutritional 
supplementation was effective in increasing 
weight (Figure 5.1: fixed effects pooled mean 
difference in % weight gain across five studies 
= 3.43%, 95% CI 2.08–4.78, random effects 
pooled within intervention group weight gain 
across six studies = 3.61%, 95% CI 1.89–5.33) 
and body mass index (Figure 5.2: random 
effects pooled mean difference across four 
studies 1.15 kg/m2, 95% CI 0.48–1.82; pooled 
within intervention group BMI gain across seven 
studies 1.09 kg/m2, 95% CI 0.72–1.46). There 
was, however, considerable variation in the 
size of the effect across studies (Table 5.1 and 
Figure 5.1). For % weight gain, mean differences 
between intervention and control groups ranged 
from 1.92% to 6.61% (Higgins’ I2 heterogeneity 
between studies = 11.1%), and within intervention 
group from 1.30% to 9.87% (I2=85.8%). Mean 
differences for BMI gain ranged from 0.70 to 
1.90 kg/m2 (I2=82.5%), and within intervention 
group from 0.50 to 1.60 (I2=71.9%). Sources 
of heterogeneity were explored using meta-
regression of within intervention group effect 
sizes for % change in body weight. The % gain 
in body weight was greater for studies with a 
carried out but with no sub-group analysis for 
trials of ONS among people with dementia. 
The evidence – macronutrient 
supplementation
Description of the trials
From the systematic reviews, we identified five 
parallel group randomised controlled trials of 
ONS with placebo or treatment as usual control 
groups53–57, one crossover trial58, and a parallel 
group RCT of micronutrient supplementation 
in which both arms received macronutrient 
ONS59. From our more recent review we 
identified a further parallel group RCT37 and 
a non-randomised controlled trial60. All of the 
studies were small in size ranging from 33 to 99 
participants. In all 440 participants with dementia 
were included in placebo or other controlled 
comparisons of ONS, and pre-post within group 
data was available for 246 individuals receiving 
ONS. One each of the studies was conducted in 
the UK, France, Sweden, Canada and Brazil, two 
in Spain and two in the Netherlands. Six of the 
studies were conducted in care homes or other 
long-stay accommodation53;54;56–58;60, and three in 
the community37;55;59. Oral nutritional supplements 
provided between 125 and 680 kcal per day, and 
were generally offered between meals and mainly 
in the morning to maximize adherence and reduce 
substitution. Duration of the intervention varied 
between three weeks and one year. Total calorie 
supplementation varied between 5,418 and 91,350 
kcal. 
Change in weight was studied as an outcome 
in seven studies, in six as a controlled 
comparison37;53;55–57;60, and in one other only 
as a within group change from baseline58. 
Change in body mass index was studied as an 
outcome in six studies, in five as a controlled 
comparison37;54–56;60, and in one other only as a 
within group change from baseline59. Mortality 
was reported in six trials37;53–57. Other outcomes 
studied included nutritional status (energy 
consumption, Mini Nutritional Assessment score 
(MNA), mid upper arm muscle circumference, 
triceps skinfold thickness, vitamins D, B1, B6, 
B12, homocysteine and folate, magnesium, zinc 
and selenium); cognitive function; disability; and 
complications (infections, days in bed, fractures, 
pressure sores, hospitalisation).
The quality of the studies was generally poor 
(Table 5.1). Most of the trials gave no information 
regarding randomisation procedures, it was 
unclear whether efforts had been made to 
conceal allocation, or to blind outcome assessors. 
Intention to treat analyses were infrequently 
conducted. Notable exceptions were Young et 
al58 and Lauque et al55. There were also problems 
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higher daily calorie supplementation (Figure 5.3: 
2.28%, 95% CI 1.00–3.57 higher gain per 100 
kcal increment), and for those with a higher total 
calorie supplementation (Figure 5.4: 0.89%, 
95% CI 0.31–1.46 per 10,000 kcal increment). 
Controlling for the duration of supplementation 
reduced variation due to heterogeneity from 
82.5% to 66.1%, controlling for daily calories to 
17.1%, and for total calories to 37.1%.
Other nutritional outcomes
Other data from these trials supported the 
broader nutritional benefits of ONS for people 
with dementia. Only two studies used the 
Mini Nutritional Assessment to assess overall 
nutritional status, both noting significant benefits 
associated with ONS54;55. ONS was associated 
with increases in upper arm circumference 
or arm muscle circumference (reflecting lean 
mass)37;53;59, and triceps skin fold thickness 
(reflecting fat deposition)54;59;60 in some but not 
all studies. Therefore the finding from one study 
that ONS was associated with selective benefits 
for lean body mass37 was not clearly replicated. 
More direct evidence comes from one trial of 
ONS among people with dementia, showing a 
statistically significant within group increase in 
fat-free mass measured using dual-energy x-ray 
absorptiometry (DEXA) scan55.
Issues in the administration and use of 
ONS
The main concerns regarding ONS are that 
older people do not like to take it; that it is 
associated with gastrointestinal side effects, 
including bloating, nausea and diarrhoea; and 
that the calorie value of supplements is offset by 
a reduction in the usual diet from regular meals. 
However, where reported, ONS was considered 
to be well tolerated, with typically high levels 
of adherence54–56, specified in three studies as 
95%53, 78.8%58 and 76%60. In only one study were 
adverse effects specifically examined, with no 
difference in the incidence of diarrhoea between 
ONS and placebo56. The trials that assessed 
overall energy consumption reported a net 
increase among those randomised to ONS55;58;59, 
suggesting that those taking supplementation 
did not compensate by reducing their customary 
dietary intake. In one crossover trial that 
addressed this directly, mean compensation 
levels were 25.8% in those receiving ONS in the 
first phase and 27.6% for those receiving ONS 
in the second phase58; however, compensation 
was greater for those with lower BMIs, worse 
cognitive functioning and worse aberrant motor 
behaviours, suggesting that these at risk groups 
might receive least benefit from ONS. In a further 
analysis of data from the same study, those who 
responded successfully to ONS with increases in Ta
bl
e 
5.
1 
De
sc
ri
pt
io
n 
of
 in
cl
ud
ed
 tr
ia
ls
 a
nd
 s
tu
di
es
Tr
ia
l a
ut
ho
rs
De
si
gn
Se
tt
in
g
In
cl
us
io
n
In
te
rv
en
tio
n
Co
nt
ro
l
Du
ra
tio
n
Qu
al
ity
Ca
rv
er
 &
 
Do
bs
on
, 
19
95
53
Pa
ra
lle
l g
ro
up
 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
Ol
de
r l
on
g 
st
ay
 p
at
ie
nt
s 
in
 p
sy
ch
ia
tri
c 
ca
re
 o
f t
he
 
el
de
rly
 fa
ci
lit
y, 
Sc
ot
la
nd
, U
K
Un
de
rw
ei
gh
t (
BM
I1
5.
1-
19
.9
) 
M
ea
n 
19
.9
 
‘S
en
ile
 d
em
en
tia
’ d
ia
gn
os
is
, a
ny
 
se
ve
rit
y
Fo
rti
si
p 
20
0m
l O
NS
 B
D,
 6
00
 
kc
al
 
R=
23
 
A=
20
Ac
al
or
ic
 v
ita
m
in
 p
la
ce
bo
 
R=
23
 
A=
20
 
‘N
or
m
al
 e
nc
ou
ra
ge
m
en
t’ 
fo
r 
m
ai
nt
en
an
ce
 o
f d
ie
t g
iv
en
 to
 
bo
th
 g
ro
up
s
12
 w
ee
ks
 
Co
nc
ea
lm
en
t –
No
 
Bl
in
di
ng
 –
 y
es
 fo
r 
an
th
ro
po
m
et
ry
 o
ut
co
m
es
 
No
 IT
T
Gi
l G
re
go
rio
 
20
03
54
Pa
ra
lle
l g
ro
up
 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
Nu
rs
in
g 
ho
m
e 
re
si
de
nt
s 
Sp
ai
n
M
od
er
at
e 
to
 s
ev
er
e 
AD
 (M
M
SE
 1
2.
7 
 
FA
ST
 5
-6
) 
M
al
no
ur
is
he
d 
M
NA
 2
0.
1 
16
.5
%
 B
M
I ≤
21
 
55
.7
%
 >
 2
3 
As
su
m
e 
m
ed
ia
n 
23
.5
Nu
tri
so
n 
ON
S 
12
5 
kc
al
 
R=
25
 
A=
21
?
No
t s
pe
ci
fie
d 
R=
74
 
A=
57
?
12
 m
on
th
s 
Ra
nd
om
is
at
io
n 
no
t d
es
cr
ib
ed
 
Co
nc
ea
lm
en
t n
ot
 d
es
cr
ib
ed
 
Bl
in
di
ng
 n
ot
 d
es
cr
ib
ed
 
No
 in
fo
rm
at
io
n 
on
 lo
ss
 
to
 fo
llo
w
-u
p,
 o
th
er
 th
an
 
m
or
ta
lit
y
La
uq
ue
 e
t a
l 
20
04
55
Pa
ra
lle
l g
ro
up
 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
Ge
ria
tri
c 
w
ar
ds
 
an
d 
da
y 
ce
nt
re
s 
To
ul
ou
se
 F
ra
nc
e
AD
 (M
M
SE
 1
5 
(s
d 
8)
 –
 m
od
er
at
e 
de
m
en
tia
 a
nd
 ri
sk
 o
f m
al
nu
tri
tio
n 
(M
NA
 
<
23
.5
). 
BM
I 2
2.
4 
(3
.1
) 
Cl
in
ut
re
n 
ON
S 
(s
ou
p,
 d
es
se
rt 
or
 li
qu
id
 s
up
pl
em
en
t).
 3
00
-
50
0 
kc
al
, m
ea
n 
36
8 
kc
al
: 
Di
et
ic
ia
n 
ho
m
e 
vi
si
ts
 
R=
46
 
A=
37
Us
ua
l c
ar
e 
R=
45
 
A=
43
3 
m
on
th
s 
(u
se
d 
fo
r 
ou
tc
om
e)
 
in
te
rv
en
tio
n.
 
FU
 to
 6
 
m
on
th
s 
Nu
tri
tio
na
l 
be
ne
fit
 
m
ai
nt
ai
ne
d 
at
 
6 
m
on
th
s
Co
nc
ea
lm
en
t u
nc
le
ar
 
Bl
in
di
ng
 y
es
 
IT
T 
no
W
ou
te
rs
-
W
es
se
lin
g 
20
02
56
Pa
ra
lle
l g
ro
up
 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
Ps
yc
ho
ge
ria
tri
c 
Nu
rs
in
g 
ho
m
e 
re
si
de
nt
s.
  
Ne
th
er
la
nd
s
De
m
en
tia
 s
yn
dr
om
e 
di
ag
no
si
s 
an
d 
lo
w
 
BM
I b
od
y 
m
as
s 
in
de
x 
(B
M
I) 
<
23
 k
g/
m
2  
fo
r m
en
 o
r <
25
 k
g/
m
2  
fo
r w
om
en
 
BM
I 2
0.
65
M
ic
ro
nu
tri
en
t e
nr
ic
he
d 
ON
S 
12
5 
m
l B
D.
 2
70
 k
ca
l 
R=
21
 
A=
19
Pl
ac
eb
o 
co
nt
ro
lle
d 
R=
21
 
A=
16
12
 w
ee
ks
 
Co
nc
ea
lm
en
t n
ot
 c
le
ar
 
 IT
T 
no
t d
on
e 
Do
ub
le
 b
lin
d
W
ou
te
rs
-
W
es
se
lin
g 
20
06
57
Pa
ra
lle
l g
ro
up
 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
Re
si
de
nt
s 
of
 
ps
yc
ho
ge
ria
tri
c 
un
it 
in
 N
H 
Ne
th
er
la
nd
s
Ea
rly
 li
qu
id
 s
up
pl
em
en
t O
D 
af
te
r o
ns
et
 o
f a
cu
te
 in
fe
ct
io
n 
30
9 
kc
al
 
R=
20
 
A=
18
St
an
da
rd
 tr
ea
tm
en
t 
Di
et
ic
ia
n 
re
fe
rr
al
 
R=
19
 
A=
16
5 
w
ee
ks
 
Co
nc
ea
lm
en
t a
nd
 b
lin
di
ng
 
no
t c
le
ar
 
IT
T 
m
en
tio
ne
d 
bu
t n
o 
re
su
lts
Yo
un
g 
et
 a
l 
20
04
58
Cr
os
so
ve
r 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
Ge
ria
tri
c 
ca
re
 c
en
te
r 
Al
zh
ei
m
er
’s
 
un
it 
re
si
de
nt
s.
 
Ca
na
da
M
od
 to
 s
ev
er
e 
de
m
en
tia
 
M
ea
n 
BM
I 2
3.
8 
¾
 o
f a
 n
ut
rie
nt
 s
up
pl
em
en
t 
ba
r a
nd
 ju
ic
e 
be
tw
ee
n 
m
ea
ls
 
25
8 
kc
al
 
R=
15
 
A=
15
 
(P
ha
se
 2
)
Cr
os
so
ve
r w
ith
 w
as
ho
ut
 p
er
io
d 
R=
19
 
A=
19
 
21
 d
ay
s 
(th
en
 
w
as
ho
ut
 a
nd
 
an
ot
he
r 2
1 
da
ys
 in
 o
th
er
 
co
nd
iti
on
)
Co
nc
ea
lm
en
t y
es
 
Bl
in
di
ng
 –
 fo
r s
om
e 
ou
tc
om
es
 
IT
T 
- 
ye
s 
Pi
vi
 e
t a
l 
20
11
37
*
Pa
ra
lle
l g
ro
up
 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
Be
ha
vi
ou
ra
l 
ne
ur
ol
og
y 
OP
D,
 
Br
az
il
Pr
ob
ab
le
 A
D,
 C
DR
 1
+
 
No
 in
fo
rm
at
io
n 
on
 n
ut
rit
io
na
l s
ta
tu
s 
at
 
ba
se
lin
e
En
su
re
 O
NS
 B
D.
 6
80
 k
ca
l 
R=
30
 
A=
26
TA
U 
R=
30
 
A=
27
6 
m
on
th
s 
No
 in
fo
rm
at
io
n 
on
 
ra
nd
om
iz
at
io
n,
 c
on
ce
al
m
en
t 
or
 b
lin
di
ng
 
IT
T 
no
t c
ar
rie
d 
ou
t 
Ch
an
ge
 s
co
re
s 
re
po
rte
d 
w
ith
ou
t S
D
Fa
xe
n-
Irv
in
g 
et
 a
l60
Co
nt
ro
lle
d 
bu
t n
ot
 
ra
nd
om
is
ed
 tr
ia
l
Gr
ou
p 
liv
in
g 
fa
ci
lit
ie
s 
fo
r 
ol
de
r p
eo
pl
e 
w
ith
 d
em
en
tia
, 
Sw
ed
en
Al
l p
ar
tic
ip
an
ts
 h
ad
 d
em
en
tia
. 
43
%
 o
f I
G 
an
d 
18
%
 o
f C
G 
ha
d 
se
ve
re
 
de
m
en
tia
. B
od
y 
m
as
s 
in
de
x 
(B
M
I) 
<
 o
r =
20
 w
as
 fo
un
d 
in
 1
9%
 o
f t
he
 
pa
rti
ci
pa
nt
s 
an
d 
44
%
 h
ad
 B
M
I<
 o
r =
23
 
BM
I m
ea
n 
22
.2
 IG
ON
S 
(4
10
 k
ca
l/d
ay
) a
nd
 s
ta
ff 
nu
tri
tio
na
l e
du
ca
tio
n 
A=
21
TA
U 
A=
12
5 
m
on
th
s 
in
te
rv
en
tio
n 
w
ith
 6
 
m
on
th
s 
FU
 
as
se
ss
m
en
t
No
 ra
nd
om
iz
at
io
n 
No
 b
lin
di
ng
Pl
an
as
, 2
00
45
9
Pa
ra
lle
l g
ro
up
 
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
tri
al
, b
ut
 
bo
th
 a
rm
s 
re
ce
iv
ed
 
pr
ot
ei
n/
en
er
gy
 O
NS
44
 A
lz
he
im
er
’s
 
di
se
as
e 
da
y 
ce
nt
re
 
pa
rti
ci
pa
nt
s 
in
 
Sp
ai
n
M
ild
 d
em
en
tia
 a
nd
 fe
ed
in
g 
pr
ob
le
m
s 
M
ea
n 
BM
I 2
5.
4/
24
.4
 
Or
al
 li
qu
id
 s
up
pl
em
en
ts
 5
00
 
kc
al
/d
 w
ith
 m
ic
ro
nu
tri
en
t 
en
ha
nc
em
en
t 
R=
23
 
A=
22
Or
al
 li
qu
id
 s
up
pl
em
en
ts
 5
00
 
kc
al
/d
 w
ith
ou
t m
ic
ro
nu
tri
en
t 
en
ha
nc
em
en
t 
R=
21
 
A=
18
Tr
ia
l o
f 
m
ic
ro
nu
tri
en
t 
on
ly
 
(e
ve
ry
on
e 
ha
d 
m
ac
ro
nu
tri
en
t)
No
 in
fo
rm
at
io
n 
on
 
ra
nd
om
iz
at
io
n,
 c
on
ce
al
m
en
t 
or
 b
lin
di
ng
 
IT
T 
no
t c
ar
rie
d 
ou
t
R 
=
 N
um
be
r r
an
do
m
is
ed
 
A 
=
 N
um
be
r a
ss
es
se
d 
IT
T 
=
 In
te
nt
io
n 
to
 tr
ea
t a
na
ly
si
s 
* T
he
 tr
ia
l b
y 
Pi
vi
 e
t a
l c
ou
ld
 n
ot
 b
e 
in
cl
ud
ed
 in
 th
e 
m
et
a-
an
al
ys
is
, d
ue
 to
 la
ck
 o
f c
la
rit
y 
re
ga
rd
in
g 
th
e 
re
po
rte
d 
ef
fe
ct
 s
iz
es
 (T
ab
le
 
3 
in
 th
e 
pu
bl
is
he
d 
pa
pe
r)
65CHAPTER 5: IMPROvING NUTRITION FOR PEOPLE WITH DEMENTIA
ALZHEIMER’S DISEASE INTERNATIONAL · NUTRITION AND DEMENTIA
Ta
bl
e 
5.
2 
Re
su
lts
Tr
ia
l 
au
th
or
s
%
 W
ei
gh
t c
ha
ng
e 
M
D
W
ei
gh
t c
ha
ng
e 
in
 O
NS
BM
I c
ha
ng
e 
M
D
BM
I c
ha
ng
e 
in
 O
NS
M
or
ta
lit
y
Ot
he
r 
si
g 
fin
di
ng
s
No
n 
si
g 
fin
di
ng
s
Ca
rv
er
 &
 
Do
bs
on
, 
19
95
53
IG
 
+
7.
50
 (3
.8
6)
 
CG
 
+
1.
32
 (3
.7
5)
 
M
D 
=
 +
6.
18
  
(-
0.
02
-+
12
.3
8)
 
SE
 =
 3
.1
6 
(F
ro
m
 M
iln
e)
 
M
D 
=
 +
6.
18
  
(3
.8
2-
8.
54
) 
SE
 =
 1
.2
0 
(re
ca
lc
 fr
om
 p
ap
er
)
7.
50
 (5
.8
1-
9.
19
)  
SE
=
0.
86
 
IG
 +
1.
3 
(1
.5
*)
 
CG
 +
0.
2 
(1
.5
*)
 
M
D 
=
 +
1.
5
No
 d
ea
th
s 
in
 e
ith
er
 
gr
ou
p
M
UA
C 
+
 
TS
F 
+
Gi
l G
re
go
rio
 
20
03
54
IG
 +
1.
6 
(0
.9
6)
 
CG
 -
0.
3 
(1
.0
8)
 
M
D 
=
  
1.
90
 (1
.4
1-
2.
39
) 
SE
=
0.
25
 
1.
60
  
(1
.1
9-
2.
01
) 
SE
=
 0
.2
1
M
or
ta
lit
y 
16
%
 4
/2
5 
vs
 2
2.
7%
 
17
/7
4 
In
fe
ct
io
n 
- 
Da
ys
 in
 b
ed
 -
 0
.0
5 
M
NA
 +
 
-0
.2
 v
s 
-3
.2
 
P=
0.
05
 
TS
F 
+
0.
01
Co
gn
iti
ve
 
Fu
nc
tio
na
l 
‘c
on
du
ct
’ v
ar
ia
bl
es
La
uq
ue
, 
20
04
55
IG
  
+
3.
46
 (4
.2
4)
 
CG
  
+
0.
69
 (4
.1
5)
 
M
D=
+
2.
77
 (0
.9
3-
4.
61
) 
SE
=
0.
94
3.
46
 (2
.0
9-
4.
83
) 
SE
 =
 0
.7
0
IG
 0
.8
0 
(0
.9
8)
 
CG
 0
.1
6 
(0
.9
0)
  
M
D=
0.
64
 (0
.2
3-
1.
05
) 
SE
 =
 0
.2
1
0.
80
  
(0
.4
8-
1.
12
) 
SE
=
0.
16
De
at
hs
 
2/
46
 tr
ea
tm
en
t 
0/
45
 c
on
tro
l
M
NA
+
 
Ca
lo
rie
 in
ta
ke
+
Fr
ac
tu
re
s 
Pr
es
su
re
 u
lc
er
s 
Ho
sp
ita
liz
at
io
n 
Co
gn
iti
on
 
AD
L
W
ou
te
rs
-
W
es
se
lin
g 
20
02
56
IG
 
+
2.
71
 (4
.6
5)
 
CG
 
-1
.5
0 
(5
.6
2)
  
M
D 
=
 +
4.
21
 (0
.7
5-
7.
67
) 
SE
=
 
Fr
om
 M
iln
e
+
2.
71
 (0
.6
2-
4.
80
) 
SE
=
1.
06
IG
 +
0.
5 
(0
.9
1)
 
CG
 -
0.
2 
(0
.9
5)
 
M
D 
=
 0
.7
0 
(0
.0
7-
1.
33
) 
SE
=
0.
32
0.
50
  
(0
.0
9-
0.
91
)
De
at
hs
 1
/2
1 
in
 O
NS
 a
nd
 
2/
32
 in
 p
la
ce
bo
 
Ho
m
oc
ys
te
in
e,
  
vi
ta
m
in
 B
1 
vi
ta
m
in
 B
6 
vi
ta
m
in
 B
12
 
fo
la
te
 a
nd
 v
ita
m
in
 D
Ba
rth
el
 in
de
x 
(A
DL
) 
Di
ar
rh
oe
a
W
ou
te
rs
-
W
es
se
lin
g 
20
06
57
IG
  
+
1.
30
 (3
.6
9)
 
CG
  
-0
.6
2 
(6
.0
0)
 
M
D=
+
1.
92
 
(-
1.
48
 to
 +
5.
32
) 
(fr
om
 M
iln
e)
+
1.
30
 
(-
0.
40
 to
 +
3.
00
) 
SE
=
1.
70
 
no
 d
ea
th
s
Di
et
ar
y 
en
er
gy
 in
ta
ke
 
m
id
-u
pp
er
 a
rm
 m
us
cl
e 
ci
rc
um
fe
re
nc
e 
tri
ce
ps
 s
ki
n 
fo
ld
 
th
ic
kn
es
s 
ca
lf 
ci
rc
um
fe
re
nc
e 
ZI
G 
sc
or
e
66
Yo
un
g 
et
 a
l 
20
04
58
Ba
se
lin
e 
w
ei
gh
t n
ot
 re
po
rte
d 
he
nc
e 
as
su
m
ed
 to
 b
e 
60
 k
g 
M
D=
1.
55
 (1
.0
1-
2.
09
) 
SE
=
0.
27
 
No
 d
ea
th
s
24
h 
en
er
gy
 p
ro
te
in
 
an
d 
ca
rb
 in
ta
ke
 +
 
Co
g 
fu
nc
tio
n,
 
be
ha
vi
ou
ra
l 
di
st
ur
ba
nc
e 
an
d 
be
ha
vi
ou
ra
l f
un
ct
io
n
Pi
vi
 e
t a
l 
20
11
37
As
su
m
e 
ba
se
lin
e 
w
t 6
0 
kg
 
an
d 
SD
 1
0%
 
IG
 +
11
.1
10
 
CG
 -
3.
71
0  
M
D 
=
 +
14
.7
 (9
.3
1-
20
.0
9)
 
SE
=
2.
75
 
11
.1
 (7
.2
6-
14
.9
4)
 
SE
=
1.
96
 
No
 S
D 
gi
ve
n 
As
su
m
e 
1.
5 
IG
 6
.5
5 
(1
.5
) 
CG
 -
2.
21
 (1
.5
) 
M
D=
8.
76
 (8
.1
6-
9.
56
) 
SE
=
0.
41
 
W
ith
in
 g
rp
6.
55
 (5
.9
7-
7.
13
) 
SE
=
0.
29
 
3 
de
at
hs
 in
 IG
 3
0,
 1
 in
 
CG
 3
0 
M
UA
C+
 
AM
C+
 
Tr
ic
ep
s 
sk
in
 
fo
ld
th
ic
kn
es
s
Fa
xe
n-
Irv
in
g 
et
 a
l6
0
CG
 
 -
0.
48
%
 (5
.8
8)
 
IG
 
+
6.
13
%
 (5
.7
0)
 
M
D 
=
 6
.6
1 
(2
.4
9-
10
.7
3)
 
SE
=
2.
10
6.
13
 (3
.6
9-
8.
57
) 
SE
=
1.
24
CG
  
-0
.1
0 
(1
.3
8)
 
IG
 
+
1.
30
 (1
.2
4)
 
M
D 
=
 1
.4
0 
(0
.5
8-
2.
22
) 
SE
=
0.
42
1.
30
 (0
.7
1-
1.
89
) 
SE
=
0.
30
M
M
SE
 w
or
se
ne
d 
in
 
th
os
e 
in
 IG
 (p
=
0.
01
)
Ka
tz
 A
DL
Pl
an
as
, 
20
04
59
Gr
p 
A 
+
 m
ic
ro
nu
tri
en
t 
N=
23
 
1.
1 
(1
.2
6)
 
1.
1 
(0
.5
9-
1.
61
) 
SE
 =
 0
.2
6 
Gr
pB
 -
 m
ic
ro
nu
tri
en
t 
N=
21
 
1.
6 
(1
.2
4)
 
1.
6 
(1
.0
7-
2.
13
) 
SE
=
0.
27
en
er
gy
 c
on
su
m
pt
io
n 
tri
ce
ps
 s
ki
n 
fo
ld
 
th
ic
kn
es
s 
m
id
-u
pp
er
-a
rm
 
ci
rc
um
fe
re
nc
e 
se
ru
m
 m
ag
ne
si
um
 
zi
nc
 
se
le
ni
um
No
 d
iff
er
en
ce
 in
 
fe
ed
in
g 
be
ha
vi
ou
r o
r 
co
gn
iti
ve
 fu
nc
tio
n.
IG
=
 In
te
rv
en
tio
n 
Gr
ou
p 
CG
 =
 C
on
tro
l G
ro
up
 
M
D 
=
 M
ea
n 
Di
ffe
re
nc
e 
SE
 =
 S
ta
nd
ar
d 
Er
ro
r 
M
NA
 =
 M
in
i N
ut
rit
io
na
l A
ss
es
sm
en
t 
M
UA
C 
=
 M
id
-u
pp
er
 a
rm
 c
irc
um
fe
re
nc
e 
 
TS
F 
=
 T
ric
ep
s 
sk
in
fo
ld
 th
ic
kn
es
s 
AD
L 
=
 a
ct
iv
iti
es
 o
f d
ai
ly
 li
vi
ng
67CHAPTER 5: IMPROvING NUTRITION FOR PEOPLE WITH DEMENTIA
ALZHEIMER’S DISEASE INTERNATIONAL · NUTRITION AND DEMENTIA
Carver
Lauque
Wouters 2002
Wouters 2006
Faxen
Overall (l-squared = 11.1%. p = 0.343)
6.18 (-0.01, 12.37)
2.77 (0.93, 4.61)
2.77 (0.93, 4.61)
4.21 (0.74, 7.68)
1.92 (-1.47, 5.31)
343 (2.08, 4.78)
4.74
53.59
15.11
15.82
10.74
100.00
Study ES (95% CI)
%
Weight
-12.4 12.40
Gil Gregorio
Lauque
Wouters 2002
Faxen
Overall (l-squared = 11.1%. p = 0.343)
Study
1.90 (1.41, 2.38)
0.63 (0.23, 1.05)
0,70 (0.07, 1.33)
1.40 (0.58, 2.22)
1.15 (0.48, 1.82)
26.64
27.80
24.42
21.15
100.00
ES (95% CI)
%
Weight
-2.39 2.390
NOTE: Weights are from random effects analysis
Figure 5.1 
Random effects meta-analysis forest-plot
Mean differences for the effect of oral nutritional supplementation on % change in body weight
Figure 5.2 
Random effects meta-analysis forest-plot
Mean differences for the effect of oral nutritional supplementation on Body Mass Index
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Figure 5.4 
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July 2008; on B1262 published in 2009 with review 
content assessed as up-to-date on 23 January 
2006; and on vitamin E63 published in 2008 with 
review content assessed as up-to-date on 15 
January 2007.
Vitamin B12
Three trials were identified. Two trials included 
those with dementia and low B12 blood 
levels64;65. One evaluated oral supplementation 
with one month follow-up (n=31)64, the other 
used B12 injections with 5 months of follow up 
(n=11)65. One much larger trial (n=140) recruited 
those aged 75 and over with B12 deficiency 
regardless of cognitive function66; at baseline 40 
participants had a MMSE score below 25, and 
the mean MMSE was 26.5 points. There was no 
evidence from any of the trials of any benefits 
of treatment on cognitive function. However, the 
two treatment trials of those with dementia were 
underpowered to detect anything other than very 
large effects64;65. For the third trial66 results were 
not presented for the subgroup of participants 
with cognitive impairment. The authors of the 
review considered the evidence to be ‘insufficient’ 
meaning that efficacy was neither demonstrated, 
nor excluded. A subsequent controlled study67 
of B12 intramuscular supplementation of those 
with deficiency in nursing homes (n=28) versus a 
non-deficient comparison group (n=28) failed to 
identify any cognitive benefit of supplementation. 
A more recent systematic review, noting 2.9 
million B12 tests in Ontario in 2010 at a cost of 
$40 million concluded that ‘moderate quality of 
evidence indicates treatment with vitamin B12 
does not improve brain function’68.
Folate
Two trials were identified that recruited patients 
with dementia, 41 patients with AD from 
Scotland69, and 11 patients with varying subtypes 
of dementia and MMSE scores between 16 and 
2770. A further UK trial included 149 participants; 
95 had dementia (AD or mixed AD/VaD) and the 
remainder cognitive impairment no dementia71. 
Combined treatment with 2 mg folate and B12 
had a significant effect on reducing serum 
homocysteine levels71. However, no such effect 
was seen with 1 mg daily folate supplementation 
alone69. In the Clarke trial there was no effect of 
folate 2 mg combined with B12 on MMSE (MD 
0.39, 95% CI -0.43 to 1.21) or ADAS-Cog (change 
from baseline at 12 weeks MD 0.41, 95% CI -1.25 
to 2.07). The only outcome for which pooling 
was possible, across two trials, was the effect of 
folate with or without B12 on MMSE for cognitive 
impairment and dementia (pooled MD 0.30, 95% 
CI -0.45 to 1.05). In the Connelly trial, while there 
was no effect of folate 1 mg on MMSE -0.13 
(-1.96, 1.70) there was a significant net benefit on 
daily energy intake maintained on average 58.8% 
of that increase post-supplementation, although 
stopping the supplement was associated with 
decreased habitual energy intake in low-BMI 
individuals who reduced their daily intakes during 
supplementation in response to the extra calories. 
For most of the trials, ONS was continued up to 
the final outcome assessment. However, in one 
other study, ONS were withdrawn after three 
months and outcomes reassessed at 6 months – 
significant increments in weight, BMI and fat-
free body mass were retained in the intervention 
group, and significant weight loss (>4% of body 
weight) was reported to have occurred less often 
than in the control group55. 
Effect of ONS on other outcomes
There was insufficient evidence to judge the 
impact of ONS on mortality among people with 
dementia. Three trials reported no deaths53;57;58, 
and 21 of the 35 deaths were observed in one trial 
with a relatively long (one year) follow-up54. The 
meta-analysed effect across four trials was RR 
0.69, 95% CI 0.00–1.46. 
No effect of ONS on cognitive function was 
observed in three trials54;55;58 and one within 
group evaluation59, while in one non-randomised 
controlled study cognitive deterioration was 
more marked in the ONS intervention group60. 
No benefit of ONS on activities of daily living was 
observed in five trials54–56;58;60. Such data as were 
provided for these outcomes did not permit meta-
analysis.
Micronutrient supplementation
Background
Micronutrient deficiencies are relatively common 
among older people, due to insufficient dietary 
intake, inefficient absorption, or both. Low 
levels of vitamin B12 and folate (folic acid) are 
associated with high blood levels of the amino 
acid homocysteine which has been linked with the 
risk of arterial disease, dementia and Alzheimer’s 
disease. Vitamin E is another dietary compound, 
with antioxidant properties. Evidence that free 
radicals may contribute to the pathological 
processes of Alzheimer’s disease (AD) has led to 
interest in the use of vitamin E in its prevention 
and treatment. Here, we specifically report studies 
and reviews that have focused on micronutrient 
supplementation for the treatment of dementia.
Results
We identified three relevant reviews each covering 
the treatment of dementia as well as the use of 
these compounds in healthy older people; on 
folate with or without B1261 published in 2009 and 
with review content assessed as up-to-date on 21 
70
Instrumental Activities of Daily Living 2.67 (0.25, 
5.09), but not social behaviour. Those randomised 
to folate were much more likely to be considered 
as ‘treatment responders’ to cholinesterase 
inhibitors (OR 4.06, 95% CI 1.22–13.53). 
The authors of the review conclude that there is 
insufficient evidence to conclude either way on 
the possible benefits or harms of folic acid. This 
is probably justified, although the evidence on 
cognitive impairment does seem conclusively 
negative. The findings of a possible positive 
interaction with acetylcholinesterase inhibitor 
medication requires replication69. For healthy 
older people, in the same review, possible 
cognitive benefits were identified in just one trial 
of those with elevated homocysteine levels; it 
may be that people with dementia with raised 
homocysteine may also be more likely to benefit. 
Vitamin E
One trial was identified that recruited people 
with dementia72, 341 patients with a diagnosis 
of probable AD of moderate severity (CDR of 
two), from 23 centres in the USA. The trial had 
a factorial design trial in which patients were 
randomised to vitamin E (2000 IU total daily) 
only, selegeline only, the two drugs combined, 
or placebo. The primary outcome was the 
survival time to any one of four endpoints, death, 
institutionalisation, progression to CDR severe 
(3.0) or change in loss of activities of daily living. 
Secondary outcomes were change in ADAS-Cog 
and MMSE, but since these were assessed on 
the basis of change between baseline and last 
follow-up with no fixed endpoint, these were not 
assessed in the Cochrane review. The Cochrane 
reviewers only compared the vitamin E and 
placebo groups, to avoid confounding. In so doing 
they confirmed the findings from the original 
analysis of a statistically significant reduction 
in the main endpoint (progression) with an OR 
of 0.49, 95% CI 0.25 to 0.96, but a statistically 
significant increase in falls OR 3.09, 95% CI 1.07 
to 8.62. (RR 0.70, P=0.08). The effect size for 
the main endpoint was similar to the survival 
analysis conducted by the trial investigators once 
baseline differences in MMSE scores had been 
accounted for (HR 0.47, p=0.001)72. The authors 
of the Cochrane review conclude that there is no 
evidence of efficacy of vitamin E in the treatment 
of people with AD, but that more research is 
needed to identify its role of vitamin E, if any, in 
the management of cognitive impairment. 
A recent trial assessed a 16-week multi-vitamin 
supplementation programme, comprising 
800 IU/d of vitamin E, 500 mg/d of vitamin C and 
900 mg/d of α-lipoic acid73. This intervention 
did not influence cerebrospinal fluid Alzheimer’s 
disease biomarkers, but the group that received 
this supplementation experienced accelerated 
cognitive decline, compared to controls, raising 
potential safety concerns. 
In 2014 results were published of the TEAM-
AD VA collaborative double-blind, placebo-
controlled, parallel-group, randomised clinical trial 
involving 613 patients with mild to moderate AD, 
comparing either 2000 IU/d of alpha tocopherol 
(vitamin E, n=152), 20 mg/d of memantine (n=155), 
the combination (n=154), or placebo (n=152)74. 
Over the mean follow-up of 2.3 years, ADCS-
ADL Inventory scores declined by 3.15 units 
(95% CI 0.92–5.39) less in the vitamin E group 
compared with the placebo group. This change 
in the vitamin E group translates into a delay in 
clinical progression of 19% per year compared 
with placebo or a delay of approximately 6.2 
months over the follow-up period. Caregiver time 
increased least in the vitamin E group. All-cause 
mortality and safety analyses did not suggest 
increased rates of adverse outcomes in the 
vitamin E group. These findings suggest benefit 
of vitamin E in mild to moderate AD by slowing 
functional decline and decreasing caregiver 
burden.
Medical food interventions
Medical foods are defined as a special category 
of products that are intended for the specific 
dietary management of a disease or condition that 
has distinctive nutritional requirements. There are 
three medical foods that claim to have benefits for 
use in dementia patients and are available in the 
USA and/or Europe: Axona® (AC-1202, Accera, 
Inc., CO, USA), Souvenaid® (Danone Research, 
France) and CerefolinNAC® (LA, USA)75. 
The rationale for the use of Souvenaid is that 
a combination of nutrients (eicosapentaenoic 
acid (EPA), docosahexaenoic acid (DHA), 
phospholipids, choline, uridine monophosphate, 
vitamins E, C, B6 and B12, selenium and folic acid) 
might be required synergistically to increase brain 
levels of phosphatide molecules that comprise the 
bulk of brain synaptic membranes. The efficacy of 
Souvenaid has been tested in a pilot randomised 
controlled trial in 225 drug-naïve patients with 
mild AD76, and two subsequent definitive trials of 
25977, and 52778 patients with mild to moderate 
AD. In the pilot trial, at 12 weeks, significant 
improvement was noted in the delayed verbal 
recall task in the treatment group compared with 
control (p = 0.02). However, there was no change 
and no significant difference in other relevant 
outcomes; ADAS-Cog, Clinician Interview Based 
Impression of Change, activities of daily living, or 
quality of life. The subsequent Souvenir II study 
was a 24-week, randomised, controlled, double-
blind, parallel-group, multi-country trial to confirm 
and extend previous findings in drug-naive 
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B12, 5.6 mg of L-methylfolate and 600 mg of 
N-acetylcysteine has also been approved by the 
FSA for the prevention and treatment of vitamin 
deficiencies associated with memory loss. One 
possible advantage of using CerefolinNAC over 
other B vitamin supplements is that it contains 
formulations of folic acid and vitamin B12, which 
are ‘active’, hence ready to use by the body 
without the need for conversion. However, no 
randomised clinical trials of this supplement have 
ever been carried out, and none are currently 
taking place. This means that there is no specific 
evidence on the effectiveness of CerofolinNAC for 
treatment of cognitive decline.
Conclusion
There is fairly consistent evidence from 
several randomised controlled trials that 
macronutrient ONS is effective in maintaining 
or improving weight among people with 
dementia. Supplements seem to be relatively 
well tolerated, with high levels of adherence at 
least under controlled clinical trial conditions. The 
nutritional benefit gained from supplementation 
seems to be proportionate to its intensity and 
duration. However, benefits gained (improved 
nutritional status and calorie intake) from 
short term supplementation, over weeks or 
months, does seem to be retained in the short 
to medium term55;79, raising the possibility that 
brief cycles of ONS may be as effective as 
long-term supplementation79. While one of the 
trials53 included only those who were markedly 
undernourished, most others focused mainly 
on those who were at risk of undernutrition, 
or normally nourished. There is therefore an 
important outstanding question as to the 
effectiveness of ONS among people with 
dementia who are already undernourished58. 
Given the health hazards of undernutrition, 
particularly when this involves protein catabolism 
and loss of lean body mass, one might expect 
that maintenance of nutritional status might 
be associated with wider health benefits than 
those identified in the studies reviewed. That 
this was not the case may be explained by the 
implausibility of direct benefits (cognition and 
behavioural disturbance), the need for a longer 
period of nutritional support and a longer follow-
up period (disability, mortality)51, and the lack of 
assessment of relevant outcomes (quality of life, 
depression, physical functioning).
Several of the studies included an element of 
nutritional education provided to caregivers 
(usually professionals in care homes)55;60. As 
such, the relative benefits of ONS and nutritional 
education may be difficult to disentangle. 
However, equivalent weight gain was observed 
when ONS was provided without nutritional 
patients with mild AD. 259 patients, recruited from 
27 AD centres in Netherlands, Germany, Belgium, 
Spain, Italy and France, were randomised 1:1 
to receive Souvenaid or an iso-caloric control 
product once daily for 24 weeks. The primary 
outcome was the memory function domain 
Z-score of the Neuropsychological Test Battery 
(NTB). Electroencephalography (EEG) measures 
served as secondary outcomes as marker for 
synaptic connectivity. The NTB memory domain 
Z-score was reported as being statistically 
significant in the active versus the control 
group over the 24-week intervention period (p 
= 0.023). However, the reported confidence 
intervals (Cohen’s d 0.21, 95% CI -0.06 to +0.49) 
do not support statistical significance, a likely 
explanation being that one-tailed rather than two-
tailed p-values were calculated although this is 
not specified. This approach, which assumes that 
the treatment can only improve and not worsen 
the outcome is unconventional. No significant 
effect was observed for the NTB total composite 
z-score (p = 0.053). EEG measures of functional 
connectivity in the delta band were significantly 
different between study groups during 24 weeks 
in favour of the active group. The definitive trial 
conducted in the USA with 579 patients with mild 
to moderate AD failed to show any beneficial 
effect of Souvenaid upon cognitive outcomes 
(ADAS-COG mean difference =+0.37 points, 
95% -0.75 to +1.49)78. Compliance was very 
high across all three studies (86–97%) with no 
indication of excess adverse events. The trials 
were sponsored by Danone Research–Centre 
for Specialised Nutrition (part of Groupe Danone 
– the manufacturers of Souvenaid), who were 
involved in study design, data collection and 
analysis. Alpha-Plus Medical Communications 
Limited were involved in drafting and editing the 
manuscript for the pilot trial. 
Two other ‘medical foods’ have been introduced 
to the market and are available by prescription in 
the USA. Axona is a medium-chain triglyceride 
product combining glycerine and caprylic acid, 
providing ketone bodies to the brain, as an 
alternative energy source to glucose. So far 
there has only been one Phase II randomised 
clinical trial in patients with mild to moderate AD. 
Cognitive function, measured by the Assessment 
Scale-cognitive subscale (ADAS-cog) were 
slightly improved at day 45 in those taking Axona, 
but these differences were not significant at day 
90, apart from in a subset of ApoE ε4-negative 
participants75. The duration of this trial was very 
short, and a Phase III trial is needed to confirm 
any finding. Discontinuation due to adverse 
events in the treatment group was also relatively 
high (23%), compared to the placebo group (6%). 
CerofolinNAC, which consists of 2 mg of vitamin 
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how chubby he/she is’. Family care for people 
with dementia is supplemented by paid workers 
whether domestic workers (hired originally to 
clean the house and prepare food), or care 
assistants in nursing homes. Domestic care 
workers are employed sometimes just during 
the daytime, or to sleep over from Monday till 
Saturday. They usually have very low education; 
some are illiterate and they tend to be underpaid. 
Dr Acosta notes: 
These are the people that for the most part we 
use as caregivers, in the private or public sector, 
in the patient’s residence or in nursing homes. 
I came to realize that one important reason for 
the high turnover of paid caregivers had to do 
with food and feeding; the patient’s decreased 
appetite, selective eating behaviours, weight 
loss, and feeding difficulties. These symptoms 
were not well known, or understood by the 
caregiver or the family member as an aspect 
of the illness. The family member would often 
accuse the caregiver of not taking good care of 
the patient, or of stealing the food to feed others 
in their own families. I also work in nursing homes 
in the Dominican Republic and realised that 
the same thing was happening there. I visited 
the homes at lunch time, when my practice 
was quieter and began to notice the chaos and 
desperation of the staff; residents refusing to eat, 
spitting rice all over the place. It was then that I 
started to analyse what was happening and was 
determined to do something to help.
The method I used
I started by reviewing the literature that I found on 
this subject. To have a clearer picture, I obtained 
consent to videotape several settings: private 
homes, nursing homes and state nursing homes 
identifying the different types of eating behaviours 
that the residents presented and how the staff 
reacted and handled them. I then watched the 
videos with the staff and explained what was 
happening. I demonstrated to them the use of the 
Mini Mental State Examination (MMSE) to assess 
cognitive impairment, and we administered this to 
each resident to assess the severity of dementia. 
We used the FAST scale to teach them to assess 
the stage of the dementia, and to understand 
how not only cognition but also functioning 
was affected in a more or less predictable 
manner with the progression of the illness. We 
worked together to assess the probable type of 
dementia that the each patient had, reviewing 
their case history. We then categorised the eating 
and feeding behaviours, using the Adversive 
Feeding Behaviour Inventory and the Feeding 
Dependency Scale14, so that they had a better 
idea of the needs of each individual resident. In 
other words, I went with them, the staff, through 
education37;53. Given the timing of interventions 
and effects, indirect evidence from one study 
where both interventions were provided 
suggested a greater impact of ONS than 
nutritional education to staff60. In one trial in which 
a randomised comparison was made of ONS and 
a 10 session nutritional education programme 
for family caregivers, the ONS intervention was 
superior for almost all outcomes37. 
There is, as yet, no evidence to recommend the 
use of micronutrient supplementation at any 
stage of dementia. The possible exception to 
this advice is that of vitamin E supplementation 
in the light of two positive trials with respect 
to cognitive and functional decline outcomes, 
although the balance of risks and benefits need to 
be more securely established. There is, currently 
no evidence to support the widespread screening 
for folate and B12 deficiency enshrined in many 
good practice post-diagnostic recommendations. 
Supplementation does not seem to affect 
cognitive function, and the cost-effectiveness 
of these non-evidence based recommendations 
needs to be established in randomised controlled 
trials. Despite the strong theoretical basis for 
micronutrient supplementation (see Chapter 4), 
there is not yet enough evidence to recommend 
the use of any medical foods for the treatment of 
Alzheimer’s disease. There have been few trials, 
most of which are small and underpowered, do 
not focus upon those with proven micronutrient 
deficiency, and have relatively short follow-up 
periods. We do recommend further research in 
this area. 
Feeding assistance – managing 
aversive feeding behaviours in 
advanced dementia
A case study from the Dominican 
Republic
Background
Dr Daisy Acosta is an old age psychiatrist 
specializing in dementia care, with a large 
practice in the Dominican Republic. She had 
noted that during the long course of Alzheimer’s 
disease, aversive behaviours develop related 
to food selection and intake that have direct 
consequences on the nutritional status and the 
physical health of these patients. In the Dominican 
Republic, food and eating are central to most 
activities, to the point that eating well is taken 
as an essential parameter of good health. In the 
same way, a well fed patient that is gaining or 
not losing weight is taken as evidence of good 
care. ‘She takes good care of him; look at his 
red cheeks’ or ‘She is good with him/her, see 
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dementia, with MMSE scores ranging from 0–5, 
and most with FAST grade 7 (severe dementia). 
Forty of them lived in state institutions, 15 were 
residents in two private nursing homes, and 
10 lived in their own homes. All patients were 
weighed at the beginning of the programme, and 
then every month for 8 months. A wide range 
of aversive feeding behaviours were identified, 
including most of the 23 categories included 
in the Aversive Feeding Behaviour Inventory14 
(Box 5.1). Many patients exhibited more than 
one of the behaviours, with some exhibiting as 
many as five. Two of the observed behaviours 
were not included in the AFBI, choking (a likely 
consequence of oropharyngeal dysphagia), 
and sucking on fingers interfering with eating 
(probably a primitive ‘release’ reflex).
Lessons learnt from the programme
The enthusiasm and active involvement of the 
staff in the process was crucial. They began to 
give ideas as to how to improve each patient’s 
behaviour and were very creative in their 
suggestions. Categorizing the behaviour was an 
essential first step in order to plan and implement 
measures to help it. These measures can be very 
simple, not costly, and some of them were quite 
effective (see Table 5.3). The education and the 
positive attitude of the feeder were crucial in 
determining the success of the intervention. The 
education of those involved, about eating and 
feeding in patients with AD, helped to reduce the 
neglect of this essential aspect of care. Another 
important lesson learnt was not to imagine that all 
people with dementia would have equal needs for 
caloric intake, and to think of hunger as a possible 
explanation for those residents who screamed 
or otherwise vocalised distress, being unable 
more clearly to articulate their needs. As well as 
calorie intake, staff needed to be taught about 
the importance of offering liquids often, and to 
avoid fluid restriction with the intention of avoiding 
incontinence or frequent diaper changes. 
Four years after the introduction of the 
programme, all of the patients with severe 
dementia involved in the study have since died. 
However, most of the staff involved in the project 
are still working in the same care settings, and 
continuing to use what they had learnt. Some of 
the home care workers, equipped now with some 
special knowledge and skills regarding dementia 
care, are still working with other patients. 
Assistive tableware
Research by the Royal College of Art design 
team revealed that assistive tableware was not 
used as much as it might have been in UK care 
homes39. Some care home managers opted 
not to use them, because of a lack of aesthetic 
a process of informal education about dementia, 
the course of dementia, and feeding and eating 
problems through the illness. In private homes, 
both the paid caregiver and the main family 
caregiver were involved in the same education 
process. 
I then worked with nursing home staff and home 
caregivers to find ways, devices, and measures, 
to help improve ‘eating time’ without incurring any 
additional expenses. 
In all, we worked with 65 people with dementia, 
22 men and 43 women. All had advanced 
Box 5.1
Behaviours observed
Linked to the taxonomy proposed in the 
Aversive Feeding Behaviours Inventory14
• Oropharyngeal dysphagia
 − Accepts food, then fails to swallow 
 − Closes the lips 
 − Accepts food into mouth, then spits it 
out 
 − Food drools from mouth
 − Close mouth tight, or bites the spoon 
impairing food entry 
 − Continuous mouth movements hinder or 
prevent food entry
• Selective feeding behaviours
 − Accept only liquids 
 − Prefers liquids 
• Resistive behaviours
 − Covers mouth with hands 
 − Pushes the food away 
 − Throws food 
• Dyspraxia/agnosia
 − Plays with food 
 − Constant vocalization interfering with 
feeding
 − Goes away from the table, pacing 
around throughout the eating time
 − Uses fingers instead of utensils 
 − Eats non-edible materials 
• Not classified in AFBI
 − Sucking fingers, preventing food from 
entering the mouth (sucking reflex)
 − Choking (indicative of oropharyngeal 
dysphagia)
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A common strategy as dementia advances 
and feeding difficulties develop is to simplify 
the amount of utensils by providing just a plate 
and spoon with pureed or diced food that can 
be eaten without needing to be cut up by the 
resident. However, residents can push the food off 
the side of the plate when they are trying to pick 
it up. To address this, the plate contains a high lip 
in its profile that helps to push the food onto the 
spoon as a person tries to scoop it up. 
The ‘care cup’ is one of the most disliked assistive 
tableware items, because of its similarity in 
appearance to a baby product (made from 
plastic with two handles and a nippled lid). The 
purpose of this item is that residents with reduced 
dexterity can grip both sides of the cup without 
spilling the liquid, or burning their hands as they 
might with a ceramic mug. The design team 
proposed an alternative approach, made from 
appeal. Since residents had different needs and 
abilities, and assistive tableware stood out from 
standard items, users of assistive table settings 
felt different, and stigmatised. The aim of the 
design team was to create a range of matching 
tableware that formed a complete set, could be 
used by people of all abilities, and resembled 
standard domestic tableware (Figure 5.5). Colour 
contrasts feature prominently – for example royal 
blue plates provide a contrast both with a white 
table covering and food on a plate. The same 
approach could be used with cups; royal blue and 
white are used to help those with low visual acuity 
or agnosia locate the handle and rim. The sides 
are angled to reduce the need to tip the cup, the 
handle is large and easily gripped, and the top is 
wide enough to allow a person’s nose to fit inside 
the cup when tipped.
Table 5.3 
Some solutions generated for managing common aversive feeding behaviours
For those who paced constantly High chairs, with trays prevented the patients from wandering, and allowed them 
to focus on their meals, with excellent results, most becoming independent eaters. 
This was the single measure that resulted in the most weight gain with one patient 
gaining 10 pounds in the first month. 
For those with sucking reflexes, sucking their 
fingers, preventing the food from entering the 
mouth
Keeping the hands busy, holding a book or a soft toy, prevented the behaviour, 
facilitating eating time.
For those who wouldn’t open their mouth A touch on the cheek with an ice cold spoon helped to open the mouth, providing a 
brief opportunity to place food in the mouth.
For those who chewed continuously and then 
spat, rather than swallowed
A change from solids to semi-liquids solved most of this behaviour.
There were three patients who used to scream 
all the time and did not sleep well
After a doubling of the food ration, they stopped screaming and began to sleep 
better. 
For those patients shaking their heads in a 
negative manner at the sight of food
Feeders were advised to ignore the negative behaviour, avoiding direct conflict, but 
gently encouraging the person to eat all of the food in the portion. 
For those choking on food The feeder was educated about oropharyngeal dysphagia, and the dangerous 
consequences of aspiration. They were instructed to put the patient in the right 
position, to feed slowly with small amounts and to use thickener in the liquids.
Colour contrast for visual 
impairment
Plate with a high lip 
helps to push food 
onto a spoon
Double sided ceramic 
cup for easy grip
Ceramic cup with lid 
to avoid spillage
Assistive plate with divide 
to ensure separation of soft 
foods and easy grip with lip 
underneath
Fig 5.5 
Examples of assistive tableware Images courtesy of Helen Hamlyn Center, Royal College of Art
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pain81, pressure sores82;83, shortness of breath84, 
infections (particularly pneumonia85), and agitation 
and other psychological symptoms86. These are 
all conditions that can cause much discomfort 
and distress, but which can be alleviated through 
effective palliative care. Communication and 
shared decision-making are key factors in end-of-
life care. Having trust in doctors and surrounding 
staff is an essential factor for patients and 
caregivers87. However, many nurses and care 
home staff do not feel well prepared to deal 
with issues related to end-of-life and dying with 
dementia, and there is a need to improve training 
for nursing home and specialist palliative care 
staff to deal with advanced dementia, and to 
achieve best practice for people with dementia at 
the end-of-life88.
Summary and conclusion
Micronutrient and macronutrient (protein and 
energy) deficiency are common in dementia 
and Alzheimer’s disease, and it is clear that 
undernutrition has important consequences for 
health, quality of life and survival. Loss of body 
weight seems on the one hand to be a natural 
part of the condition, with complex multifactorial 
determinants, and yet to be amenable to 
intervention. 
Standard recommendations for dietary 
management in dementia emphasise the role of 
dietary advice including fortification of existing 
diet to boost the protein and energy content, 
before resorting to oral nutritional supplements 
(ONS). This approach could be characterised as 
‘food first’, and is grounded in common sense. 
Boosting calorie intake should improve nutritional 
status, and doing this through natural foods is 
likely to be more appealing than supplements, 
which can be costly. However, the evidence 
indicates that dietary advice alone is not effective 
in maintaining or increasing weight among 
people with dementia, whereas oral nutritional 
supplementation is highly effective with weight 
gain directly proportionate to the dose and 
duration of the supplementation. Therefore, 
there is a strong case for being more proactive 
in the use of oral nutritional supplements, which 
are probably underutilised, well tolerated and 
associated with few if any adverse effects. 
Supplements need not be costly – for example, 
a current feasibility trial in India is evaluating the 
acceptability and feasibility for frail dependent 
older people of a locally developed protein and 
energy rich product comprising ragi, green gram, 
roasted Bengal gram, roasted groundnut, and 
soya flour prepared as a powder that can be 
consumed as a soup or sprinkled on food, and 
provides 1854 kcal per daily 500g bag (personal 
ceramic but from a mould with a double skin and 
an air-filled cavity between the inside and outside 
surfaces. With this insulation, the liquid is kept 
warm while the outside of the cup remains cool 
and can be gripped without risk of burning. The lid 
minimises the association to the nipple of a baby 
cup by elongating the form around the rim.
Feeding a person with dementia is one of the 
most challenging and time-consuming tasks 
in a caregiver’s day. The tableware includes 
items designed specifically for use with assisted 
feeding, including a plate, a bowl and lids for 
cups. The items are reduced in weight, and 
designed so that they can be easily and securely 
grasped by the carer, with one hand. The plate 
allows the carer to orientate it in an ‘offering 
position’ (in the sensory range of the person 
being fed so that they can see and smell what 
they are eating) and draw it under the person’s 
chin to minimise the risk of spilling. A version of 
the plate with a central divide is also available for 
people who require a soft food diet. This ensures 
that different food groups stay separated and 
that people can still enjoy the uniqueness of each 
flavour.
Managing oropharyngeal dysphagia in 
advanced dementia through enteral tube 
feeding
Problems with swallowing are common in 
advanced dementia. However, the use of 
nasogastic or of percutaneous endoscopic 
gastrostomy (PEG) feeding tubes, while quite 
widespread, is controversial, and needs to 
be evaluated carefully with respect to patient 
and caregiver preferences, and the balance 
of risks and benefits for individual patients. A 
nasogastric tube is passed through the nose and 
into the stomach, while a PEG tube is inserted 
into the stomach via a permanent incision in the 
abdominal wall requiring a surgical procedure 
and anaesthetic. A Cochrane systematic review 
suggests that tube feeding for people with 
dementia does not confer any benefit regarding 
nutritional status, reduction of pressure sores, 
mortality risk or survival time80. Families and 
health professionals often have unrealistic 
expectations of the outcomes of tube feeding. 
Potential for harm exists from an increase in 
urinary and faecal incontinence, leading to 
pressure sores; from discomfort, and attempts 
to remove the tubes, which may lead to sedation 
being given; and from an increase in pulmonary 
secretions80. 
Advanced eating and swallowing problems 
need to be seen more in the context of holistic 
palliative end-of-life care. In addition to eating 
and swallowing problems, symptom burden at the 
end-of–life for people with dementia arises from 
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unequivocally until more data is available on the 
balance of risks and benefits. 
Likewise, there is strong evidence, although not 
from randomised controlled trials, that systems 
level interventions, for example small scale 
household level dining, ‘family style’ eating 
arrangements, and use of appropriate tableware 
and lighting levels may be associated with 
increased calorie consumption and increases 
in weight. Much more work needs to be carried 
out into the effectiveness of assistive feeding 
interventions to address aversive feeding 
behaviours.
Although much of the work on nutritional 
interventions has been carried out in long-
term care facilities, many of the findings are 
generalisable to home care by informal carers. 
This would include the benefits of ONS (and 
the relative inefficacy of dietary advice alone), 
the importance of a home dining environment, 
and including the person with dementia as 
part of the family social dining activity. Many 
informal caregivers struggle with aversive feeding 
behaviours, and the benefits of focused support 
and training interventions needs to be evaluated in 
this group. 
communication AT Jotheeswaran). The cost is 
substantially less than one US dollar per day. 
Certainly ONS should be used in all those people 
with dementia found to be undernourished89. For 
those at risk of undernutrition, if nutritional status 
is not improved with dietary advice, then ONS 
should be implemented without delay89. Given the 
relative lack of large definitive long-term trials in 
this area, there are still some important questions 
to be resolved:
• Should those with undernutrition receive 
continuous ONS (and is this feasible and 
acceptable), or is short interval ONS equally 
effective and more acceptable?
• Is ONS as effective for those with undernutrition 
as for those at risk of undernutrition? 
• Is long-term ONS associated with net benefits 
for cognition, functional status, depression, 
quality of life, and survival?
Dietary advice should remain a standard 
recommendation, not least because of the need 
to ensure that ONS is used appropriately, and 
that use of ONS does not lead to substitution 
(a compensatory reduction of the customary 
diet). There is a clear demand from caregivers 
for advice and support, particularly with aversive 
feeding behaviours. There has been remarkably 
little research into nutritional training and 
education of care assistants in long-term care 
facilities, with many anecdotal examples of the 
potential benefits of this approach.
While many people with dementia use 
micronutrient supplements, usually at their 
own cost, there is little or no evidence of any 
benefit as regards progression of the condition. 
On the current evidence, the recommendation 
would be that these supplements should neither 
be marketed nor used for the treatment of 
Alzheimer’s disease or other forms of dementia. 
B12 or folate deficiency, if identified, should be 
corrected. However, the overall cost-benefits of 
screening for these deficiencies in all patients with 
newly diagnosed dementia are not established, 
and current recommendations are not based on 
evidence. Very few older people are deficient in 
vitamin E. However, hypersupplementation of 
this vitamin (2000 IU total daily) does seem to be 
associated, in two randomised controlled trials, 
with slower progression of the cognitive and 
functional impairment of Alzheimer’s disease. 
However, these hypersupplementation levels are 
100 times higher than the recommended daily 
allowance to maintain vitamin E levels (22 IU) and 
exceed the tolerable upper intake levels of 1500 
IU daily. Excess intake of vitamin E, particularly 
over the longer term may be associated with risk 
of bleeding and haemorrhagic stroke. Therefore 
the use of this agent cannot be recommended 
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Northeast Health (NEH), New York
Submitted by Carole DeBonte
Northeast Health has two assisted living dementia 
dedicated communities. The communities serve 
meals in country kitchen style dining venues. 
Food is provided to the units and placed in the 
kitchen steam tables. Nursing staff serve the 
meals to the residents in the dining rooms (3 at 
each community) in a home like atmosphere. 
Residents are offered a variety of seating options 
including tables in front of the “kitchens” as in 
your home. Dining is also offered in a “dining 
room” adjacent to the kitchen area, or in quiet 
locations. Menus are offered to the residents to 
view in menu jackets. Residents enjoy stopping 
by the kitchen island and viewing the menu during 
the day. Snacks and sandwiches are available in 
the kitchens throughout the day and night. High 
calorie and protein snacks are planned in place 
of supplements whenever possible. Dishware 
is selected based on the resident needs, for 
example a large mug like bowl is used for soups 
offering the residents the opportunity to feed 
themselves and enjoy a home like soup service. 
Different color dishware is used based on the 
resident’s cognitive needs. 
Menu planning is community process. The 
nursing staff are very involved in evaluating 
foods that are well accepted. We start with the 
main menu and modify for appropriate sides and 
condiments. We typically offer one hot entrée and 
sides and an alternative menu is offered based 
on the always available menu choices. This has 
minimized difficulty with menu choice concerns at 
the meals. 
Sample entrée plates are presented at each 
kitchen area to aid the nursing staff in dishing up 
the food in a pleasing manner, and in the correct 
portions. The food is delivered to the kitchens, 
then one nursing staff is in the kitchen and the 
other aides bring the food to the residents. 
Food is served based on the resident’s dining 
preference. 
Success is measured by the residents’ enjoyment 
at meals and successful nutrition outcomes. The 
dining process is a continual work in progress 
noting that residents with dementia may change 
stages and their needs are evolving. Good team 
work by the nursing staff, activities, dietitian and 
food and nutrition services staff are recipe for 
successful dining services!
Fellowship Senior Living, New Jersey
Submitted by Brian Lawrence
Fellowship Senior Living is just about ready 
to start a three-year development project that 
includes new memory care households following 
the person centered care philosophy. There will 
be two new households which will house between 
16 – 20 residents each. Each household will be 
on the first floor and will have a 4 seasons porch 
(sunroom), a covered outside porch and a private 
courtyard. They will also have their own hair salon, 
art studio, living room, dining room, kitchen and 
den plus a private dining room for entertaining 
guests. Each bedroom will be private with at 
least two windows to allow for an abundance of 
natural light. The household will be set up to look 
like a real house, with a front door and doorbell, 
common living areas in the front and bedrooms in 
the back. Aside from the front door, exits will be 
tucked in corners or out of site to avoid tempting 
the residents. 
Meals will be made by the homemakers; menus 
planned with the resident’s help. Homemakers 
will serve food much the same as you’d do in 
your home. Resident’s will be able to participate 
in multiple activities involving food preparation. 
Breakfast will be made to order as the residents 
awaken and wander down to the kitchen on their 
own time schedule; pajamas welcome!
Holly Creek – Christian Living 
Communities, Colorado
Submitted by Kara Emig
Our memory care is assisted living but we focus 
on resident-led food activities. Every afternoon 
they bake/make something to enjoy. Yesterday 
it was mini corndogs made from scratch. 
Sometimes it’s cookies or just cutting up the 
apples for a pie. Anything to bring back the 
memories. It is a small community of 12 residents 
with very involved staff, so it’s a family-type 
setting. 
Examples of dementia care best practice
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Aldersgate Village, Mississippi
Submitted by Lindsey Bevans
At Aldersgate Village we have expanded our 
breakfast always available menu in our dementia 
neighborhoods with items that nursing staff can 
prepare during non-traditional meal times when 
there is not a dining services aide to assist. The 
Breakfast Always Available Menu contains new 
items such as homemade biscuits and gravy, 
fresh muffins, fresh pastries (ex: cinnamon rolls 
and Danishes), waffles, pancakes, a variety of 
seasonal fresh fruit and more. The dietitians 
trained the nursing staff on how to correctly 
prepare and serve these items to ensure the 
residents receive appropriate diet (type and 
texture) and that it is completed in a safe way. 
Nursing staff were also educated about the 
different diet textures and shown how they 
can use the diet manual as a reference any 
time they have questions pertaining to diets. 
There have been many benefits observed from 
these changes. The residents are now able to 
receive food at their desired time and I have 
heard multiple comments from residents (and 
family members) reporting that they like the 
new menu and being able to eat when they 
want. Nursing staff have gained knowledge 
regarding differences in diets and now feel 
more comfortable dealing with the different diet 
types. And from a nutritional point of view, I have 
seen a decrease in weight loss in the dementia 
neighborhoods.
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Appendix 1
Literature searches for nutrients on Medline
Fatty acids
((“Fatty Acids, Omega-3”[MeSH Terms] OR “omega-
3”[All Fields] OR (“fatty”[All Fields] AND “acid”[All Fields]) 
OR “n-3 PUFA”[All Fields] OR “n-3 polyunsaturated fatty 
acid”[All Fields] OR “PUFA”[All Fields] OR (“unsaturated 
fatty acid”[All Fields] OR “essential fatty acid”[All Fields]) OR 
“EFA”[All Fields] OR “eicosapentaenoic acid”[All Fields]) OR 
(“Docosahexaenoic acid”[All Fields] OR (“docosapentanoic 
acid “[All Fields] OR “DPA”[All Fields]) OR (“ethyl-
eicosapentaenoic acid”[All Fields] OR EPA “E-EPA”[All Fields]) 
OR (“alpha-linolenic acid”[All Fields] OR “ALA”[All Fields]) 
OR (“fish oil”[All Fields] OR “n-3 fatty acid”[All Fields] OR 
“long chain fatty acids”[All Fields]) OR (“primrose oil”[All 
Fields] OR “linseed oil”[All Fields] OR “oily fish”[All Fields] 
OR “flaxseed oil”[All Fields])) AND ((“memory”[MeSH Terms] 
OR “memory”[All Fields]) OR (“cognition”[MeSH Terms] OR 
“cognition”[All Fields]) OR cognitive[All Fields] OR (“alzheimer 
disease”[MeSH Terms] OR (“alzheimer”[All Fields] AND 
“disease”[All Fields]) OR “alzheimer disease”[All Fields] OR 
“alzheimer”[All Fields]) OR (“dementia”[MeSH Terms] OR 
“dementia”[All Fields])) AND “humans”[MeSH Terms])
Mediterranean diet
(“Diet, Mediterranean”[Mesh] OR “Mediterranean diet” 
OR (“Mediterranean” AND “Diet”)) AND ((“alzheimer 
disease”[MeSH Terms] OR “alzheimer”[All Fields] AND 
“disease”[All Fields]) OR (“alzheimer disease”[All Fields] OR 
“alzheimer”[All Fields]) OR (“dementia”[MeSH Terms] OR 
“dementia”[All Fields]))
Vitamins B
((“homocysteine”[MeSH Terms] OR “homocysteine”[All Fields]) 
OR (“homocysteine”[MeSH Terms] OR “homocysteine”[All 
Fields]) OR (“hyperhomocysteinemia”[MeSH 
Terms] OR “hyperhomocysteinemia”[All Fields]) 
OR (“hyperhomocysteinemia”[MeSH Terms] 
OR “hyperhomocysteinemia”[All Fields] OR 
“hyperhomocysteinaemia”[All Fields]) OR (“vitamin b 
complex”[MeSH Terms] OR “vitamin b complex”[All 
Fields] OR “b vitamins”[All Fields] OR “vitamin b 
complex”[Pharmacological Action]) OR (“vitamin b 12”[MeSH 
Terms] OR “vitamin b 12”[All Fields] OR (“vitamin”[All Fields] 
AND “b12”[All Fields]) OR “vitamin b12”[All Fields]) OR 
(“vitamin b 12”[MeSH Terms] OR “vitamin b 12”[All Fields]) 
OR (“vitamin b 12”[MeSH Terms] OR “vitamin b 12”[All 
Fields] OR “cobalamin”[All Fields]) OR (“vitamin b 12”[MeSH 
Terms] OR “vitamin b 12”[All Fields] OR “cyanocobalamin”[All 
Fields]) OR (“vitamin b 6”[MeSH Terms] OR “vitamin b 6”[All 
Fields] OR (“vitamin”[All Fields] AND “b6”[All Fields]) OR 
“vitamin b6”[All Fields]) OR (“vitamin b 6”[MeSH Terms] OR 
“vitamin b 6”[All Fields]) OR (“pyridoxine”[MeSH Terms] OR 
“pyridoxine”[All Fields]) OR (“folic acid”[MeSH Terms] OR 
(“folic”[All Fields] AND “acid”[All Fields]) OR “folic acid”[All 
Fields] OR “folate”[All Fields]) OR (“folic acid”[MeSH Terms] 
OR (“folic”[All Fields] AND “acid”[All Fields]) OR “folic 
acid”[All Fields]) OR (“folic acid”[MeSH Terms] OR (“folic”[All 
Fields] AND “acid”[All Fields]) OR “folic acid”[All Fields] OR 
(“vitamin”[All Fields] AND “b9”[All Fields]) OR “vitamin b9”[All 
Fields]) OR ((“vitamins”[MeSH Terms] OR “vitamins”[All Fields] 
OR “vitamin”[All Fields] OR “vitamins”[Pharmacological 
Action]) AND B-9[All Fields])) AND ((“memory”[MeSH Terms] 
OR “memory”[All Fields]) OR (“cognition”[MeSH Terms] OR 
“cognition”[All Fields]) OR cognitive[All Fields] OR (“alzheimer 
disease”[MeSH Terms] OR (“alzheimer”[All Fields] AND 
“disease”[All Fields]) OR “alzheimer disease”[All Fields] OR 
“alzheimer”[All Fields]) OR (“dementia”[MeSH Terms] OR 
“dementia”[All Fields])) AND “humans”[MeSH Terms])
Antioxidants
((“vitamin E”[MeSH Terms] OR “vitamin E”[All Fields] OR 
“tocopherol”[All Fields] OR “tocopherols” [MeSH Terms] 
“tocotrienol”[All Fields] OR “tocotrienols”[MeSH Terms]) 
OR (“vitamin C”[All Fields] OR (“ascorbic”[All Fields] AND 
“acid”[All Fields]) OR “ascorbic acid”[MeSH Terms]) OR 
“tocopherols” [MeSH Terms] “tocotrienol”[All Fields] OR 
“tocotrienols”[MeSH Terms]) OR (“beta Carotene”[MeSH 
Terms] OR (“beta”[All Fields] AND “carotene”[All Fields]) OR 
“betacarotene”[All Fields]) OR (“carotene”[All Fields] OR 
“Carotenoids”[MeSH Terms] OR “carotenoids”[All Fields] 
OR “vitamin A”[MeSH Terms] OR “vitamin A”[All Fields] ) OR 
(“flavonoids”[MeSH Terms] OR “flavonoids”[All Fields]) OR 
(“antioxidants”[MeSH Terms] OR “antioxidants”[All Fields] 
OR “anti-oxidants”[All Fields]) OR (“Ginkgo biloba”[MeSH 
Terms] OR “Ginkgo biloba”[All Fields])) AND ((“memory”[MeSH 
Terms] OR “memory”[All Fields]) OR (“cognition”[MeSH 
Terms] OR “cognition”[All Fields]) OR cognitive[All Fields] OR 
(“alzheimer disease”[MeSH Terms] OR (“alzheimer”[All Fields] 
AND “disease”[All Fields]) OR “alzheimer disease”[All Fields] 
OR “alzheimer”[All Fields]) OR (“dementia”[MeSH Terms] OR 
“dementia”[All Fields])) AND “humans”[MeSH Terms])
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Compass Group PLC
Compass House, Guildford Street, Chertsey, Surrey KT16 9BQ, UK · Tel: +44 1932 573000 · www.compass-group.com
Compass Group PLC is a world leading food and support services company, which generated annual revenues of £17.6bn in the year 
to 30 September 2013. It operates in around 50 countries, employs over 500,000 people and serves over 4 billion meals every year. 
The company specialises in providing food and a range of support services across the core sectors of Business & Industry, Healthcare 
& Seniors, Education, Defence, Offshore & Remote, Sports & Leisure and Vending with an established brand portfolio. Compass 
operates with a number of brands in the senior living sector. For more information, please visit www.compass-group.com.
Alzheimer’s Disease International
64 Great Suffolk Street, London, SE1 0BL, UK · Tel: +44 20 7981 0880 · Fax: +44 20 79282357 · www.alz.co.uk
ADI is the international federation of 79 Alzheimer associations around the world, in official relations with the World Health Organization 
since 1996 and with the United Nations since 2012. Each member is the Alzheimer association in their country who support people with 
dementia and their families. ADI’s vision is an improved quality of life for people with dementia and their families throughout the world. Its 
main objectives are to raise awareness, to support and strengthen its member associations and to make dementia a global health priority.
Alzheimer’s Disease 
International: The 
International Federation of 
Alzheimer’s Disease and 
Related Disorders Societies, 
Inc. is incorporated in Illinois, 
USA, and is a 501(c)(3) not-for-
profit organization
Alzheimer’s Disease International
64 Great Suffolk Street
London SE1 0BL
UK
Tel: +44 20 79810880
Fax: +44 20 79282357
www.alz.co.uk
Supported by
